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diseases	 (Taqi	 et	 al.	 2011)	 and	 complex	 diseases	 such	 as	 diabetes	 and	 cancer.	 A	
recent	study	examining	40	previously	identified	diabetes	risk	SNPs	found	nearly	half	
introduced	or	removed	a	CpG	site	(Dayeh	et	al.	2013),	while	an	extensive	genome-




































































































































































































































































































































Figure 2.2 Tas PCa Family 9 abridged pedigre .   
A section of the larger pedigree for Family 9 highlights the high rate of prostate cancer within the family, particularly in the later generations.  Males are shown as squares and females circles.  Men affected by prostate cancer are represented by filled in black squares, unaffected men by unfilled 
squares and individuals diagnosed with other cancers are indicated by a small filled box in the top left corner.  A subset of  samples analysed for methylation data are indicated by red arrow heads. Family 9 extends over nine generations and contains fifty-three men affected by prostate cancer.  The 
























Figure 2.3 Tas PCa Family 11 abridged pedigree. 
Two branches of the larger pedigree for Family 11 are illustrated, with men represented as squares and females circles.  Men affected by prostate cancer are filled in black, unaffected men are unfilled and individuals diagnosed 
with other cancers are indicated by a small filled box in the top left corner. A subset of samples analysed for methylation data are indicated by red arrow heads. These abridged pedigrees for Family 11 cover five generations and 















Figure 2.4 Tas PCa Family 22 abridged pedigree. 
Two branches of the larger pedigree for Family 22 are illustrated, with men represented as squares and females circles.  Men affected by prostate cancer are filled in black, unaffected are unfilled and individuals diagnosed with 















































Figure 2.5 Tas PCa Family 72 abridged pedigree. 
A section of the larger pedigree for Family 72 is illustrated, with men represented as squares and females circles. Men affected by prostate cancer are filled in black, unaffected are unfilled and individuals diagnosed with other 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Peripheral	 blood	 samples	were	 collected	with	 informed	 consent	 obtained	 from	 all	
participants,	 following	 ethics	 approval	 from	 the	 University	 of	 Tasmania	 (H9999,	




purified	 using	 the	 Zymo	 Clean	 &	 Concentrator	 (TM)-5	 Kit	 (Zymo).	 DNA	 was	 then	
quantified	 using	 a	 Qubit®	 Flourometer.	 To	 ensure	 selected	 samples	 had	 sufficient	
quantity	 and	 quality	 of	 DNA	 to	 perform	 methylation	 and	 genotype	 arrays,	 each	
sample	was	quantified	on	the	Nanodrop	8000	(Thermo	Scientific)	and	samples	with	





































































+' Quality M RepM Quality G RepG Age$*
1 PC1)03 M Affected 1 NA NA Good No 82
2 PC2)01 M Affected 2 NA NA Good No 52
3 PC2)02 M Affected 2 NA NA Good No 53
4 PC2)03 M Affected 2 NA NA Good No 58
5 PC3)01 M Affected 3 NA NA Good No n/a
6 PC4)01 M Affected 0 NA NA Good No 74
7 PC9)01$ M Affected 2 Good No Good No 64
8 PC9)04$ M Affected 0 Good No Good No 65
9 PC9)12$ M Affected 0 Good No Good No 72
10 PC9)121$ M Unaffected 1 Good No Good No 48
11 PC9)129 F NA 1 Good No Good No 61
12 PC9)24$ F NA 1 Good No Good No 45
13 PC9)286 M Unaffected 1 Good No Good No 47
14 PC9)29 F NA 1 Good No Good No n/a
15 PC9)338 M Affected 0 Good No Good No 63
16 PC9)357 M Unaffected 1 Good No Good No 42
17 PC9)477$ M Affected 1 Good No Good No 52
18 PC11)03 M Affected 1 Good No Good No 89
19 PC11)04 M Affected 1 Good No Good No 73
20 PC11)09 M Affected 2 Good No Good No 83
21 PC11)147 M Affected 1 Good No Good No 61
22 PC11)180 M Unaffected 1 Good No Good No 42
23 PC11)213 M Affected 0 Poor x2 NA NA 62
24 PC11)233 M Unaffected 3 Poor x2 NA NA 92
25 PC11)234 M Unaffected 1 Good No Good No 55
26 PC11)415 M Unaffected 1 Good No NA NA 61
27 PC12)04 M Affected 2 NA NA Good No n/a
28 PC22)02 M Affected 2 Good No NA NA 64
29 PC22)03 M Affected 2 Good No Good No 74
30 PC22)04 M Affected 1 Good No Good No 62
31 PC22)16 M Affected 3 Good x2 Good No 76
32 PC22)162 M Unaffected 2 Good No Good No 56
33 PC22)17 M Affected 3 Good x4 Good x2 63
34 PC22)195 F NA 1 Good No NA NA 40
35 PC22)203 M Affected 3 Good No Good No 75
36 PC22)21 M Affected 2 Good No Good No 70
37 PC22)210 F NA 4 Good No Good No 73
38 PC22)274 M Unaffected 1 Good No Good No 45
39 PC22)386 F NA 1 Good No NA NA 56








41 PC22)388 M Unaffected 3 Good No Good No 73
42 PC22)393$ F NA 1 Good No Good No 44
43 PC22)414 F NA 3 Good No Good No 66
44 PC22)416 M Affected 2 Good No Good No 61
45 PC22)418 M Unaffected 3 Good No Good No 54
46 PC22)468 M Affected 0 Good No NA NA 69
47 PC22)476 M Unaffected 1 Good No Good No 36
48 PC27)01 M Affected 1 NA NA Good No 64
49 PC72)02 M Affected 1 NA NA Good No 85
50 PC72)03 M Affected 3 Good No Good No 70
51 PC72)04 M Affected 4 Good No Good x2 78
52 PC72)106 M Unaffected 2 Good No Good No 46
53 PC72)126 M Affected 1 Good No Good No 49
54 PC72)136 M Other$Cancer 0 Good No NA NA 57
55 PC72)187 F NA 2 Good No Good No 41
56 PC72)188 M Other$Cancer 1 Good No Good No 23
57 PC72)213 M Unaffected 0 Good x2 NA NA 41
58 PC72)291 M Unaffected 1 Poor x2 NA NA 42
59 PC72)77 M Affected 0 Good No NA NA 75
60 PC72)94 M Other$Cancer 1 NA NA Good No 61
61 PC72)97 F Other$Cancer 2 NA NA Good No n/a












Raw	 data	was	 combined	 from	 all	 batches	 generated	 in	 both	 the	 overseas	 and	 in-
house	 laboratories,	 and	 analysed	 together.	 Illumina’s	 GenomeStudio	 software	
package	provides	only	basic	quality	control	and	pre-processing,	which	is	insufficient	
to	 analyse	 familial	 methylation	 data,	 as	 this	 type	 of	 data	 requires	 specialised	
normalisation	methods	to	remove	technical	bias.	As	such,	IDAT	files	were	analysed	in	
the	R	environment	 (R	Core	Team,	2014).	A	combination	of	 three	R	packages,	minfi	(Aryee	 et	 al.	 2014),	 methylumi	 (Davis,	 S	 et	 al.,	 2012)	 and	 ChAMP	 (Morris	 et	 al.	2014),	were	used	to	load	IDAT	files	into	R	and	perform	basic	quality	control	analysis.	
Different	normalization	methods	require	the	data	to	be	in	different	formats	and	it	is	
often	 difficult	 or	 impossible	 to	 change	 the	 format	 of	 the	 data	 between	 packages	
once	 it	 is	 loaded	 in	R.	As	 such,	 a	number	of	 different	packages	were	used	 to	 load	
data,	 with	 the	 chosen	 package	 dependent	 on	 the	 normalization	 method	 tested.	




on	 the	 array	 (such	 as	 staining,	 hybridization,	 bisulphite	 conversion	 and	 negative	
controls)	as	well	as	the	ability	to	exclude	probes	and	samples	based	on	probe	signal	
intensity.	 Samples	 failing	 this	 initial	 quality	 control	 were	 excluded	 from	 further	
analysis	 according	 to	 the	 recommendations	 of	 the	 minfi	 package	 authors.	
Specifically,	 samples	 were	 excluded	 if	 the	 sample	 profile	 deviated	 markedly	 from	
that	of	the	other	samples	on	both	the	density	plot	and	bean	plot.		
	 56	
Biological	 replicate	 samples	 were	 included	 across	 batches	 to	 allow	 assessment	 of	
quality	control	and	technical	bias.	Of	the	50	unique	blood	samples	and	8	replicates	
initially	 interrogated,	 47	 unique	 and	 5	 replicate	 samples	 passed	 quality	 control	
metrics	and	were	used	 for	 further	analysis,	as	 indicated	 in	Figure	2.6	 (green	arrow	
heads	indicating	samples	for	which	good	quality	data	was	generated	and	red	arrow	
heads	 indicating	 samples	 which	 generated	 poor	 quality	 data)	 and	 in	 Table	 2.1.	





To	 account	 for	 sex	 differences	 in	methylation,	 driven	 particularly	 by	 X-inactivation	
dosage	 compensation,	 probes	 on	 the	 sex	 chromosomes	 were	 removed	 prior	 to	
normalisation.	While	ChAMP	includes	this	option	as	default	when	loading	data,	most	
packages	 require	 manual	 separation,	 normalisation	 and	 recombination	 of	 sex	
chromosomes	 or	 their	 complete	 manual	 removal.	 Thus	 to	 permit	 appropriate	
comparison	of	normalization	methods,	a	homogenous	set	of	loci	across	all	packages	
was	required	and	therefore	sex	chromosomes	were	removed	at	this	stage	of	analysis	

































































































































































Row Sample&ID No&Calls Calls
Call&
Rate Row Sample&ID No&Calls Calls
Call&
Rate
1 PC2@01 8389 2383350 0.997 28 PC22@418 63055 2328684 0.974
2 PC2@02 3738 2388001 0.998 29 PC11@234 64334 2327405 0.973
3 PC2@03 9141 2382598 0.996 30 PC9@04 35040 2356699 0.985
4 PC22@03 3311 2388428 0.999 31 PC9@29 13796 2377943 0.994
5 PC22@04 4275 2387464 0.998 32 PC27@01 10986 2380753 0.995
6 PC22@16 3963 2387776 0.998 33 PC11@04 9259 2382480 0.996
7 PC22@17_a 14596 2377143 0.994 34 PC22@393 6633 2385106 0.997
8 PC22@21 4360 2387379 0.998 35 PC72@04_b 21515 2370224 0.991
9 PC22@162 6119 2385620 0.997 36 PC22@476 5537 2386202 0.998
10 PC22@203 6875 2384864 0.997 37 PC9@129 19829 2371910 0.992
11 PC22@274 12465 2379274 0.995 38 PC9@01 2895 2388844 0.999
12 PC22@387 2252 2389487 0.999 39 PC22@210 4130 2387609 0.998
13 PC22@388 2870 2388869 0.999 40 PC12@04 39723 2352016 0.983
14 PC72@106 6116 2385623 0.997 41 PC4@01 44277 2347462 0.982
15 PC72@188 3577 2388162 0.999 42 PC75@01 44266 2347473 0.982
16 PC72@02 2993 2388746 0.999 43 PC11@09 19405 2372334 0.992
17 PC72@03 3552 2388187 0.999 44 PC9@286 19285 2372454 0.992
18 PC72@04_a 3569 2388170 0.999 45 PC9@338 6608 2385131 0.997
19 PC72@94 2544 2389195 0.999 46 PC3@01 38797 2352942 0.984
20 PC72@97 4048 2387691 0.998 47 PC22@414 79204 2312535 0.967
21 PC72@126 2417 2389322 0.999 48 PC11@147 53769 2337970 0.978
22 PC9@477 63674 2328065 0.973 49 PC11@03 39124 2352615 0.984
23 PC22@17_b 16957 2374782 0.993 50 PC72@187 48661 2343078 0.980
24 PC1@03 7542 2384197 0.997 51 PC9@12 12555 2379184 0.995
25 PC9@121 10428 2381311 0.996 52 PC22@416 56758 2334981 0.976
26 PC11@180 57113 2334626 0.976 53 PC9@24 16873 2374866 0.993













Child&ID &Parent&ID &Correct &Errors &Total
&Parent?Child
Heritability&Freq
1 PC22@274 PC22@21 2375467 188 2375655 0.9999
2 PC72@106 PC72@04 2382249 156 2382405 0.9999
3 PC72@188 PC72@126 2385723 162 2385885 0.9999
4 PC72@94 PC72@02 2386361 155 2386516 0.9999
5 PC72@97 PC72@02 2384796 177 2384973 0.9999
6 PC72@126 PC72@04 2385891 136 2386027 0.9999
7 PC9@121 PC9@04 2347202 616 2347818 0.9997
8 PC11@180 PC11@04 2325376 2186 2327562 0.9991
9 PC9@357 PC9@338 2331699 2144 2333843 0.9991
10 PC11@234 PC11@09 2306769 2863 2309632 0.9988
11 PC22@476 PC22@416 2327717 2715 2330432 0.9988
12 PC72@187 PC72@04 2337712 2186 2339898 0.9991



























































































































To	 date,	 genome-wide	 epigenetic	 studies	 have	 largely	 focused	 on	 epigenetic	
alterations	 that	 occur	 in	 diseased	 tissues,	 where	 epigenetic	 changes	 across	 the	
genome	 are	 mapped	 through	 comparing	 ‘normal’	 and	 affected	 tissues	 from	 the	
same	 individual.	 Indeed	 epigenetic	 drugs,	 currently	 in	 clinical	 use	 are	 designed	 to	
correct	 the	 epigenetic	 alterations	 acquired	 during	 disease	 development	 (Sharma,	Kelly	 and	 Jones	 2010);	 the	 assumption	 being	 that	 these	 acquired	 epigenetic	
alterations	 are	 driven	 by	 the	 disease	 process	 itself.	 More	 recently	 it	 has	 been	
hypothesised	 that	 inherited	 genetic	 variation	 can	 drive	 epigenetic	 alterations	 and	
further	that	these	contribute	to	disease	susceptibility	or	disease	course.	To	date	the	
large	 majority	 of	 genome-wide	 methylation	 studies	 and	 consequently	 the	
bioinformatics	 pipelines	 used	 to	 interpret	 these	 data	 have	 been	 designed	 to	
compare	diseased	tissue	with	‘normal’	tissue,	in	order	to	map	epigenetic	changes	in	
the	diseased	 tissue	 itself.	 This	 analysis	necessarily	 screens	out	 inherited	epigenetic	










be	 tracked	 through	 generations.	 A	 number	 of	 challenges	 exist	 in	 the	 analysis	 of	
genome-wide	 methylation	 mapping	 in	 samples	 and	 these	 include	 technical	
challenges	dealing	with	batch	effects	and	the	underlying	biochemistry	employed	by	
the	 array	 methods.	 This	 has	 necessitated	 the	 development	 of	 numerous	 pre-
processing	quality	control	methods	to	ensure	reliable,	high	quality	data	generation.	
As	 mentioned	 above,	 most	 studies	 examining	 epigenetic	 profiles	 typically	 assess	
differences	between	two	distinct	groups	(normal	tissue	versus	tumour	tissue	or	case	
vs	control	status),	and	as	such	the	majority	of	normalisation	methods	for	the	analysis	
of	 methylation	 array	 data	 are	 designed	 for	 these	 types	 of	 comparisons.	 These	
methods	 frequently	 require	 two	 data	 groups	 to	 normalise	 negative	 and	 positive	
control	 probes	 or	 genomic	 regions.	 Such	methods	 are	 incompatible	with	 pedigree	
data,	which	lack	a	distinct	second	comparison	group	for	normalisation.	While	other	
methods	 such	 as	 BMIQ	 (Teschendorff	 et	 al.	 2013)	 do	 not	 rely	 on	 cancer-normal	
differences,	 they	 often	 focus	 on	 intra-array	 normalisation	 and	 do	 not	 necessarily	
address	technical	bias	between	samples.	To	avoid	unwanted	technical	noise	such	as	






probe	 signals,	 adjust	 for	 technical	 bias	 and	 prepare	 data	 for	 analysis	 of	 biological	
differences.	 As	 such,	 the	 aim	 of	 this	 chapter	 is	 to	 establish	 and	 test	 a	 pipeline	 to	












































































each	 individual	 normalisation	 package,	 which	 had	 different	 requirements.	 This	
dictated	 whether	 normalisation	 methods	 were	 compatible	 and	 could	 be	 used	 in	
conjunction.	The	methods	 involve	various	degrees	of	 type	 I	and	 II	probe	scaling	 to	
account	 for	underlying	 technical	differences	between	 the	probe	 types,	background	
and	dye	bias	 correction	and	 initial	batch	correction	between	arrays.	Depending	on	
the	 normalisation	 method,	 data	 was	 either	 used	 in	 the	 red/green	 signal	 format	
(RGset),	 converted	 into	 methylated	 and	 unmethylated	 values	 (MethylSet)	 or	
converted	 to	 β	 values	 by	 the	 function	 β	 =	 M/	 (M	 +	 U	 +100),	 where	 M	 is	 the	
methylated	signal	and	U,	unmethylated.	In	some	normalisation	methods,	the	offset	
of	 100	 is	 included	 to	 regularize	 scores	 when	 both	 methylated	 and	 unmethylated	
values	are	very	low.	While	the	β	value	is	more	biologically	intuitive	(it	ranges	from	0-
1	 indicating	 the	 proportion	 of	methylation	 at	 that	 site	 for	 the	 population	 of	 cells	
analysed),	it	suffers	from	severe	heteroskedasticity	at	very	high	or	low	values	(Du	et	
al.	 2010).	 Logit	 transforming	 to	 an	M-value	 removes	 this	 unequal	 variance.	 Thus	
wherever	possible,	calculations	in	this	study	have	been	performed	on	the	M-values	
and	 transformed	 back	 to	 β	 values	 if	 required	 for	 biological	 interpretation.	 Eight	
performance	 metrics	 were	 then	 used	 to	 compare	 methods	 and	 determine	 the	
optimal	normalisation	approach	for	familial	datasets.	Visual	tools	such	as	density	and	
MDS	 plots	 and	 unsupervised	 hierarchical	 clustering	 were	 used	 to	 compare	 the	
various	methods	between	all	samples	and	particularly	replicate	samples.		See	Table	




Table	 3.2	 Qualitative	 and	 Quantitative	 metrics	 used	 to	 assess	 normalisation	

































































































































Since	 an	 obvious	 batch	 effect	 remained	 after	 normalisation,	 the	 ComBat	 function	
from	the	sva	package	(Frommer	et	al.	1992)	was	used	to	further	remove	technical	





various	 normalisation	methods.	 In	 addition	 to	 density	 and	MDS	 plots,	 the	 ANOVA	
test	 and	 quantitative	measures,	mean	 absolute	 difference	 between	 replicates	 and	
the	 differentially	methylated	 region	 standard	 error	 (DMRSE)	measures	were	 used.	
Additionally,	 two	 approaches	 were	 taken	 to	 test	 the	 underlying	 biological	
information	 was	 preserved	 between	 samples;	 namely,	 an	 association	 analysis	




hierarchical	 cluster	 dendrograms	 were	 generated	 using	 all	 probes	 with	 the	 hclust	
function	 using	 the	 Euclidean	 distance	 method	 from	 the	 default	 R	 package,	 stats.	
Cluster	 dendrograms	 group	 samples	 by	 differences,	with	 similar	 samples	 grouping	
together.		
	
MDS	 plots	 were	 clustered	 by	 batch	 or	 family,	 then	 analysis	 of	 variance	 was	
performed	 on	 the	 first	 principal	 component	 from	 a	 principal	 component	 analysis	
	 76	
(PCA)	on	the	1000	most	variable	beta	values	using	the	aov	and	prcomp	functions	in	
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control	 metric	 (Pidsley	 et	 al.	 2013).	 These	 regions	 are	 expected	 to	 have	 allele-
specific	methylation	and	a	β	value	of	0.5,	and	therefore	deviation	from	this	value	can	
be	examined	as	a	standard	error-type	measure,	denoted	DMRSE	in	the	wateRmelon	
package.	 	The	dmrse_row	 function	was	used	 to	measure	dispersion	of	methylation	
between	 samples	 for	 each	 normalisation	 method.	 A	 lower	 value	 indicates	
methylation	values	are	more	tightly	aligned	with	expected	methylation	levels.	
	
Whilst	 evidence	 of	 clustering	 according	 to	 familial	 relationships	 following	
normalisation	 correction	 provides	 some	 confidence	 that	 biological	 integrity	 of	 the	
data	 is	 preserved,	 to	 further	 test	 the	 preservation	 of	 biologically	 relevant	
information,	 we	 examined	 detectable	 associations	 of	 known	meQTLs	 in	 our	 data.	
Shoemaker	and	colleagues	have	previously	identified	736	CpG	sites	to	be	associated	
with	 SNPs	 in	 cis	 (Zhang	 et	 al.	 2010).	 Here,	 cg17749961,	 one	 of	 the	 ten	 most	
significant	hits	reported	by	Shoemaker	et	al.,	was	examined	in	a	subset	(22	males)	of	
the	 39	 individuals,	 for	 whom	 both	 methylation	 and	 genotyping	 SNP	 data	 was	
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available.	 Association	 analysis	 was	 performed	 between	 this	 probe	 site	 and	 SNPs	
located	 within	 a	 2Mb	 window	 adjacent	 to	 this	 site,	 using	 linear	 regression,	 and	
assuming	an	additive	disease	model.	Relatedness	was	adjusted	for	by	fitting	a	linear	
mixed	model	on	the	methylation	of	cg17749961	and	a	kinship	matrix,	determined	by	
the	 Identity-by-State	 function	 in	 the	 GenABEL	 R	 package	 (GenABEL	 project	






















one	 sample	 in	 each	 of	 the	 three	 batches	 was	 replicated,	 providing	 five	 technical	
replicates	 in	 addition	 to	 the	 three	 unique	 samples	 on	 each	 batch,	 to	 permit	
generation	 of	 data	 from	 analysis	 of	 the	 same	 biological	 sample.	 In	 data	 lacking	
technical	 bias,	 replicate	 samples	 would	 be	 expected	 to	 generate	 the	most	 similar	
methylation	 profiles,	 while	 methylation	 profiles	 generated	 from	 closely	 related	
individuals	should	also	cluster	tightly	compared	to	distantly	or	unrelated	individuals.	
However,	 if	 technical	bias	such	as	a	batch	effect	has	been	 introduced,	 this	distorts	
the	 profiles	 and	 samples	 no	 longer	 cluster	 by	 biological	 similarity	 but	 instead	 the	
most	evident	grouping	would	be	by	batch.		
	
Batch	 effect	 (between	 array	 variation)	 was	 initially	 examined	 using	 density	
distribution	plots	(Figure	3.2).	Figure	3.2A	comprising	raw	values	from	all	3	batches	
reveals	 significant	 bias.	 The	 greatest	 contributor	 to	 batch	 effect	 was	 the	 date	 on	
which	the	BeadChips	were	processed,	with	bisulphite	conversion	performed	on	the	
same	 day	 as	 BeadChip	 processing.	 Employing	 a	 stratified	 QN	 (Figure	 3.2C)	 and/or	
ComBat	 normalisation	 (Figure	 3.2E)	 dramatically	 reduced	 this	 observed	 effect.	 For	
between	array	biases,	Figure	3.2	shows	the	density	distribution	of	β	values	for	raw	
data	 samples	 (A),	 after	 Stratified	 QN	 (C)	 and	 after	 Stratified	 QN	 combined	 with	


















of	 probe	 I	 and	 II	 types	 become	more	 uniform	 (Figure	 3.2	 B,	 D	 and	 F).	 This	 bias	 is	
driven	 by	 the	 differing	 biochemistry	 of	 the	 probes,	with	 type	 I	 employing	 a	 single	
colour	 channel	 with	 a	 different	 bead	 for	 methylated	 and	 unmethylated	 DNA	 and	
type	II	containing	one	bead	in	two	colour	channels.			The	underlying	biology	targeted	
by	each	probe	 is	 confounded	by	 this	 technical	bias,	 as	 type	 I	measures	CpG	dense	
regions	(such	as	 islands)	while	type	 II	can	only	tolerate	three	CpGs	 in	the	 length	of	
the	 probe.	 As	 such,	 type	 I	 interrogate	 a	 greater	 proportion	 of	 unmethylated	 to	
methylated	 DNA,	 while	 type	 II	 perform	 the	 opposite.	 Removing	 the	 probe	 bias	 is	
imperative	 for	 accurate	 comparisons	 between	 these	 probe	 types	 when	 pooling	
probe	 I	 and	 II	 data,	 which	 is	 necessary	 for	 accurate	 genome-wide	 methylation	
information	of	both	CpG	rich	and	poor	regions.	
	
In	 contrast,	 the	 density	 plots	 of	 β	 values	 for	 other	 normalisation	 (SWAN	 and	
FunNorm)	methods	do	not	 improve	to	the	same	degree	and	 in	some	cases	greater	
variation	is	introduced	(Figure	3.3C-G).	For	example,	a	worsening	of	the	batch	effect	
is	 seen	 for	 SWAN	normalisation	 (Figure	3.3D),	 compared	 to	 raw	data	 (Figure	3.3A)	
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The	 second	 approach	 employed	 to	 examine	 the	performance	of	 the	normalisation	
methods	 was	 to	 generate	multi-dimensional	 scaling	 (MDS)	 plots.	 These	 permitted	
the	 visualization	 of	 the	 two-dimensional	 projection	 of	 the	 differences	 between	





significantly	 reduced	 following	 normalisation	 using	 Stratified	QN	 (Figure	 3.1C)	 and	
Combat	 (Figure	 3.1E)	 corrected	 data.	 The	 strong	 batch	 effect	 masks	 the	 familial	
relationships	 in	the	raw	data,	however	following	correction,	clustering	according	to	
kinship	 is	 clearly	 evident	 (Figure	 3.1F).	 Similarly	 the	 replicate	 samples	 (Figure	 3.4)	
which	group	disparately	 in	 the	raw	data	 (A,B),	co-locate	or	cluster	 tightly	 following	
Stratified	QN	(C,D)	and	ComBat	(E,F).	The	MDS	plots	for	each	normalisation	method	
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MDS plot: Stratified QN with ComBat correction 
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This	 efficacy	 of	 normalisation	methods	 in	 reducing	 clustering	 of	 samples	 by	 batch	
was	 assessed	 quantitatively	 by	 ANOVA	 to	 test	 the	 effect	 of	 batch	 on	 the	 first	
principal	 component.	 The	 ANOVA	 was	 repeated	 for	 each	 normalisation	 method,	
using	M-values	from	the	top	1000	most	variable	sites.	Consistent	with	the	visualized	




For	 a	 final	 qualitative	 measure	 to	 examine	 effectiveness	 of	 between	 array	
normalisation,	 hierarchical	 cluster	 dendrograms	 were	 generated.	 Application	 of	
Stratified	QN	and	ComBat	 (Figure	3.6),	 again	demonstrated	 superior	normalisation	
when	visualized	by	this	method,	with	raw	data	samples	clearly	clustering	into	three	
distinct	groups	(Figure	3.6A),	stratified	QN	resulting	in	improved	clustering	(B)	while	
ComBat	 batch	 correction	 following	 Stratified	 QN	 completely	 removes	 the	 batch	
effect	 (C)	 permitting	 the	 desired	 outcome	 with	 related	 individuals	 clustering	
















To	 quantitatively	 assess	 the	 performance	 of	 these	 normalisation	 methods,	 the	
median	absolute	difference	in	M-values	was	calculated	for	6	replicate	pairs,	with	one	
sample	from	each	pair	interrogated	on	a	separate	batch.	With	the	exception	of	one	
pair,	 Stratified	 QN	 with	 ComBat	 was	 found	 to	 have	 the	 lowest	 absolute	 median	
difference	 between	 technical	 replicate	 pairs,	 corresponding	 to	 the	 highest	








Normalisation	Method	 Pair.1	 Pair.2	 Pair.3	 Pair.4	 Pair.5	 Pair.6	
Raw	 0.557	 0.397	 0.639	 0.255	 0.974	 0.721	
Quantile	Normalisation	 0.335	 0.612	 0.378	 0.322	 0.610	 0.414	
Stratified	Quantile	
Normalisation	 0.258	 0.377	 0.309	 0.268	 0.381	 0.330	
BMIQ	 0.569	 0.414	 0.646	 0.271	 0.980	 0.726	
SWAN	 0.676	 0.375	 0.751	 0.247	 1.003	 0.808	
Functional	Normalisation	 0.334	 0.511	 0.378	 0.312	 0.590	 0.398	
Dasen	 0.250	 0.399	 0.290	 0.253	 0.399	 0.313	
Noob	 0.414	 0.646	 0.410	 0.411	 0.916	 0.621	
Raw	with	ComBat	 0.263	 0.268	 0.258	 0.236	 0.336	 0.261	
Stratified	Quantile	
Normalisation		with	ComBat	 0.193	 0.313	 0.218	 0.210	 0.270	 0.223	
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Finally,	 standard	 error	 measures	 for	 imprinted	 regions	 were	 calculated	 and	
compared	 between	methods	 as	 described	 in	 the	 statistical	 analysis	 section	 of	 the	
methods.	 	 Smaller	 values	 indicate	 lower	errors	and	more	 reliable	data.	A	 standard	
error	measure	 (DMRSE)	of	0.0048	was	 calculated	 for	 the	 raw	data,	with	 this	 value	
increasing	 with	 following	 normalisations	 using	 QN	 (0.0052),	 Noob	 (0.0052)	 and	
Functional	Normalisation	(0.0056).	The	remaining	normalisation	methods	generated	










































Critical	 to	 any	 normalisation	 method	 is	 the	 maintenance	 of	 true	 biological	
differences	between	samples.	As	described	 in	 the	 statistical	analysis	 section	of	 the	
methods,	 a	 previously	 identified	 meQTL	 (cg17749961,	 	 (Zhang	 et	 al.	 2010))	 was	
selected	 to	perform	association	analysis	with	prior	 to	 and	 following	normalisation.	
Following	 Bonferoni	 correction,	 a	 significant	 association	 was	 detected	 in	 the	 raw	
data	(Figure	3.8A,	p-value=7.29e-06),	increasing	markedly	after	Stratified	QN	(Figure	
3.8B,	p-value=3.53e-07).	After	ComBat	(C)	there	was	a	drop	in	significance	compared	
to	 Stratified	 QN	 and	 Raw	 data,	 yet	 the	 p-value	 was	 still	 highly	 significant	 (p-
value=1.05e-05)	indicating	preservation	of	the	biological	information	of	interest.	The	
drop	in	significance	after	batch	correction	may	be	explained	as	confounding	between	
batch	 and	 family,	 which	 is	 removed	 after	 ComBat.	 Ideally,	 samples	 would	 be	
randomised	across	experiments,	however	the	nature	of	familial	studies	is	such	that	
this	 is	not	always	possible,	as	 samples	are	collected	at	different	 time	points,	often	





















analysis	 of	 methylation	 array	 data,	 and	 comprehensive	 review	 articles	 evaluating	
their	utility	have	been	published	(Touleimat	and	Tost	2012;	Marabita	et	al.	2013;	Pidsley	et	al.	2013;	Morris	and	Beck	2015).	The	majority	of	these	are	designed	for	
specific	 types	 of	 sample	 sets,	 particularly	 those	 comprised	 of	 two	 distinct	 groups	
such	 as	 case-control	 or	 cancer-normal	 with	 substantial	 methylation	 differences	
between	the	two	groups.	For	different	data	sets,	such	as	those	from	familial	studies,	
which	 include	 complex	 pedigree	 structures	 instead	 of	 two	 distinct	 groups,	 these	
methods	 may	 be	 ineffective	 or	 even	 worse,	 detrimental	 in	 that	 they	 introduce	
technical	bias,	as	identified	with	selected	methods	in	the	analysis	reported	here.	To	
correctly	 normalise	 data,	 it	 is	 critical	 to	 choose	 the	most	 appropriate	method,	 yet	
there	 has	 been	 little	 focus	 on	 developing	 appropriate	 processing	 pipelines	 for	
familial	methylation	array	analysis,	despite	the	current	interest	in	inherited	drivers	of	
methylation	patterns.	Further	barriers	are	the	various	format	requirements	and	the	
lack	of	 integration	 to	provide	 a	 seamless	 processing	pipeline.	Here,	 eight	 different	
methods	have	been	tested	and	a	best-practice	pre-processing	pipeline	presented	for	
familial	data	(depicted	 in	Figure	3.9).	This	pipeline	creates	a	template	to	guide	and	

















































A	 fundamental	 requirement	 for	 processing	 methylation	 array	 data	 is	 effective	
adjustment	 for	 technical	 bias,	 including	 batch	 effects	 and	 adjusting	 for	 the	 two-
probe	biochemistry	of	the	array.	Batch	effects	may	be	introduced	through	bisulphite	
conversion	or	downstream	processing	or	variation	in	array	quality.	Various	methods	
have	 been	 developed	 to	 adjust	 for	 these	 effects,	 mostly	 involving	 variations	 in	
quantile	 normalisation,	 a	 technique	 commonly	 used	 in	 analysis	 of	 microarray	









the	 best	 available	 knowledge,	 optimal	 pre-processing	 methods	 for	 familial	 based	
data,	 such	 as	 performed	 here,	 have	 not	 been	 previously	 reported.	 Normalisation	
methods	 necessarily	 make	 assumptions	 about	 data,	 with	 the	 accuracy	 of	 these	








genomic	 region	and	 is	 thus	 ideal	 for	data	where	 the	differences	between	adjacent	
genomic	 loci	 are	maintained.	 This	 is	 in	 contrast	 to	 tumour-normal	 tissue	 datasets	









technical	 bias	 while	 maintaining	 known	 biologically	 relevant	 information	 such	 as	
relatedness	 and	 familial	 clustering	 by	methylation.	 A	 diagnostic	metric	 accounting	
for	 a	 known	 relationship	 could	 be	 used	 to	 test	 the	 efficacy	 of	 pre-processing	
methods	 in	 a	 similar	 manner	 to	 the	 standard	 error	 associated	 with	 imprinted	
differentially	methylated	regions	(iDMRs)	from	the	wateRmelon	package.		
	
It	may	also	be	of	 importance	 for	 researchers	 to	 consider	 the	undesirable	effect	of	
non-specific	binding	and	the	presence	of	SNPs	in	the	probe	body.	A	study	from	the	
Weksberg	 lab	 found	 around	 6%	 of	 probes	 on	 the	 array	 cross-hybridised	 to	 non-
targeted	 genomic	 regions	 (Chen	 et	 al.	 2013).	 They	 have	 catalogued	 these	 probes	
and	 suggest	 removing	 them	 prior	 to	 downstream	 analysis.	 Their	 study	 also	
demonstrates	SNPs	in	the	probe	body	can	interfere	with	probe	binding,	altering	the	
	 99	
methylation	 signal	 at	 around	 14%	 of	 sites.	 Illumina	 recommends	 all	 probes	
containing	 a	 SNP	within	 10bp	 of	 the	 interrogated	 CpG	 site	 ought	 to	 be	 removed,	
while	 others	 suggest	 the	 ‘probe	effect’	 continues	 to	 the	 entire	 50bp	 length	of	 the	







type	 for	both	methylated	and	unmethylated	sites	of	 interest,	with	 the	methylation	
status	of	the	loci	designated	by	the	addition	of	a	different	coloured	nucleotide	(red	
or	 green)	 at	 the	 single	 base	 extension.	 As	 type	 II	 probes	 terminate	 one	 base	 pair	
before	the	cytosine	of	the	CpG	dinucleotide,	a	mutation	at	the	cytosine	itself	would	
not	 affect	 probe	 binding.	 As	 such,	 probes	 without	 SNPs	 in	 the	 probe	 body	 but	
present	 at	 the	 single	base	extension	 can	 reliably	be	used	 to	examine	 the	effect	of	




imperative	 and	 requires	 appropriate	 pre-processing	 to	 minimize	 technical	 errors,	
which	will	be	dictated	by	the	type	of	data.	Stratified	QN	in	combination	with	ComBat	
batch	 correction	 performed	 the	 best	 of	 those	 methods	 tested	 for	 normalising	
	 100	
familial	 data	 interrogated	 on	 methylation	 array.	 This	 method	 was	 observed	 to	
remove	technical	biases	while	maintaining	biologically	relevant	information;	allowing	
true	 biological	 differences	 and	 similarities	 to	 inform	 the	 search	 for	 the	 role	 of	
methylation	 patterns	 driving	 disease	 processes.	 The	workflow	 presented	 in	 Figure	
3.9	outlines	the	methodology	adopted	to	pre-process	familial	data	in	this	study.	This	
may	 also	 be	 instructive	 for	 other	 studies	 using	 familial	 data,	 including	 longitudinal	


































































































































































































































































































A	 SNP	 genome	 wide	 scan	 using	 the	 Affymetrix	 CNV370	 array	 using	 Tasmanian	
Familial	 Prostate	 Cancer	 dataset	 comprising	 265	 individuals	 of	 which	 171	 were	
affected	cases,	and	one	or	two	offspring	of	deceased	cases	representing	a	further	71	
cases.	Plot	generated	using	IBD	sharing	calculated	using	the	fast	IBD	sharing	option	
in	 BEAGLE	 for	 265	 individuals	 representing	 prostate	 cancer	 cases	 and	 children	 of	
diseases	cases.	A	reference	group	of	373	unrelated	Tasmanian	controls	was	used	as	a	
control	 dataset.	 Each	 individual	 chromosome	 is	 numbered.	 Note,	 the	 major	














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Number	of	windows	 143	 5723	 242	 6108	










significance	threshold	of	10	 4	 8	 36	 48	
Number	of	CpG-SNPs	with	a		–log10(p-value)	above	the	
adjusted	significance	using	Bonferroni	Correction	 6	 16	 30	 52	
Number	of	CpG-	with	a		–log10(p-value)	above	the	
adjusted	significance	threshold	of	10	 4	 7	 22	
33		
(69%)	













































































































































1	 cg13387643	 no	 rs284310	 CASZ1	 Zinc	finger	transcription	factor,	may	function	as	tumor	suppressor	




3	 cg25013753	 no	 rs1051508	 ARHGAP22	 Regulates	cell	motility	&	angiogenesis.	May	be	involved	in	transcription	regulation	via	interaction	with	VEZF1	
4	 cg08210706	 no	 rs10135403	 SERPINA5	 Inhibits	urinary-type	plasminogen	activator-dependent	tumor	cell	invasion	and	metastasis	
5	 cg00231519	 no	 rs36101953	 C10orf46	 Cell	cycle	associated	protein	capable	of	promoting	cell	proliferation	
6	 cg02978201	 no	 rs737008	 PRM1	 Protamines	substitute	for	histones	in	the	chromatin	of	sperm	during	the	haploid	phase	of	spermatogenesis	
7	 cg00345083	 no	 rs7517857	 AJAP1	 Plays	a	role	in	cell	adhesion	and	cell	migration	









9	 cg20592836	 yes	 rs2378256	 TP53INP2	 Dual	role	as	transcription	factor	&	in	autophagy	
10	 cg02464073	 no	 rs1721	 ITGB2	 Important	role	in	immune	response.	Defects	in	gene	cause	leukocyte	adhesion	deficiency	&	gastrointestinal	carcinoma	
11	 cg08146865	 yes	 rs3197223	 NME6		 Inhibitor	of	p53-induced	apoptosis	
12	 cg23698271	 no	 rs11199030	 TIAL1	 RNA-binding	protein,	regulates	various	activities	including	translational	control,	splicing	&	apoptosis	
13	 cg21927991	 yes	 rs5025124	 ZFAT	 Puatively	binds	DNA	&	functions	as	a	transcriptional	regulator	involved	in	apoptosis	and	cell	survival	




15	 cg06330797	 yes	 rs7357046	 RPS6KA2		 Implicated	in	cell	growth	&	differentiation,	may	function	as	tumor	suppressor	in	ovarian	cancer		









18	 cg01891583	 yes	 rs2304466	 USP7		 May	induce	p53/TP53-dependent	cell	growth	repression	&	apoptosis	
19	 cg05161773	 yes	 rs426439	 S	EPT9	 Involved	in	cytokinesis	&	cell	cycle	control,	possible	ovarian	tumor	suppressor	gene.	Chromosomal	translocation	results	in	
	 133	
acute	myelomonocytic	leukemia	
20	 cg11251367	 yes	 rs12403072	 FMN2	 Role	in	organization	of	cytoskeleton	&	cell	polarity.	Involved	in	responses	to	DNA	damage		
21	 cg09993319	 yes	 rs7898151	 MGMT		 Involved	in	Cell	Cycle	&	DNA-methyltransferase	activity	
22	 cg04610028	 yes	 rs2967607	 RAB11B		 Involved	in	regulating	exocytotic	and	endocytotic	pathways		
23	 cg05338731	 no	 rs5751591	 RAB36	 Associated	with	rhabdoid	cancer	
24	 cg02658043	 yes	 rs7465214	 NRBP2	 Associated	with	medulloblastoma	
25	 cg26365090	 yes	 rs11700304	 TOX2	 RNA	polymerase	II	transcription	factor	binding.	Putative	transcriptional	activator	
26	 cg17662493	 yes	 rs6006744	 SMC1B	 Involved	in	chromatid	cohesion	and	DNA	recombination	during	meiosis	and	mitosis		
27	 cg03796003	 yes	 rs117229426	 KCTD5		 Associated	with	rectal	neoplasm		







29	 cg03036702	 No	 rs4714482	 FOXP4	 Transcription	factor,	may	play	a	role	in	tumors	of	the	kidney	&	larynx	








		 CpG	Name	 Variable	Approach	 CpG-SNP	 Gene	 Gene	Function	
		 cg11251367	 Yes	 rs12403072	 FMN2		 Role	in	organization	of	actin	cytoskeleton	&	cell	polarity.	Involved	in	responses	to	DNA	damage,	cellular	stress	&	hypoxia		
31	 cg00069771	 No	 rs17452776	 C1orf57	 Involved	in	purine	metabolism		
32	 cg23209941	 No	 rs12137417	 DISC1-TSNAX	 DISC1:	involved	in	neurite	outgrowth	&	cortical	development	
33	 cg07134368	 No	 rs12034296	 TSNAX-DISC1	
TSNAX:	Interacts	with	DNA-binding	protein	that	binds	consensus	
sequences	at	breakpoint	junctions	of	chromosomal	translocations	
	 	 	 	 	 		
E)	meQTLs	identified	through	published	prostate	cancer	GWAS		
		 CpG	Name	 Variable	Approach	 CpG-SNP	 Gene	 Gene	Function	
34	 cg23069046	 No	 rs6920276	 REXO2	 Possible	role	in	DNA	repair,	replication,	recombination	
		 cg03036702	 No	 rs4714482	 FOXP4	 Transcription	factor,	implicated	in	kidney	&	larynx	tumors	
35	 cg09349613	 No	 rs72828989	 CTBP2	 One	alternative	transcript	is	a	transcriptional	repressor	
36	 cg13301327	 No	 rs11696871	 ZBTB46	 Zinc	Finger,	GO	annotations	include	nucleic	acid	binding	

















































































































































































































































































































































































































1 CASZ1 930 2 cg13387643 rs284310 C/00>/T No Yes T=0.30 OpenSea Body intron 29 YES 34
2 ITGB2 1217 21 cg02464073 rs1721 C/00>/T Yes NA T=0.46 Shore TSS1500 UTR 16 YES 27
3 NME6 751 3 cg08146865 rs3197223 C/00>/T Yes NA T=0.18 OpenSea 3'UTR UTR 11 NO/ 27
4 C10orf46 946 10 cg00231519 rs36101953 C/00>/T No Yes T=0.26 Shore TSS1500 intron 12 NO 24
5 PRM1 680 16 cg02978201 rs737008 C/00>/A Yes NA A=0.49 OpenSea Body exon/+++ 27 NO 22
6 FOXK2 880 17 cg05331763 rs79974293 G/00>/A No No A=0.03 Shore Body intron 33 NO 22
7 USP7 817 16 cg01891583 rs2304466 G/00>/A Yes NA A=0.42 OpenSea Body intron 28 YES 22
8 SEPT9 1183 17 cg05161773 rs426439 C/00>/T No Yes T=0.33 OpenSea Body intron 20 YES 21
9 MGMT= 945 10 cg09993319 rs7898151 /G/00>/A/ No Yes G=0.43 OpenSea Body intron 21 YES 19
10 RAB11B 782 19 cg04610028 rs2967607 C/00>/T No No T=0.36 Shore Body intron 51 NO 19
11 AJAP1 735 1 cg00345083 rs7517857 G/00>/A Yes NA G=0.50 Shore Body intron 22 NO 15
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WHY EPIGENETICS AND WHY NOW?
The genomics era brought with it dra-
matic advances in our understanding of
the molecular basis of disease. High-
density genome mapping strategies
have proven particularly successful for
the identification of genes underlying
mendelian disorders, such as hemochro-
matosis, cystic fibrosis and muscular
dystrophy (1). The advent of genome-
wide association studies (GWAS) was
heralded with the promise of providing
a comprehensive map of genetic suscep-
tibility to complex disease. While un-
covering thousands of variants associ-
ated with disease risk, their promise is
yet to be fully realized, with a persistent
gap emerging between the fraction of
disease accounted for by genetic varia-
tion and the heritability estimates for
many traits (2). Several explanations
have been proposed for this unex-
plained genetic component to disease
susceptibility, including the impact of
large deletions, inversions or copy num-
ber variants, complex gene–gene and
gene–environment interactions, overes-
timated heritability, poor modeling and
statistical application and common vari-
ants masking rare variants or driving
synthetic association (2). Notably, dele-
terious variants occurring in coding re-
gions account for the minority of
 disease-associated single nucleotide
polymorphisms (SNPs), with estimates
that over 90% of variants identified in
GWAS are located in noncoding regions
of the genome (3). At least some of these
SNPs affect gene regulatory mecha-
nisms, modifying gene expression by al-
tering transcription factor binding and
directing altered epigenetic profiles (4).
Studies involving genetically identical
individuals such as monozygotic (MZ)
twins have been invaluable in investigat-
ing the role of genetics and environment
in complex disease. While providing in-
sight into the genetic basis of disease,
these studies have also strongly impli-
cated a nongenetic contribution to many
diseases. For example, MZ twins have
much less than 100% concordance rates
for common diseases such as Alz-
heimer’s disease and certain cancers (5).
The effect of the environment and ran-
dom factors on the epigenome poses a
possible explanation for this discordance,
since while MZ twin epigenetic profiles
show a high level of heritability early in
development, they diverge with age and
differing lifestyles and epigenetic marks
differ according to disease state (5).
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Our understanding of the factors affect-
ing the epigenome is increasing at a rapid
rate. The role of the underlying genetic se-
quence in determining epigenetic profiles
and the mechanisms by which environ-
mental and stochastic factors then modify
these epigenetic patterns are becoming
clearer. Our increased understanding of
these mechanisms and their role in dis-
ease processes is being driven by rapid
advances in laboratory and statistical
tools and the creation of extensive public
databases. This result makes it possible to
integrate genomic, epigenomic and phe-
notypic data with a greater level of detail
and scale than ever before (6) (see Figure 1
for a timeline of epigenetic milestones, in-
cluding the advent of online annotation
databases). This information is providing
a valuable resource for the investigation
of complex disease, revealing new oppor-
tunities for disease prevention in at-risk
individuals, identifying new therapeutic
targets and providing the prospect of in-
creased sensitivity and specificity of dis-
ease diagnosis (7).
A BRIEF HISTORY OF EPIGENETICS
Conrad Waddington first coined the
term “epigenetics” in the early 1940s to
integrate the existence of two related phe-
nomena: that genetically identical cells
possess the capacity to differentiate into
tissue-specific structures with correlated
functions and that gene–environment 
interactions can affect phenotypes
(reprinted in Waddington [8]). The term
“epigenetics” has since come to refer to
the environment surrounding the DNA,
with a current working definition charac-
terizing an epigenetic trait as “a stably
heritable phenotype resulting from
changes in a chromosome without alter-
ations in the DNA sequence” (9). This
term is most often used in reference to
the inheritance of traits to a daughter cell
during mitosis, but there is evidence, al-
though still controversial, of germ line
transmission of epigenetic traits between
generations (transgenerational inheri-
tance) (10,11).
Eukaryotic DNA is assembled into
chromatin; repeating units of nucleo-
somes consisting of 147 base pairs of
DNA wrapped around an octamer of his-
tones. Mechanisms that affect the ge-
nomic environment include modifications
to the DNA itself, absence/presence of hi-
stone modifications and histone variants,
and also processes involving noncoding
Figure 1. Timeline of key advances in the epigenetics field. Key milestones in the epigenetics field are shown.
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RNA and chromatin remodeling com-
plexes (12) (Figure 2). Although there is
contention over the extent of heritability
of the outcomes of many of these mecha-
nisms and whether they should therefore
strictly be regarded as epigenetic mecha-




DNA methylation, the addition of a
methyl group to a cytosine residue im-
mediately preceding a guanine (CpG
dinucleotides), is the most widely stud-
ied epigenetic modification. CpG dinu-
cleotides are enriched in clusters called
CpG islands, associated with the pro-
moter regions of up to 60% of genes (13).
DNA methylation is generally associated
with gene silencing, inhibiting gene ex-
pression by recruiting proteins that facili-
tate chromatin condensation and to a
lesser extent by physically blocking tran-
scription factor binding (13).
DNA methylation patterns are influ-
enced by the underlying genetic se-
quence, stochastic changes, environmen-
tal factors and other epigenetic
mechanisms, resulting in differing
methylation patterns across populations,
age, tissue and loci (14). DNA methyl-
transferases (DNMTs) ensure tissue-spe-
cific DNA methylation patterns, once es-
tablished, are maintained through
mitosis with high precision and fidelity
(13). In contrast, at a global level, methy-
lation is substantially wiped clean during
gametogenesis to provide the developing
embryo the capacity for totipotency and
prevent accumulation of epigenetic
changes from previous generations (15).
This reprogramming occurs in two
waves: first, during pre-implantation
Figure 2. Epigenetic characteristics of heterochromatin and euchromatin. Nucleosome complexes consisting of eight core histone pro-
teins and 147 bp of DNA are configured in higher order structures that regulate the accessibility of DNA to the transcriptional machinery.
(A) Heterochromatin is characterized by DNA hypermethylation (filled black circles), de-acetylated histones (clear purple stars) and
tightly packed nucleosomes. Noncoding RNA is involved in maintaining heterochromatin structure. (B) Euchromatin contains unmethy-
lated CpGs (unfilled circles), acetylated histones (purple stars) and histone variants H2A.Z and H3.3 and is more accessible to the tran-
scription machinery (green). Writers, readers and erasers of epigenetic modifications work in concert with chromatin remodeling com-
plexes to move and modify nucleosomes, altering chromatin composition. TF, transcription factor; TSS, transcription start site.
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and, second, after primordial germ cell
migration, including the removal of im-
printed marks (16).
Genomic reprogramming involves
both active and passive demethylation,
which has long perplexed the scientific
community because of their inability to
identify the enzyme responsible for this
demethylation. Insight into this process
has been gained only recently after the
discovery of the additional DNA modifi-
cation, hydroxymethylation, enriched in
Purkinje cells in the brain (17) and also
embryonic stem cells (18,19). The ten-
eleven translocation (TET) family of pro-
teins are responsible for this modifica-
tion, and there is evidence that it is an
intermediate in the process of active
demethylation (20). However, the high
levels of the modification, particularly in
neural cells and during embryonic devel-
opment, suggests that it may have a yet-




Packaging of the vast quantity of DNA
into the eukaryotic nucleus is facilitated
by the assembly of DNA into nucleo-
somes followed by their compaction into
higher-order structures. This structural
organization also plays a fundamental
role in regulating accessibility of the
DNA to the cellular transcription ma-
chinery (12) (Figure 2).
Up to a dozen posttranslational modi-
fications of histone proteins have been
reported to date, including methylation,
acetylation, phosphorylation and ubiqui-
tination (12), and technological advances
have made it possible to map these mod-
ifications genome-wide (21). These modi-
fications have together been proposed to
form a histone code, which can be inter-
preted by cellular proteins to specify
downstream functions (22). In addition,
chromatin structure is altered by the ac-
tions of ATP-dependent chromatin re-
modeling enzymes and the exchange of
canonical histones with histone variants.
This step creates a highly dynamic,
adaptable epigenetic landscape that
plays a key role in regulating genome
function and provides an interface be-
tween the environment and the genome.
Although histone modifications can be
subject to rapid turnover, there is also ev-
idence that they can be stably inherited
during cell division and thus contribute
to the maintenance of cellular identity.
However, this apparent epigenetic mem-
ory may be initiated by other factors
such as DNA methylation, noncoding
RNA (ncRNA), transcription factors or
the underlying DNA sequence (12).
Three recent studies point to an impor-
tant role of genetic variants in determin-
ing histone modification patterns
(23–25). In these studies, hundreds of
variants were associated with changes to
histones and gene expression, with the
underlying mechanism thought to be al-
tered transcription factor binding.
Noncoding RNA
In recent years, the existence of a com-
plex network of ncRNAs transcribed
from the human genome has become ap-
parent. These ncRNAs have regulatory
functions and play a key role in the es-
tablishment and maintenance of other
epigenetic marks (26), with evidence that
they constitute a mechanism for trans-
generational epigenetic inheritance (27).
There is also mounting evidence for the
involvement of ncRNAs in disease devel-




Diminished genetic noise and the in-
nate advantage of perfect age and often
sex matching, frequently coupled with
similar environmental and socioeco-
nomic upbringing, ensures twin studies
play an invaluable role in understanding
epigenetic mechanisms (29). The first
twin studies examining DNA methyla-
tion focused on X-chromosome inactiva-
tion, finding that the selection of which
X-chromosome is inactivated is not as
random as previously thought, but is in-
fluenced to a degree by underlying heri-
table patterns (30). Vickers et al. (30) also
showed that, with increasing age, there
was a greater skew in inactivation pat-
terns, suggesting twins become epigenet-
ically dissimilar with age. This result was
later reinforced by several larger studies
that found a high degree of epigenetic
heritability among MZ twins that de-
creased with age and that found larger
discrepancies between twins that lead
different lifestyles (5).
More recently, the advent of methyla-
tion array technology has enabled more
extensive studies that have found MZ
twins to be more epigenetically similar
than dizygotic twins. These studies also
found that the most heritable CpG sites
correlated with functional regions and
promoters, indicating these regions are
under tighter genetic control (31). Addi-
tionally, MZ DNA methylation patterns
may be influenced by the chorionicity of
the prenatal environment. Perhaps, sur-
prisingly, monochorionicity (a single
shared placenta) has been linked to more
divergent methylation patterns, yet
chorionicity is not always accounted for
in MZ twin studies (32). These studies
provide evidence for epigenetic differ-
ences in genetically identical individuals,
suggesting epigenetic metastability inde-
pendent of genotype can occur in hu-
mans, as has been previously shown in
mouse models (33). However, they also
point to certain regions where genetic in-
fluences exert greater control on the
epigenome.
Further evidence from studies examin-
ing DNA methylation patterns among
family members and unrelated individu-
als found SNPs induce subtle epigenetic
variation. One of the first studies to ex-
amine the relationship between genetic
variants and DNA methylation patterns
found evidence for allele-specific methy-
lation (ASM) outside imprinted regions,
some linked to allele-specific gene ex-
pression (34). Examination of the effect of
genetic variants on DNA methylation in
a three-generation family and among un-
related individuals found that heterozy-
gous SNPs associated with different
methylation patterns (35). This differen-
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tial methylation also correlated with
gene expression. Globally, genetic vari-
ants were found to be more influential
than imprinting, and most of the ASM
(75%) observed in the family was also
present in unrelated individuals, sug-
gesting genotype influences heritable re-
gions of differential methylation.
Other studies estimate around 20% of
heterozygous SNPs are linked to ASM
(36). Alternative terms have been pro-
posed for these variants, including
methylation-associated SNPs (mSNPs)
(37), CpG-SNPs (36) and methylation
quantitative trait loci (meQTL) (38). Hun-
dreds of these genetic variants have been
linked to DNA methylation patterns and,
similar to genetic quantitative trait loci,
these variants can affect gene expression
and phenotype (34,36–38). While SNPs in
the vicinity of CpG sites influence methy-
lation levels, the most obvious variant af-
fecting methylation is a mutation at the
CpG site itself. Indeed, most of the SNPs
linked to ASM are located at the CpG site
and are designated meSNPs (36,39).
These meSNPs also influence the methy-
lation levels of neighboring CpGs, partic-
ularly those close by (within 45 base pairs
[bp]) but have also been show to affect
CpGs up to 10 kb away (39).
GENETIC VARIANTS CAUSING
EPIGENETIC CHANGE IN DISEASE
Although there is no shortage of stud-
ies demonstrating a role for epigenetic
changes in driving disease, there are now
a number of examples in which cis-acting
variants have been clearly demonstrated
to drive the disease-associated epimuta-
tions. The term “epimutation” refers to an
altered epigenetic state resulting in altered
transcriptional activity of a gene. Such cis-
acting variants have been shown to alter
DNA methylation patterns and gene ex-
pression in a variety of human tissues
(34,36). These changes are likely an indi-
rect result of altered binding of transcrip-
tion factors, which can either lead to al-
tered recruitment of chromatin modifiers
and remodelers and subsequent epige-
netic changes or can cause changes in
gene expression that predispose the gene
to epigenetic silencing (40). Comprehen-
sive genetic analysis facilitated by im-
proved technology has revealed that sev-
eral diseases involving epigenetic
dysfunction have genetic origins.
One such example is the X-linked neu-
rodevelopmental disorder, fragile X syn-
drome. The genetic defect involves ex-
pansion of a trinucleotide repeat
sequence (CGG) at the promoter of the
fragile X mental retardation gene
(FMR1), with up to 45 repeats in unaf-
fected individuals and up to 200 in af-
fected individuals (41). The repeat ex-
pansion results in methylation of the
region and subsequent epigenetic silenc-
ing of the gene.
A more distally acting example of se-
quence variation contributing to disease
through altered gene regulation involves
the Myc transcription factor. Activation
of the Myc transcription factor is sug-
gested to occur in up to 70% of cancers,
arising through a range of mechanisms
including translocations, gene amplifica-
tion, enhanced protein translation and
stability, or indirectly through signaling
pathways that regulate Myc (42). In addi-
tion, a number of GWAS have found
multiple SNPs on chromosome 8q24 as-
sociated with different types of cancer
(43). These SNPs occur in a gene desert
but have since been found to influence
regulation of the Myc oncogene located
hundreds of kilobases away. These re-
gions have been shown to contain distal
enhancers of the Myc gene and highlight
that changes to long-range chromatin
structures can result in altered gene ex-
pression (44).
Imprinting Disorders
Imprinted genes escape the initial
phase of epigenetic reprogramming after
fertilization, retaining their parental
methylation marks and are expressed in
a parent of origin manner (45). Around
100 such imprinted genes are currently
known, with this number continuing to
increase (45). Imprinting provides clear
evidence that epigenetic modifications
can be inherited through meiosis, and
specific diseases ensue when there is an
abnormality in either the erasure of exist-
ing marks or reestablishment and main-
tenance of new marks (45). These dis-
eases can result from underlying genetic
defects or be due to epimutations (46).
Prader-Willi syndrome and Angelman
syndrome are neurological disorders with
distinct phenotypes that occur when the
same imprinted region on chromosome
15 is nonfunctional. While the vast major-
ity of cases are caused by a single gene
mutation or chromosomal deletion, be-
tween 1% (Prader-Willi syndrome) and
up to 4% in Angelman syndrome are due
to an imprinting defect, with the majority
of these being primary epimutations, oc-
curring in the absence of DNA sequence
mutations (47). Maternally inherited de-
fects lead to Angelman syndrome,
whereas paternal imprinting errors lead
to Prader-Willi syndrome (47).
Several different disorders result from
disruption of epigenetic regulation at the
IGF2/H19 locus, a region in which herita-
ble factors have been shown to have a
greater impact on DNA methylation than
the accumulation of stochastic and envi-
ronmental-induced changes (48). DNA
methylation at the imprinting control re-
gion upstream of the paternal H19 allele
normally silences H19 expression and ac-
tivates IGF2, whereas the maternal IGF2
allele is silenced (49). In the Silver-Rus-
sell syndrome, a rare developmental dis-
order, 45% of cases are attributed to an
epimutation in the imprinting control re-
gion of the paternal H19 allele (50).
Beckwith-Weidemann syndrome is a
congenital overgrowth syndrome with
83% of cases occurring sporadically, of
which around 60% are thought to in-
volve epimutations of two imprinting
control regions regulating H19, IGF2,
KCNQ1 and CDKN1C (51). Female MZ
twins represent a high proportion of
Beckwith-Weidemann syndrome cases,
and a study of five discordant female
MZ twins found that all affected twins
had a defect at the imprinted locus
KCNQ1OT1, which encodes a noncoding
RNA that regulates the expression of
other imprinted genes (52). Loss of im-
printing at the IGF2/H19 locus is also an
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epigenetic cause of around one-third of
Wilms tumor, the most common renal
cancer in children (49). The defect is also
associated with heightened colorectal
cancer risk (53) and esophageal squa-
mous cell carcinoma (54).
Lynch Syndrome
Whereas epigenetic changes are well
described in disease, particularly cancer,
there are now several clear examples of
cancer-associated epigenetic changes
being genetically driven. These types of
interactions can help to explain features
of these diseases such as late onset, envi-
ronmental effects, tissue specificity and
also familial associations that do not fol-
low mendelian inheritance patterns.
Combining genomic and epigenomic
data is also proving to be of value in the
search for prognostic signatures in cancer
(55), as seen in the Lynch syndrome, an
autosomal dominant cancer susceptibil-
ity condition. Approximately two-thirds
of Lynch syndrome cases result from het-
erozygous loss-of-function mutations in
DNA mismatch repair genes, most com-
monly mutL homolog 1 (MLH1) and
mutS protein homolog 2 (MSH2) (56).
However, such mutations are not ap-
parent in around one-third of Lynch syn-
drome cases, some of which (~4% for
MLH1 [56]) can be explained by epimu-
tations in MLH1 and MSH2. These
epimutations lead to transcriptional inac-
tivation of the gene, essentially having
the same effect as a genomic sequence
mutation seen in other Lynch syndrome
cases. One possible mechanism underly-
ing these epimutations involves primary
DNA methylation changes independent
of any sequence change, resulting in la-
bile epimutations, which can be reversed
in the germline and are therefore inher-
ited in an unpredictable, nonmendelian
manner or not passed on at all.
Alternatively, secondary epimutations
may result from underlying sequence
changes, including promoter deletions
and SNPs (57); for example, the c.-
27C>A germline variant in the 5′UTR of
the MLH1 gene has been linked to can-
cer susceptibility through transcrip-
tional silencing (58). In these cases, the
disease follows a more predictable in-
heritance pattern, since the epimutation
is driven by a genetic variant. As yet
undiscovered sequence mutations may
also be the underlying carcinogenic
mechanism in subsets of cancers such as
Cowden syndrome, where some indi-
viduals have hypermethylation epimu-
tations in the absence of known se-
quence mutations (59).
Underlying genetic drivers have also
been linked to epimutations in sporadic
cases of renal cell cancer, where SNPs
were associated with promoter hyperme-
thylation of the von Hippel-Lindau
(VHL) gene in tumor tissue, a gene previ-
ously shown to be genetically altered in
individuals with the familial form of the
cancer (60). Similarly, in colorectal cancer,
a C>T point mutation at an enhancer ele-
ment of the mismatch repair gene O(6)-
methylguanine-DNA methyltransferase
(MGMT) has been linked to aberrant pro-
moter methylation and gene silencing
(61). Given the recent technological ad-
vances that are enabling integration of
genetic, epigenetic and phenotypic data,
it is likely that more of examples of dis-
eases resulting from genetic drivers of
epigenetic change will be described in
the future.
Genetic Mutations in Epigenetic
Modifiers
Mutations in genes encoding epige-
netic modifiers also contribute to com-
plex diseases, again with cancer being
the best described example. Transloca-
tions, mutations or overexpression of
modifiers such as DNMTs, histone modi-
fying enzymes or chromatin remodeling
proteins are well documented in many
cancers (62). Aberrant epigenetic modi-
fiers can directly affect regulation of tar-
get genes as well as interacting with spe-
cific genetic variants of common
disease-causing SNPs (63). Whereas the
study of other complex diseases are at an
earlier stage, there is accumulating evi-
dence to suggest that disruption to epi-
genetic modifiers plays a role in a range
of other diseases, including diabetes, im-
mune diseases and intellectual disabili-
ties such as autism (63).
The simplest example of a genetic mu-
tation driving an epigenetic change and
contributing to disease is when the
change occurs in a gene encoding an epi-
genetic modifying enzyme. Some of the
more recently described examples in-
clude Kabuki syndrome with mutations
in the histone methyltransferase gene
MLL2 (64) and Coffin-Siris syndrome in-
volving mutations in SWI/SNF subunit
genes (65). Such disorders have been re-
cently reviewed (66). Another straightfor-
ward example of this is in the ICF syn-
drome (immunodeficiency, centromeric
instability and facial anomalies), which
usually arises because of biallelic muta-
tions in the gene encoding the DNMT3B
methylating enzyme (67). The syndrome
is a consequence of loss of DNMT activ-
ity resulting in genomic hypomethyla-
tion. Genomic hypomethylation is a rare
disease, which is invariably fatal in early
childhood. However, the disease displays
phenotypic variability, which is likely
due to the differing effects of individual
mutations on DNMT3B activity (67).
Rett syndrome, an X-linked neurode-
velopmental disorder usually affecting
girls, is also due to genetic defects in an
epigenetic modifier (in this case, the
methyl CpG binding protein MeCP2)
(68). The disease displays delayed onset,
with children developing normally until
1–2 years of age, when they present with
progressive neurological dysfunction.
The largely neurological phenotype of
this disease is likely a result of the re-
quirement for tight regulation of a num-
ber of important neural targets of MeCP2
(69). Variability in disease phenotype is
likely a function of the range of muta-
tions that give rise to the disease as well
as an effect of X-inactivation skewing.
THE EPIGENOME: AN INTERFACE
BETWEEN THE GENOME AND THE
ENVIRONMENT
While the underlying genome plays a
role in determining epigenetic profiles,
stochastic factors and environmental cues
including diet, exercise and toxins bring
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about subsequent changes in the
epigenome, as previously reviewed com-
prehensively (70). There is evidence that
at least some of these changes can then be
passed down through meiosis as trans-
generational epigenetic inheritance
(26,71,72). Whereas the evidence for this
and mechanisms involved are beyond the
scope of this article, they have recently
been comprehensively reviewed (11).
Stochastic Factors
It is now thought that randomly in-
duced epigenetic patterns may also con-
tribute to variation in development and
aging as well as providing a possible
mechanism for the rapid selection of
epigenotypes in response to environmen-
tal pressures. X-chromosomal inactivation
is a classic example of how epigenetic
profiles can be regulated by stochastic
factors. These factors may also explain
discordance between MZ twins (73).
While the effect of environment on
epigenetic profiles, particularly DNA
methylation, is widely acknowledged,
stochastic changes may in fact be more
common than environmentally induced
changes, with a study examining 4,000
human genes, finding 300 to have ran-
dom monoallelic expression (74). Epige-
netic stochasticity can be defined as a
combination of epigenetic variation in
the germline and somatic instability. Sim-
ilar to Richards’ “facilitated epigenetic
variation” model (75), Feinberg and
Irizarry’s “inherited stochastic variation
model” proposes genetic sequence varia-
tion underlies the propensity for epige-
netic variation, since certain DNA se-
quences are not only directly responsible
for particular traits but also increase nat-
ural methylation variation for that trait
(76). Various stochastic and environmen-
tal factors then influence DNA methyla-
tion at these variably methylated regions,
resulting in increased phenotypic differ-
ences, which are then acted on by Dar-
winian selection in a similar manner to
selection pressures affecting purely ge-
netic traits. Subsequent studies found the
sites of greatest DNA methylation vari-
ability in colon cancer corresponded to
the sites of greatest variability in other
cancers, including lung, breast and ovar-
ian cancers, with these sites normally
having distinct tissue-specific DNA
methylation patterns (77). Thus, heritable
DNA methylation variation could pro-
vide some contribution to the unex-
plained heritable genetic component of
common complex diseases.
THE PROMISE OF EPIGENETIC THERAPY
Whereas genetic mutations and chro-
mosomal defects permanently alter the
genome, epigenetic alterations, whether
driven by changes to the underlying ge-
nome or by environmental or stochastic
influences, can potentially be pharmaco-
logically reversed or modified, providing
the promise of restoring gene function,
altered as a result of epigenetic changes
in disease. There is currently consider-
able interest in the development and
clinical translation of pharmacological
agents that target either the writers or
the readers of the epigenetic code. Be-
cause these are mainly enzymes, they
provide an easier target than other gene
regulators such as transcription factors.
For obvious reasons, the use of such
agents is at the most progressed stage in
the treatment of cancers, with two
DNMT and two HDAC inhibiting com-
pounds approved for cancer treatment in
the United States and numerous others
in clinical trials (78) (Figure 3).
In 2004, 5-azacytidine (aza-C) became
the first U.S. Food and Drug Administra-
tion (FDA)-approved epigenetic drug
when it was approved for treatment of
myelodysplastic syndrome (79). An ana-
log of cytidine, the nucleoside is incorpo-
rated into nucleic acid of dividing cells
with a preference for RNA over DNA.
The presence of nitrogen at carbon-5
blocks the addition of a methyl group by
DNMTs, preventing the methylation of
the DNA after cell division. The bound
DNMTs, unable to detach due to the ni-
trogen, form permanent adducts with the
nucleic acid resulting in functional deple-
tion of DNMT from the cell (Figure 3C).
In addition, DNA replication is blocked
(80), and the DNA is functionally com-
promised, activating the p53 damage
pathway, leading to degradation of the
DNA (81) (Figure 3D).
Aza-2-deoxycytidine (decitabine) is
the deoxy form of aza-C and is solely in-
corporated into DNA, avoiding the indi-
rect effects on RNA and protein synthe-
sis of 5-aza-C. Approved in 2006 for
treatment of myelodysplastic syndrome,
it is the only other demethylating agent
currently approved by the FDA. Other
cytidine analogs such as zebularine and
5-fluoro-deoxycytidine are in clinical tri-
als, as are direct DNMT inhibitors in-
cluding procaine, procanamide and hy-
dralazine (78). The two other
FDA-approved epigenetic drugs fall
under the umbrella of histone deacety-
lase inhibitors. Both vorinostat in 2006
and romidepsin in 2009 were approved
for treatment of cutaneous T-cell lym-
phoma (78) (Figure 3A). Interest in tar-
geting epigenetic modifiers in cancer
and other diseases continues to grow,
with a wide range of targets now being
explored in both preclinical and clinical
trials. For example, inhibitors of several
histone methyltransferases, including
EZH2 and DOT1L are also in preclinical
trials for certain lymphomas and
leukemias, respectively (78) (Figure 3B).
Combining various epigenetic thera-
pies may prove to be the most effective
strategy because of the high degree of bi-
ological interaction between DNA
methylation, histone modifications and
chromatin remodeling complexes. In-
deed, clinical trials examining the syner-
gistic action of these therapies are prom-
ising (82). These therapies are also most
likely to be effective when combined
with conventional cancer treatments (78).
Epigenetic pharmaceuticals are still in
their infancy, and clearly more is to be
learned about the underlying mecha-
nisms determining epigenetic states,
since only some cancers can be repro-
grammed to a normal state and
demethylating agents and HDAC in-
hibitors are unable to bring about perma-
nent expression changes. This result is
particularly true if the abnormal epige-
netic state is driven by underlying ge-
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netic factors and would therefore require
ongoing pharmacological intervention to
prevent reversion of the epigenetic state.
Disease screening and diagnosis may
also be vastly improved with the inclu-
sion of epigenetic information. In 2012,
Teschendorff et al. (83,84) were able to
predict risk of cervical neoplasia 3 years
before morphological changes by examin-
ing DNA methylation variability. Feinberg
and Irizarry (85) suggest that if such tests
are used to identify subgroups for further
traditional follow-up screening (for exam-
ple, mammogram, colonoscopy), the posi-
tive predictive value of these more inva-
sive and expensive tests could rise to over
90% and greatly reduce cancer deaths.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
Many questions remain regarding the
underlying mechanisms that determine
epigenetic patterns. Rapid improvements
in technology and our increasing ability
to effectively analyze and interpret the
immense quantities of data produced are
allowing the generation of comprehen-
sive epigenomic maps and characteriza-
tion of the differences in epigenetic state
between individuals and the changes
that occur during development, aging
and disease processes. This information
is also aiding in our understanding of
the underlying mechanisms involved, in-
cluding the relative contribution of envi-
ronmental influences, stochastic factors
and genetic variants. Numerous studies
across a range of tissue types and popu-
lations are providing strong evidence for
a key role for genetic variants in estab-
lishing inherited methylation patterns.
Over recent years, we have gained
considerable insight into the role of ge-
netic variants and epigenetic change in
diseases. Attention is now turning to un-
derstanding the interactions between ge-
netic and epigenetic factors and their
concerted roles in disease processes. This
Figure 3. Advances in epigenetic therapy. Epigenetic modifiers and modifications provide targets for therapeutic intervention in disease.
(A) Two histone deacetylase inhibitors are FDA approved for treatment of subtypes of leukemia. (B) Inhibitors of a range of epigenetic
modifiers, including histone methyltransferase enzymes, are in preclinical trials. (C) DNA demethylating agents decrease genomic methy-
lation, restoring aberrantly silenced gene expression by acting directly to inhibit methylating enzymes or as cytidine analogs are incorpo-
rated into nucleic acid of dividing cells, preventing methylation. (D) Cytidine analogs have the secondary effect of activating the p53
damage pathway and inducing apoptosis.
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approach is providing advances in dis-
ease prevention, diagnosis and surveil-
lance. It is also offering hope that a
heightened understanding of how inher-
ited factors regulate gene expression
through epigenetic mechanisms will 
provide more personalized diagnostic
tools and effective treatments for com-
plex disease.
ACKNOWLEDGMENTS
The authors were supported by grants
from the David Collins Leukaemia Foun-
dation and The Cancer Council Tasma-
nia. JL Dickinson is an Australian Re-
search Council Future Fellow. E Cazaly
was supported by a scholarship from the
Royal Hobart Hospital Cancer Auxiliary.
The authors acknowledge the many re-
searchers whose work has contributed to
this field, but they are not specifically
cited here because of space and referenc-
ing constraints.
DISCLOSURE
The authors declare that they have no
competing interests as defined by Molecu-
lar Medicine, or other interests that might
be perceived to influence the results and
discussion reported in this paper.
REFERENCES
1. Botstein D, Risch N. (2003) Discovering geno-
types underlying human phenotypes: past suc-
cesses for mendelian disease, future approaches
for complex disease. Nat. Genet. 33:228–37.
2. Eichler EE, et al. (2010) Missing heritability and
strategies for finding the underlying causes of
complex disease. Nat. Rev. Genet. 11:446–50.
3. Hindorff LA, et al. (2009) Potential etiologic and
functional implications of genome-wide associa-
tion loci for human diseases and traits. Proc. Natl.
Acad. Sci. U. S. A. 106:9362–7.
4. Furey TS, Sethupathy P. (2013) Genetics: genetics
driving epigenetics. Science. 342:705–6
5. Steves CJ, et al. (2012) Ageing, genes, environ-
ment and epigenetics: what twin studies tell us
now, and in the future. Age Ageing. 41:581–6.
6. Laird PW (2010) Principles and challenges of ge-
nome-wide DNA methylation analysis. Nat. Rev.
Genet. 11:191–203.
7. Montavon C, et al. (2012) Prognostic and diag-
nostic significance of DNA methylation patterns
in high grade serous ovarian cancer. Gynecol.
Oncol. 124:582–8.
8. Waddington CH. (2012) The epigenotype. Int. J.
Epidemiol. 41:10–3.
9. Berger SL, et al. (2009) An operational definition
of epigenetics. Genes Dev. 23:781–3.
10. Skinner MK. (2011) Environmental epigenetic
transgenerational inheritance and somatic epige-
netic mitotic stability. Epigenetics. 6:838–42.
11. Pembrey M, et al. (2014) Human transgenera-
tional responses to early-life experience: potential
impact on development, health and biomedical
research. J. Med. Genet. 51:563–72.
12. Dawson MA, Kouzarides T. (2012) Cancer epige-
netics: from mechanism to therapy. Cell. 150:12–27.
13. Cedar H, Bergman Y. (2012) Programming of
DNA methylation patterns. Annu. Rev. Biochem.
81:97–117.
14. ENCODE Project Consortium. (2012) An inte-
grated encyclopedia of DNA elements in the
human genome. Nature. 489:57–74.
15. Seisenberger S, et al. (2012) The dynamics of ge-
nome-wide DNA methylation reprogramming in
mouse primordial germ cells. Mol. Cell. 48:849–62.
16. Sasaki H, Matsui Y. (2008) Epigenetic events in
mammalian germ-cell development: reprogram-
ming and beyond. Nat. Rev. Genet. 9:129–40.
17. Kriaucionis S, Heintz N. (2009) The nuclear DNA
base 5-hydroxymethylcytosine is present in Purk-
inje neurons and the brain. Science. 324:929–30.
18. Ito S, et al. (2010) Role of Tet proteins in 5mC to
5hmC conversion, ES-cell self-renewal and inner
cell mass specification. Nature. 466:1129–33.
19. Cimmino L, et al. (2011) TET family proteins and
their role in stem cell differentiation and trans-
formation. Stem Cell. 9:193–204.
20. Hackett JA, et al. (2013) Germline DNA demethy-
lation dynamics and imprint erasure through 5-
hydroxymethylcytosine. Science. 339:448–52.
21. Barski A, et al. (2007) High-resolution profiling of
histone methylations in the human genome. Cell.
129:823–37.
22. Wang Y, et al. (2004) Beyond the double helix:
reading and writing the histone code. Novartis
Found. Symp. 259:3–17.
23. McVicker G, et al. (2013) Identification of genetic
variants that affect histone modifications in
human cells. Science. 342:747–9.
24. Kilpinen H, et al. (2013) Coordinated effects of se-
quence variation on DNA binding, chromatin
structure, and transcription. Science. 342:744–7.
25. Kasowski M, et al. (2013) Extensive variation in
chromatin states across humans. Science. 342:750–2.
26. Daxinger L, Whitelaw E. (2012) Understanding
transgenerational epigenetic inheritance via the
gametes in mammals. Nat. Rev. Genet. 13:153–62.
27. Liebers R, et al. (2014) Epigenetic regulation by
heritable RNA. PLoS. Genet. 10:e1004296.
28. Kasinski AL, Slack FJ. (2011) Epigenetics and ge-
netics. MicroRNAs en route to the clinic:
progress in validating and targeting microRNAs
for cancer therapy. Nat. Rev. Cancer. 11:849–64.
29. Bell JT, Spector TD. (2011) A twin approach to
unraveling epigenetics. Trends Genet. 27:116–25.
30. Vickers MA, et al. (2001) Assessment of mecha-
nism of acquired skewed X inactivation by anal-
ysis of twins. Blood. 97:1274–81.
31. Kaminsky ZA, et al. (2009) DNA methylation
profiles in monozygotic and dizygotic twins. Nat.
Genet. 41:240–5.
32. Race JP, et al. (2006) Chorion type, birthweight
discordance and tooth-size variability in Aus-
tralian monozygotic twins. Twin Res. Hum. Genet.
9:285–91.
33. Morgan HD, et al. (1999) Epigenetic inheritance at
the agouti locus in the mouse. Nat. Genet. 23:314–8.
34. Kerkel K, et al. (2008) Genomic surveys by
methylation-sensitive SNP analysis identify 
sequence-dependent allele-specific DNA methy-
lation. Nat. Genet. 40:904–8.
35. Gertz J, et al. (2011) Analysis of DNA methylation
in a three-generation family reveals widespread
genetic influence on epigenetic regulation. PLoS.
Genet. 7:e1002228.
36. Shoemaker R, et al. (2010) Allele-specific methyla-
tion is prevalent and is contributed by CpG-SNPs
in the human genome. Genome Res. 20:883–9.
37. Zhang D, et al. (2010) Genetic control of individ-
ual differences in gene-specific methylation in
human brain. Am. J. Human Genet. 86:411–9.
38. Bell JT, et al. (2011) DNA methylation patterns as-
sociate with genetic and gene expression varia-
tion in HapMap cell lines. Genome Biol. 12:R10.
39. Zhi D, et al. (2013) SNPs located at CpG sites
modulate genome-epigenome interaction. Epige-
netics. 8:802–6.
40. Hesson LB, et al. (2010) Epimutations and cancer
predisposition: importance and mechanisms.
Curr. Opin. Genet. Dev. 20:290–8.
41. Fu Y-H, et al. (1991) Variation of the CGG repeat at
the fragile X site results in genetic instability: reso-
lution of the Sherman paradox. Cell. 67:1047–58.
42. Meyer N, Penn LZ. (2008) Reflecting on 25 years
with MYC. Nat. Rev. Cancer. 8:976–90.
43. Haiman CA, et al. (2007) Multiple regions within
8q24 independently affect risk for prostate can-
cer. Nat. Rev. Cancer. 39:638–44.
44. Sotelo J, et al. (2010) Long-range enhancers on
8q24 regulate c-Myc. Proc. Natl. Acad. Sci. U. S. A.
107:3001–5.
45. Ferguson-Smith AC. (2011) Genomic imprinting:
the emergence of an epigenetic paradigm. Nat.
Rev. Genet. 12:565.
46. Banno K, et al. (2012) Epimutation and cancer: a
new carcinogenic mechanism of Lynch syndrome
(Review). Int. J. Oncol. 41:793–7.
47. Buiting K, et al. (2003) Epimutations in Prader-
Willi and Angelman syndromes: a molecular
study of 136 patients with an imprinting defect.
Am. J. Hum. Genet. 72:571–7.
48. Heijmans BT, et al. (2007) Heritable rather than age-
related environmental and stochastic factors domi-
nate variation in DNA methylation of the human
IGF2/H19 locus. Hum. Mol. Genet. 16:547–54.
49. Ludgate JL, et al. (2013) Global demethylation in
loss of imprinting subtype of Wilms tumor. Genes
Chromosomes Cancer. 52:174–84.
50. Fuke T, et al. (2013) Molecular and clinical stud-
ies in 138 Japanese patients with Silver-Russell
syndrome. PLoS One. 8:e60105.
R E V I E W  A R T I C L E
M O L  M E D  2 1 : 4 0 0 - 4 0 9 ,  2 0 1 5  |  C A Z A L Y  E T  A L .  |  4 0 9
51. Murrell A, et al. (2004) An association between vari-
ants in the IGF2 gene and Beckwith-Wiedemann
syndrome: interaction between genotype and
epigenotype. Hum. Mol. Genet. 13:247–55.
52. Weksberg R, et al. (2002) Discordant KCNQ1OT1
imprinting in sets of monozygotic twins discor-
dant for Beckwith-Wiedemann syndrome. Hum.
Mol. Genet. 11:1317–25.
53. Cui H, et al. (2003) Loss of IGF2 imprinting: a po-
tential marker of colorectal cancer risk. Science.
299:1753–5.
54. Murata A, et al. (2014) IGF2 DMR0 methylation,
loss of imprinting, and patient prognosis in eso-
phageal squamous cell carcinoma. Ann. Surg.
Oncol. 21:1166–74.
55. Yi JM, et al. (2011) Genomic and epigenomic inte-
gration identifies a prognostic signature in colon
cancer. Clin. Cancer Res. 17:1535–45.
56. Ward RL, et al. (2013) Identification of constitu-
tional MLH1 epimutations and promoter vari-
ants in colorectal cancer patients from the Colon
Cancer Family Registry. Genet. Med. 15:25–35.
57. Hitchins MP, Lynch HT. (2014) Dawning of the
epigenetic era in hereditary cancer. Clin. Genet.
85:413–6.
58. Hitchins MP, et al. (2011) Dominantly inherited
constitutional epigenetic silencing of MLH1 in a
cancer-affected family is linked to a single nu-
cleotide variant within the 5′UTR. Cancer Cell.
20:200–13.
59. Bennett KL, et al. (2010) Germline epigenetic reg-
ulation of KILLIN in Cowden and Cowden-like
syndrome. JAMA. 304:2724–31.
60. Moore LE, et al. (2011) Von Hippel-Lindau (VHL)
inactivation in sporadic clear cell renal cancer:
associations with germline VHL polymorphisms
and etiologic risk factors. PLoS Genet. 7:e1002312.
61. Ogino S, et al. (2007) MGMT germline polymor-
phism is associated with somatic MGMT pro-
moter methylation and gene silencing in colorec-
tal cancer. Carcinogenesis. 28:1985–90.
62. You JS, Jones PA. (2012) Cancer genetics and epi-
genetics: two sides of the same coin? Cancer Cell.
22:9–20.
63. Bjornsson H. (2004) An integrated epigenetic and
genetic approach to common human disease.
Trends Genet. 20:350–8.
64. Ng SB, et al. (2010) Exome sequencing identifies
MLL2 mutations as a cause of Kabuki syndrome.
Nat. Genet. 42:790–3.
65. Tsurusaki Y, et al. (2012) Mutations affecting com-
ponents of the SWI/SNF complex cause Coffin-
Siris syndrome. Nat Genet. 44:376–8.
66. Berdasco M, Esteller M. (2013) Genetic syn-
dromes caused by mutations in epigenetic genes.
Hum. Genet. 132:359–83.
67. Hansen RS, et al. (1999) The DNMT3B DNA
methyltransferase gene is mutated in the ICF im-
munodeficiency syndrome. Proc. Natl. Acad. Sci.
U.S.A. 96:14412–7.
68. Liyanage VRB, Rastegar M. (2014) Rett syndrome
and MeCP2. Neuromol. Med. 16:231–64.
69. Chen WG, et al. (2003) Derepression of BDNF
transcription involves calcium-dependent phos-
phorylation of MeCP2. Science. 302:885–9.
70. Feil R, Fraga MF. (2012) Epigenetics and the envi-
ronment: emerging patterns and implications.
Nat. Rev. Genet. DOI: 10.1038/nrg3142.
71. Veenendaal MVE, et al. (2013) Transgenerational
effects of prenatal exposure to the 1944–45 Dutch
famine. BJOG. 120:548–53.
72. Guerrero-Bosagna C, Skinner MK. (2011) Envi-
ronmentally induced epigenetic transgenera-
tional inheritance of phenotype and disease. Mol.
Cell. Endocrinol. 354:1–6.
73. Petronis A. (2010) Epigenetics as a unifying prin-
ciple in the aetiology of complex traits and dis-
eases. Nature. 465:721–7.
74. Gimelbrant A, et al. (2007) Widespread monoal-
lelic expression on human autosomes. Science.
318:1136–40.
75. Richards EJ. (2006) Inherited epigenetic variation:
revisiting soft inheritance. Nat. Rev. Genet. 7:395–401.
76. Feinberg AP, Irizarry RA. (2010) Evolution in
health and medicine Sackler colloquium: stochas-
tic epigenetic variation as a driving force of de-
velopment, evolutionary adaptation, and disease.
Proc. Natl. Acad. Sci. U. S. A. 107:1757–64.
77. Hansen KD, et al. (2011) Increased methylation
variation in epigenetic domains across cancer
types. Nat. Genet. 43:768–75.
78. Bojang P Jr, Ramos KS. (2014) The promise and
failures of epigenetic therapies for cancer treat-
ment. Cancer Treat. Rev. 40:153–69.
79. Kaminskas E, et al. (2005) FDA drug approval
summary: azacitidine (5-azacytidine, Vidaza™)
for injectable suspension. Oncologist. 10:176–82.
80. Kuo HK, et al. (2007) 5-Azacytidine-induced
methyltransferase-DNA adducts block DNA
replication in vivo. Cancer Res. 67:8248–54.
81. Karpf AR, et al. (2001) Activation of the p53 DNA
damage response pathway after inhibition of
DNA methyltransferase by 5-aza-2’-deoxycyti-
dine. Mol. Pharmacol. 59:751–7.
82. Garcia-Manero G, et al. (2006) Phase 1/2 study of
the combination of 5-aza-2′-deoxycytidine with
valproic acid in patients with leukemia. Blood.
108:3271–9.
83. Teschendorff AE, Widschwendter M. (2012) Dif-
ferential variability improves the identification of
cancer risk markers in DNA methylation studies
profiling precursor cancer lesions. Bioinformatics.
28:1487–94.
84. Teschendorff AE, et al. (2012) Epigenetic variabil-
ity in cells of normal cytology is associated with
the risk of future morphological transformation.
Genome Med. 4:24.
85. Feinberg AP. (2014) Epigenetic stochasticity, nu-
clear structure and cancer: the implications for
medicine. J. Intern. Med. 276:5–11.
Cite this article as: Cazaly E, Charlesworth J, Dickin-
son JL, Holloway AF. (2015) Genetic determinants of
epigenetic patterns: providing insight into disease.
Mol. Med. 21:400–9.
## Chapter.2 Appendix -- Analysis pipeline for initial quality 
control of Methylation Array Data ## 
#### Overview #### 
# 1. Read in data 
# 2. Remove failed samples 
# 3. Background correction & Control normalisation
# 4. Convert from RGset to MethylSet
# 5. Remove sex chr and normalise separately then recombine.  This 
is tricky for Methylumi objects as annotation seems impossible
#  ** Below 3 steps performed in next chapter --> normalisation **
### 5. Normalisation: swan, QN, BMIQ, Dasen
### 6. Remove failed probes based on detP- nonsignificant signal 
compared to background 0.05 threshold




# 1. Load data #
################
library(minfi)
baseDir <- file.path("/Users/ecazaly/Desktop/PhD_Analysis/450K/Raw 












# which are the poor quality samples?
RGsetE[,bad]@phenoData$Sample_Name
# [1] "pc11-233a"     "PC11-213a"     "pc72-291a"    
# [4] "pc72-291b"     "PC9-4T (AH3)"  "PC9-12T (AH5)"
# [7] "PC11-233b"     "PC11-213b"  
densityPlot(RGsetE2,sampGroups=RGsetE2@phenoData$Batch, pal = 




        xlim=c(-4.5,9), ylim=c(-5,8),legendNCol=5, legendPos = 
"bottom", main="MDS RGsetE2")
###################################################
# 3. Background correction, control normalisation #
###################################################
#preproIllumina will return a methylSet or bgcorrect.illumina and 
normalize.illumina.control will return an RGset
RGsetE2_bgcorrect=bgcorrect.illumina(RGsetE2)
densityPlot(RGsetE2_bgcorrect,sampGroups=RGsetE2_bgcorrect@phenoData





        xlim=c(-8.5,5), ylim=c(-5,8),legendNCol=5, legendPos = 
"bottom", main="MDS RGsetE2_bgcorrect")
RGsetE2_control_norm=normalize.illumina.control(RGsetE2_bgcorrect, 








noData$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="control norm ref1")
densityPlot(RGsetE2_control_norm2,sampGroups=RGsetE2_control_norm2@p
henoData$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="control norm ref2")
densityPlot(RGsetE2_control_norm3,sampGroups=RGsetE2_control_norm3@p
henoData$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="control norm ref3")
densityPlot(RGsetE2_control_norm4,sampGroups=RGsetE2_control_norm4@p
henoData$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="control norm ref4")



















        xlim=c(-10.5,4.5), ylim=c(-8.5,5),legendNCol=5, legendPos = 
"bottom", main="MDS RGsetE2_control_norm4")
# As do these, although the 3rd one inverts
####################################################################
#########





# MethylSet (storageMode: lockedEnvironment)
# 485512 features, 52 samples  - this has lost 136887 sites
####################################################################
########





drop=FALSE)  # this is a dataframe, could be an issue downstream
dim(Annotated) # 485512     33  - cuts it down to the same number of 
probes in Raw_preprocess.  
chrs=Annotated@listData$chr
Autosomes=Raw_preprocess[chrs!="chrX" & chrs !="chrY"]  # Methylset
dim(Autosomes) #  473864       52
dim(Raw_preprocess) # 485512       52  : have removed 11648 sex chr
Annotated_Autosomes=getAnnotation(Autosomes, what="everything", 
drop=FALSE)  #dataframe 
 #check:
dim(Annotated_Autosomes)  # [1] 473864     33
which(Annotated_Autosomes[,1]=="chrY") #integer(0)
which(Annotated_Autosomes[,1]=="chrX") #integer(0)
# normalise these automsomes separately to sex chr then somehow 
recombine
Raw_Male <- Raw_preprocess[,Raw_preprocess@phenoData$Sex=="M"]
Male_chr <- Raw_Male[chrs=="chrY" | chrs=="chrX"]
dim(Male_chr) # Features  Samples   11648       43
Raw_Female <- Raw_preprocess[,Raw_preprocess@phenoData$Sex=="F"]
Female_chr <- Raw_Female[chrs=="chrX"] 
dim(Female_chr) # Features  Samples 11232        9
## Chapter.2  Appendix.2  Analysis Pipeline for Omni2.5 genotyping 
array quality control using PLINK ##
# navigate to correct directory on HPC :  cd ~/Data/Omni25/
pipeline_omni
# ------ Add phenotype data -------
# To add phenotypes; transpose to t.ped and t.fam files and then 
manually edit t.fam files in VI or nano
plink --noweb --file All_Chips_1_5Cutoff_noReps --transpose --recode 
--out cutoff_15
# in nano modify final column with 2 (A), 1 (UA), 0 (NA) and then 
exit, will ask to save on exiting
nano cutoff_15.tfam  # 
# at this point there are 2,391739 SNPs
# 27534 heterozygous haploid genotypes; set to missing 
# haploid chromosomes are only counted once (i.e. male X and Y 
chromosome SNPs and all MT SNPs).
# genotypes have been set to missing if they are not valid (female Y 
genotype, heterozygous haploid chromosome)
# 192 SNPs with no founder genotypes observed
# ------- QC per individual -------
# 2,391739 SNPs
# 1. Check gender assignment
plink --noweb --tfile cutoff_15 --check-sex --out sexcheck_15
#look at the file, 5th column gives status as OK or otherwise.  All 
ok for my samples
less sexcheck_15.sexcheck
# 2. Missingness: remove indivs with >10% missing genotypes
# 2,391739 SNPs
plink --noweb --tfile cutoff_15 --mind 0.1 --make-bed --out 
cutoff_15_clean
# Check plink log. file to see if any excluded.  No all left in, so 
must have less than 10% which agrees
# with genomeStudio as call rates only down to 96% and mostly 99% 
# 3. Mendelian errors - can't use this as have no trios
#plink --noweb --bfile cutoff_15_clean --mendel --out 
cutoff_15_clean_mendel 
###Currently, PLINK only scans full trios for Mendel errors. 
Families with fewer than 2 parents in the dataset will not be 
tested.###
# ------- QC per SNP -------
# 1. Remove SNPs with high rate of missing genotype calls -more than 
10% missing genotypes... this is actually set at 5%  
# 2,391739 SNPs
plink --noweb --bfile cutoff_15_clean --geno 0.05 --make-bed --out 
cutoff_15_clean2
# 61217 SNPs failed missingness test ( GENO > 0.05 ), so now have 
2330522 SNPs
# 2330522 SNPs
# 2. Remove SNPs out of Hardy-Weinberg equilibrium
# 2330522 SNPs
###plink --noweb --bfile cutoff_15_clean2 --hardy --out 
cutoff_15_clean2_hardy
# 335 markers to be excluded based on HWE test ( p <= 0.001 )
#1303 markers failed HWE test in cases
#335 markers failed HWE test in controls
#Total genotyping rate in remaining individuals is 0.993477
# 2330187 SNPs
# is this too stringent? should I perhaps use 0.0001 which doesn't 
exclude any?
plink --noweb --bfile cutoff_15_clean2 --hwe 1E-4 --hardy --make-bed 
--out cutoff_15_clean_hwe_1E-4
# 0 markers to be excluded based on HWE test ( p <= 0.0001 )
# 419 markers failed HWE test in cases
# 0 markers failed HWE test in controls
# Total genotyping rate in remaining individuals is 
0.993679
# 2330522 SNPs
###plink --noweb --bfile cutoff_15_clean2 --hardy2 --out 
cutoff_15_clean2_hardy2
# --hardy2 is a lot more stringent and less accurate for rare 
genotypes, it takes out about 10 thousand more
#10522 markers to be excluded based on HWE test ( p <= 
0.001 )
#15887 markers failed HWE test in cases
#10522 markers failed HWE test in controls
#Total genotyping rate in remaining individuals is 0.993477
# check in R
hwe2 <- read.delim("cutoff_15_clean_hwe_1E-4.hwe", header=T, 
as.is=T, sep="")
str(hwe2)
hweALL2 <- hwe2[which(hwe2$TEST=="ALL"),]  # get rid of the rows 
that specify AFF, UNAFF
# order by p-val, p-vals are generated per SNP depending on the 
deviation from HWE, low p-values indicate a 
# SNP is out of HWE.  
hweOrderALL2 <- hweALL2[order(hweALL2$P),]
hwe2_less10_5 <- hweALL2[which(hweALL2$P<1E-5),]  # which SNPs have 
a p-val less than 1E-5? 289
hwe2_less10_4 <- hweALL2[which(hweALL2$P<1E-4),]  # 517 which is not 
quite the same as in PLINK as above
# 2. Set minimum MAF
plink --noweb --bfile cutoff_15_clean_hwe_1E-4 --maf 0.05 --out 
cutoff_15_clean3_maf
# 1,108728 SNPs failed frequency test ( MAF < 0.05 )
# 1221794 SNPs
# I think this is too stringent as it will cut of everything under 
5% frequency which could be quite 
# interesting for familial data.  will set to 0.01 and then 
investigate what ppl using set it to
plink --noweb --bfile cutoff_15_clean_hwe_1E-4 --maf 0.01 --out 
cutoff_15_clean3_maf_0.01
# 829,316 SNPs failed frequency test ( MAF < 0.01 )
plink --noweb --bfile cutoff_15_clean_hwe_1E-4 --maf 0.001 --make-
bed --out cutoff_15_clean3_maf_0.001
# 713,687 SNPs failed frequency test ( MAF < 0.001 )
# Use this cutoff. 
# 1,616835 SNPs remaining
# ---- final PLINK file:  cutoff_15_clean3_maf_0.001 ----------
# missingness, hwe, het
plink --noweb --bfile cutoff_15_clean3_maf_0.001 --missing --hwe 
1E-4 --hardy --het --make-bed --out cutoff_15_final
#1616835 SNPs
#12543 heterozygous haploid genotypes; set to missing
#Total genotyping rate in remaining individuals is 0.993451
plink --noweb --bfile cutoff_15_final --het --out cutoff_15_final
# create the individual (missingness vs homozygosity) and per SNP 
(missingness vs hwe) plots using this
# ------- Per Individual ---------










     main="Summary per individual, Post QC (51 samples 1.5 
cutoff)",cex=1.5,cex.lab=1.5,cex.axis=1.5,cex.main=1.5,)
dev.off()
# compare this to pre-QC
plink --noweb --tfile cutoff_15 --het --missing --out 
cutoff_15_preQC
#2391739 SNPs







png("Individual 1.5 cutoff Pre QC.png")
plot(het_1.5pre$O.HOM./het_1.5pre$N.NM.,imiss_1.5pre
$F_MISS,ylab="missingness",xlab="Homozygosity",
     main="Summary per individual, Pre QC (51 samples 1.5 
cutoff)",cex=1.5,cex.lab=1.5,cex.axis=1.5,cex.main=1.5,)
dev.off()
# ----- heterozygosity ------
# plot missingness against heterozygosity




     main="Summary per individual, Post QC, 
     heterozygosity (51 samples 1.5 
cutoff)",cex=1.5,cex.lab=1.5,cex.axis=1.5,cex.main=1.5,)
dev.off()
png("Individual 1.5 cutoff Pre QC, heterozygosity.png")
plot(1-(het_1.5pre$O.HOM./het_1.5pre$N.NM.),imiss_1.5pre
$F_MISS,ylab="missingness",xlab="Homozygosity",
     main="Summary per individual, Pre QC, 
     heterozygosity (51 samples 1.5 
cutoff)",cex=1.5,cex.lab=1.5,cex.axis=1.5,cex.main=1.5,)
dev.off()
# ------- per SNP -------- 
hardy_1.5post=read.delim("cutoff_15_final.hwe", header=T, as.is=T, 
sep="")
hardy_1.5postb <- hardy_1.5post[seq(1,nrow(hardy_1.5post),3),] 


















$F_MISS)]),-1*log10(p_post[snp_1.5post$F_MISS!=0 & !is.na(p_postb) 
& !is.na(snp_1.5post$F_MISS)]),f=0.1),col="red",lwd=2)
#### This still doesn't work!!!!!! -- maybe several points there
#identify(-1*log10(snp_1.5post$F_MISS),-1*log10(p_postb), n=2)
# [1] 1614455 1614479
#dev.off()
# compare this to pre-QC
plink --noweb --tfile cutoff_15 --hardy --missing --out 
cutoff_15_preQC
hardy_1.5pre=read.delim("cutoff_15_preQC.hwe", header=T, as.is=T, 
sep="")
p_pre <- hardy_1.5pre$P[3*(1:(length(hardy_1.5pre$P)/3))-2]
png("Missing per SNP vs HWE Pre QC zoomC.png",width=800,height=500)
par(mar=c(6,5,4,2)+0.1)
plot(-1*log10(snp_1.5pre$F_MISS),-1*log10(p_pre),ylab="-log10(HW-














# [1] 2386673 2386736
# get rid of these and then recheck graph 
snp_1.5pre2 <-snp_1.5pre[-c(2386673,2386736),]
plot(-1*log10(snp_1.5preb$F_MISS),-1*log10(p_pre),ylab="-log10(HW-














#  cutoff 5
~/Data/Omni25/pipeline_omni
plink --noweb --file All_Chips_5_0Cutoff --transpose --recode --out 
cutoff_50
nano cutoff_50.tfam
plink --noweb --tfile cutoff_50 --check-sex --out sexcheck_50
plink --noweb --tfile cutoff_50 --mind 0.1 --geno 0.1 --make-bed --
out cutoff_50_clean
plink --noweb --bfile cutoff_50_clean --maf 0.001 --make-bed --out 
cutoff_50_clean_maf_0.001
plink --noweb --bfile cutoff_50_clean_maf_0.001 --missing --hwe 1E-4 
--hardy --het --make-bed --out cutoff_50_final
plink --noweb --bfile cutoff_50_final --het --out cutoff_50_final








png("Individual 5.0 cutoff Post QC.png")
plot(het_50$O.HOM./
het_50$N.NM.,imiss_50$F_MISS,ylab="missingness",xlab="Homozygosity",
     main="Summary per individual, Post QC (51 samples 5.0 
cutoff)",cex=1.5,cex.lab=1.5,cex.axis=1.5,cex.main=1.5,)
dev.off()
## Chapter.3 Appendix_1 -- perform normalisation ##
## Overview ## 
____________________________________________________________________
_________________
# first 5 steps performed in ch.2 as part of QC protocol
## 1. Read in data 
## 2. Remove failed samples 
## 3. Background correction & Control normalisation
## 4. Convert from RGset to MethylSet
## 5. Remove sex chr and normalise separately then recombine.  This 
is tricky for Methylumi objects as annotation seems impossible
# 6. Normalisation: swan, QN, BMIQ, Dasen
# 7. Remove failed probes based on detP- nonsignificant signal 
compared to background 0.05 threshold





# 6. Normalisation:   Compare RAW to StratQN, FunNorm, SWAN, QN, 
BMIQ, Dasen, RUV #
####################################################################
###############
# use Autosomes object as need to normalise sex chr separately, 
still need to put RGsetE2 argument but make the mset the Autosomes 
object and then do the same for both sex chr





autosomes_RGsetE2 <- RGsetE2[chrs!="chrX" & chrs !="chrY"]
dim(autosomes_RGsetE2 )
###  2. Stratified Quantile Normalisation ###
#Stratified quantile normalization for Illumina amethylation arrays. 
This function implements stratified quantile normalization 
preprocessing for Illumina methylation microarrays. Probes are 
stratified by region (CpG island, shore, etc.) This function 
implements stratified quantile normalization preprocessing for 
Illumina methylation microarrays. If removeBadSamples is TRUE we 
calculate the median Meth and median Unmeth sig- nal for each 
sample, and remove those samples where their average falls below 
badSampleCutoff. The normalization procedure is applied to the Meth 
and Unmeth intensities separately. The distri- bution of type I and 
type II signals is forced to be the same by first quantile 
normalizing the type II probes across samples and then interpolating 
a reference distribution to which we normalize the type I probes. 
Since probe types and probe regions are confounded and we know that 
DNAm dis- tributions vary across regions we stratify the probes by 
region before applying this interpolation. For the probes on the X 
and Y chromosomes we normalize males and females separately using 
the gender information provided in the sex argument. If gender is 
unspecified (NULL), a guess is made using by the getSex function 
using copy number information. Background correction is not used, 
but very small intensities close to zero are thresholded using the 
fixMethOutlier. Note that this algorithm relies on the assumptions 
necessary for quantile normalization to be applicable and thus is 
not recommended for cases where global changes are expected such as 
in cancer-normal comparisons. 
Note that this normalization procedure is essentially similar to one 
previously presented (Touleimat and Tost, 2012), but has been 
independently re-implemented due to the present lack of a released, 
supported version. 
library(minfi)
StratQN <- preprocessQuantile(Autosomes, fixOutliers=TRUE, 
removeBadSamples=FALSE, quantileNormalize=TRUE, stratified=TRUE, , 
mergeManifest=TRUE, sex=Autosomes@phenoData$Sex, verbose=TRUE)
# can't use RGset as get an error saying subset out of bounds
# dont actually need to use the autosome object as the function 
normalised sex chr separately when sex is provided
type_autosomes <- data.frame(row.names(StratQN), 
getProbeType(StratQN))
colnames(type_autosomes) <- c("Name", "Type")
StratQN_betas <- getBeta(StratQN)
StratQN_all <- preprocessQuantile(Raw_preprocess, fixOutliers=TRUE, 
removeBadSamples=FALSE, quantileNormalize=TRUE, stratified=TRUE, , 
mergeManifest=TRUE, sex= Raw_preprocess@phenoData$Sex, verbose=TRUE)
### 3. Functional Normalisation ### 
library(minfi)
FunNorm <- preprocessFunnorm(RGsetE2, nPCs=2, sex=RGsetE2@phenoData
$Sex, bgCorr=TRUE, dyeCorr=TRUE, verbose=TRUE)
FunNorm_betas <- getBeta(FunNorm)
#FunNorm_autosomes <- preprocessFunnorm(autosomes_RGsetE2, nPCs=2, 
sex=autosomes_RGsetE2@phenoData$Sex, bgCorr=TRUE, dyeCorr=TRUE)
# Error in getGreen(object)[IRed$AddressA, ] : subscript out of 
bounds
# Also can't use Autosomes as needs to be RGset object not methylset
probeTypes_FunNorm <- data.frame(row.names(FunNorm), 
getProbeType(FunNorm))






# These look quite different, there is a greater skew towards 
unmethylated for the normalised data whereas the RGset has much more 
methylated
### 4. SWAN ###
swan=preprocessSWAN(RGsetE2, mSet=Raw_preprocess)  
# will perform preprocessRaw on the RGset if NULL for mset, this 
looks diff between my Raw_preprocess which I've done background 
correction on and the default, don't use default
#swan2=preprocessSWAN(RGsetE2) #default
#par(mfrow=c(1,2))
#plotBetasByType(swan[,7], main="SWAN by probe, my Raw")
#plotBetasByType(swan2[,7], main="SWAN by probe, default")
swan_autosomes <- preprocessSWAN(RGsetE2, mSet=Autosomes)
swan_maleChr <- preprocessSWAN(RGsetE2, mSet=Male_chr)
swan_femaleChr <- preprocessSWAN(RGsetE2, mSet=Female_chr)
par(mfrow=c(1,3))
plotBetasByType(swan_autosomes[,7], main="SWAN by probe, autosomes")
plotBetasByType(swan_maleChr[,7], main="SWAN by probe, male chr")
plotBetasByType(swan_femaleChr[,7], main="SWAN by probe, female 
chr")
# female chr look pretty odd, guessing this is a reflection of X 
inactivation






MethylumiSet=methylumIDAT(barcodes = pdat$barcodes, pdat = pdat, 








# For HumanMethylation450 data, the function delegates to 
normalizeViaControls() the task of scaling red and green intensities 
against a reference array (chip) which defaults to the first chip in 
a set. The code to do this is based on code from the 'minfi' package 
and uses the built-in normalization controls to scale the #channels 
of the samples, so that a consistent degree of dye bias is 





type_methylumi <- data.frame(row.names(lumiQN_prepro), 
lumiQN_prepro@featureData@data$DESIGN)




### 6. BMIQ ###
library(wateRmelon)
library(RPMM)
# BMIQ_autosomes=BMIQ(getBeta(Autosomes), probeTypes_autosomes) # 
this doesn't work, looks like you need all the probes, 
Raw_preprocess and RGset also don't either  
BMIQ=BMIQ(methylumi_prepro) # just have to do it with all 
chromosomes
BMIQ_betas <- betas(BMIQ)
type_BMIQ <- data.frame(row.names(BMIQ), BMIQ@featureData@data
$DESIGN)
colnames(type_BMIQ) <- c("Name", "Type")
### 7. Dasen ###
Dasen=as.matrix(dasen(methylated(Raw_preprocess),unmethylated(Raw_pr
eprocess),onetwo= getProbeType(Raw_preprocess), fudge=100))
probeTypes_Dasen <- data.frame(row.names(Raw_preprocess), 
getProbeType(Raw_preprocess))
⁃ colnames(probeTypes_Dasen) <- c("Name", "Type")
Dasen_autosomes=as.matrix(dasen(methylated(Autosomes),unmethylated(A
utosomes),onetwo=getProbeType(Autosomes), fudge=100))
probeTypes_autosomes2 <- data.frame(row.names(Autosomes), 
getProbeType(Autosomes))
colnames(probeTypes_autosomes2) <- c("Name", "Type")
plotBetasByType(Dasen[,1], probeTypes= probeTypes_autosomes2, 




probeTypes_autosomes2_male <- data.frame(row.names(Male_chr), 
getProbeType(Male_chr))
colnames(probeTypes_autosomes2_male) <- c("Name", "Type")
plotBetasByType(Dasen_male[,1], probeTypes= 
probeTypes_autosomes2_male, main="Dasen by probe, male chr")




probeTypes_autosomes2_female <- data.frame(row.names(Female_chr), 
getProbeType(Female_chr))
colnames(probeTypes_autosomes2_female) <- c("Name", "Type")
plotBetasByType(Dasen_female[,1], probeTypes= 
probeTypes_autosomes2_female, main="Dasen by probe, female chr")






mValues_autosomes = getMvals(Autosomes,RGsetE2) 
ctl_autosomes <- !(rownames(mValues_autosomes) %in% 
featureNames(Autosomes))  ## create logical vector marking NCPs, 613 
probes from 479078- 479690 
mValues_raw <- getMvals(Raw_preprocess, RGsetE2)
ctl_raw <- !(rownames(mValues_raw) %in% 
featureNames(Raw_preprocess))
result_autosomes= naiveRandRuv(t(mValues_autosomes), ctl_autosomes, 





pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 









plotBetasByType(BetaRUV_autosomes[,1], type , main="Autosomes 




        xlim=c(-14,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- RUV Autosomes")
# change variables when generating result and see if this affects 
the density plot
result_autosomes_by2= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e-3, k=ceiling(ncol(mValues_autosomes)/2)) 
## perform normalization 
result_autosomes_by6= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e-3, k=ceiling(ncol(mValues_autosomes)/6)) 
## perform normalization 
result_autosomes_by8= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e-3, k=ceiling(ncol(mValues_autosomes)/8)) 









$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data by2, Autosomes")
densityPlot(BetaRUV_autosomes_by6,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data by6, Autosomes")
densityPlot(BetaRUV_autosomes_by8,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data by8, Autosomes")
# changes the height of the graph
result_autosomes_nuCoeff_1e5= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e-5, k=ceiling(ncol(mValues_autosomes)/4)) 
## perform normalization 
result_autosomes_nuCoeff_1e1= naiveRandRuv(t(mValues_autosomes), 
ctl_autosomes, nuCoeff=1e-1, k=ceiling(ncol(mValues_autosomes)/4)) 
## perform normalization 
result_autosomes_nuCoeff_1ePos5= naiveRandRuv(t(mValues_autosomes), 











Data$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), 
xlab="Beta", main="Density plot RUV data nuCoeff 1e-5, Autosomes")
densityPlot(BetaRUV_autosomes_nuCoeff_1e1,sampGroups=Autosomes@pheno
Data$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), 
xlab="Beta", main="Density plot RUV data nuCoeff 1e-1, Autosomes")
densityPlot(BetaRUV_autosomes_nuCoeff_1ePos5,sampGroups=Autosomes@ph
enoData$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), 
xlab="Beta", main="Density plot RUV data nuCoeff 1e +5, Autosomes")
# this one is starting to look better.  Back to being biomdal 
distribution
# from the above looks like nuCoeff of ~5 and dividing by ~6 is best
result_autosomes_optimal= naiveRandRuv(t(mValues_autosomes), 





$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.5), 




pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.5), xlab="Beta", 
main="Density plot Preprocessed Autosomes")
densityPlot(BetaRUV_autosomes,sampGroups=Autosomes@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV Autosomes")
densityPlot(BetaRUV_autosomes_optimal,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.5), 




        xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 




        xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 




        xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- RUV Autosomes_optimal")
# the raw and optimal look pretty similar and there is still a batch 
effect after RUV when I adjust the variables
# Male and female chr
mValues_male = getMvals(Male_chr,RGsetE2) 
ctl_male <- !(rownames(mValues_male) %in% featureNames(Male_chr))




mValues_female <- getMvals(Female_chr, RGsetE2)
ctl_female <- !(rownames(mValues_female) %in% 
featureNames(Female_chr))




# Male and female OPTIMAL








### 7. Remove failed probe sites based on detection P value ###
# compared to background.  I think 0.01 is too stringent, use 0.05 
which is the default for wateRmelon.
####
# Creates an RGset, dan't use this method on MethylSet, needs to be 
RGset
detP <- detectionP(RGsetE2_control_norm)  # from minfi
failed_detP=detP>0.05
failed_sites_0.05_1=which(rowMeans(failed_detP)>0.001) # Which 
positions failed in >1% of samples?
Raw_minfi_0.05_1=RGsetE2_control_norm[-(failed_sites_0.05_1),]
dim(Raw_minfi_0.05_1)
#Features  Samples 
#615237       52 
dim(RGsetE2_control_norm)-dim(Raw_minfi_0.05_1)
# Features  Samples 
# 7162        0   # this is the same as when you use the wateRmelon 
method below :)
# But there are less sites in Raw_filter because it has been 
converted to a methylset and this removes probes
dim(Raw_minfi_0.05_1)-dim(Raw_filter)  # Features  Samples 2450      
0
## OR:  Use pfilter method wateRmelon, removes 2450 probes, still 
RGset 
# this is still a lot less than removed when using preprocess 
(136,887)
Raw_filter  <- pfilter(mn=RGsetE2_control_norm,pn=detP)    # Can 
change threshold from default of 0.05 to 0.01 with additional 
arguments
# 0 samples having 1 % of sites with a detection p-value greater 
than 0.05 were removed 
# 719 sites were removed as beadcount <3 in 5 % of samples 
# 7162 sites having 1 % of samples with a detection p-value greater 
than 0.05 were removed
dim(Raw_filter) 
#  Features  Samples 
#  612787       52 
densityPlot(Raw_filter, sampGroups=Raw_filter@phenoData$Batch, 





        xlim=c(-8.5,5), ylim=c(-5,8),legendNCol=5, legendPos = 
"bottom", main="MDS Raw_filter")
# can't plot:  Error in getGreen(rgSet)[getProbeInfo(rgSet, type = 






# 0 samples having 1 % of sites with a detection p-value greater 
than 0.05 were removed  
# 1437 sites were removed as beadcount <3 in 5 % of samples 
# 5604 sites having 1 % of samples with a detection p-value greater 




#this removes the same number of sites, shouldnt it remove less 
since there is background correction?
# pval.detect does sfa, it just generates one value of 0.05 for all 
the data











#Found 3 batches Found 0  categorical covariate(s) Found 908 Missing 
Data Values Standardizing Data across genes Fitting L/S model and 
finding priors Finding parametric adjustments Adjusting the Data
### limma correction then RUV ###
#################################
library(limma)
mValues2 = getMvals(Autosomes,RGsetE2)  ## calculate M-values from 
intensity data, include negative control probes (NCPs)
## create design matrix, this can include additional covariates 




fit = lmFit(mValues2, design)
fit = eBayes(fit)
result2 = topTable(fit,coef=coef,num=Inf)
ctl2 <- rownames(mValues2) %in% rownames(result2)
[ceiling(nrow(result2)*0.5):nrow(result2)]  ## select empirical 
controls
results = naiveRandRuv(t(mValues2), ctl2, nuCoeff=1e-3, 





= rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 




        xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_limma")
# use optimal settings as above
results_optimal = naiveRandRuv(t(mValues2), ctl2, nuCoeff=1e5, 





$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.5), 




        xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_limma_optimal")
# this looks identical to RUV without limma
### ISVA ###
library(isva)
#Independent Surrogate Variable Analysis is an algorithm for feature 
selection in the presence of potential confounding factors, 
specially designed for the analysis of large-scale high-dimensional 
quantitative genomic data (e.g microarrays). It uses Independent 
Component Analysis (ICA) to model the confounding factors as 
independent surrogate variables (ISVs). These ISVs are included as 
covariates in a multivariate regression model to subsequently 
identify features that correlate with a phenotype of interest 
independently of these confounders. The ICA implementation used is 
that of the fastICA R-package.
# try NULL and 3 and 5 for the batches for potential confounders









var <- ifelse(var =="A", 1, 2)
isva<- DoISVA(data.m=ISVAdata, pheno.v=var, cf.m=NULL, pvthCF=0.01, 
th=0.05, ncomp=NULL)
# no matterv what I do :
#Error in lm.fit(x, y, offset = offset, singular.ok = 
singular.ok, ...) : 0 (non-NA) cases
isvaFn(data.m=ISVAdata, pheno.v=pheno, ncomp=NULL )
#same error as above
### CpGassoc ###
#cpg.assoc is designed to test for association between an 
independent variable and methylation at a number of CpG sites, with 
the option to include additional covariates and factors. cpg.assoc 
assesses sig- nificance with the Holm (step-down Bonferroni) and FDR 
methods. 
library(CpGassoc)
cpgAss <- cpg.assoc(beta.val=ISVAdata, indep=Autosomes$Batch, 
covariates= NULL, logit.transform=TRUE, chip.id=Autosomes$Slide, 
random=FALSE)
#use it to check if there is a batch effect still present after norm 
etc???
#Warning messages:
1: In rm(non.m.beta, sser, ssef, beta0, r.ressq) : object 'sser' not 
found
2: In rm(non.m.beta, sser, ssef, beta0, r.ressq) : object 'ssef' not 
found
3: In rm(non.m.beta, sser, ssef, beta0, r.ressq) :
  object 'beta0' not found
4: In rm(non.m.beta, sser, ssef, beta0, r.ressq) :
  object 'r.ressq' not found
### Streamlined processing ###
# ChAMP -- seems to be able to do practically everything and has an 
inbuilt all in one pipeline command 'champ.process'
library(ChAMP)
champ <- champ.process(fromIDAT=TRUE, directory="/Users/ecazaly/
Desktop/R Dec14/Raw IDATs/IDATs_passed", methValue="B", 
filterDetP=TRUE, detPcut=0.05, filterXY=TRUE, QCimages=TRUE, 
filterBeads=TRUE, beadCutoff=0.05, batchCorrect=TRUE, runSVD=TRUE, 
norm="SWAN", adjust.method="BH", runDMR=FALSE, runCNA=FALSE, 
plotBMIQ=TRUE)
# this removes practically all the proibes because of the failed 
samples.  Run only the samples that have previously passed QC
bad=c(9,17,22,24,27,29,40,42)
densityPlot(RGsetE[,bad],sampGroups=RGsetE[,bad]@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="RGsetE bad")
colnames(RGsetE[,bad])
[1] "8795207059_R05C01" "8784225156_R03C01" "8784225156_R05C02"
[4] "8784225156_R06C02" "5975827011_R03C01" "5975827011_R05C01"
[7] "9221197159_R02C02" "9221197159_R03C02"
# these have been removed form the directory "IDATs_passed" used 
above to call the champ function
# won't let me run combat with the batches as Sample_Group
# Combat failed...Your slides may be confounded with batch or with 
each other. Analysis will proceed without batch correction
# and the normalisation is pretty shit, density plots look worse 
than raw- ie. more prominent batches
# compare norm methods, have XY filter included
champ_data <- champ.load(directory="/Users/ecazaly/Desktop/R Dec14/
Raw IDATs/IDATs_passed", resultsDir="/Users/ecazaly/Desktop/R Dec14/
ChampLoad", methValue="B", filterXY=TRUE, QCimages=TRUE, 
filterDetP=TRUE, detPcut=0.05, filterBeads=TRUE, beadCutoff=0.05, 
filterNoCG=FALSE)
# creates a list of 6 objects which include: 1. minfi MethylSet 
object, 2. minfi RGset, 3.pd, 4. intensity, 5. beta, 6. detP
# removes the same DetP failed probes as other methods: Filtering 
probes with a detection p-value above 0.05 in more than one sample 
has removed 6740 probes from the analysis. If a large number of 
probes have been removed, ChAMP suggests you look at the 
failedSample.txt file to identify potentially bad samples. Filtering 
probes with a beadcount <3 in at least 5% of samples, has removed 
478 from the analysis. Zeros in your dataset have been replaced with 
0.000001 
# The analysis will proceed with 467448 probes and 52 samples.  
Takes out 10846 sex chr: 478294-467448
# it also removed sex chr
champ_Annotated<- getAnnotation(champ_data$mset)
which(champ_Annotated@listData$chr=="chrX")  #integer(0)
champ_data_withXY <- champ.load(directory="/Users/ecazaly/Desktop/R 
Dec14/Raw IDATs/IDATs_passed", resultsDir="/Users/ecazaly/Desktop/R 
Dec14/ChampLoad_withXY", methValue="B", filterXY=FALSE, 
QCimages=TRUE, filterDetP=TRUE, detPcut=0.05, filterBeads=TRUE, 
beadCutoff=0.05, filterNoCG=FALSE)
#The analysis will proceed with 478294 probes and 52 samples.
## Norm methods ##
champ_preprocess <- preprocessRaw(champ_data$rgSet)   
    
champ_StratQN <-preprocessQuantile(champ_data$mset, 
fixOutliers=TRUE, removeBadSamples=FALSE, quantileNormalize=TRUE, 
stratified=TRUE, , mergeManifest=TRUE, sex= champ_data
$mset@phenoData@data$Sex, verbose=TRUE)
champ_FunNorm <- preprocessFunnorm(champ_data$rgSet, nPCs=2, 
sex=champ_data$mset@phenoData@data$Sex, bgCorr=TRUE, dyeCorr=TRUE, 
verbose=TRUE)




mValues_champ = getMvals(champ_data$mset,champ_data$rgSet) 
ctl_champ <- !(rownames(mValues_champ) %in% 
featureNames(champ_data))  
result_champ= naiveRandRuv(t(mValues_champ), ctl_champ, 
nuCoeff=1e-3, k=ceiling(ncol(mValues_champ)/4))  
champ_RUV <-t(result_champ) 






$mset),unmethylated(champ_data$mset)))  #... doesn't work:Error in 
#normalizeMethylation.quantile(champ_data$rgSet) : The input should 
include 'methylated' and 'unmethylated' elements in the assayData 
slot!
design.v <- getProbeType(champ_data$mset)
design.v <- ifelse(design.v=="I", "1","2")
champ_BMIQ <- BMIQ(getBeta(champ_data$mset), design.v=design.v2))
# looks the same if I poerform the norm on dat initially leaving in 
the Xy but filtering during norm
# From minfi; Noob is a background correction method with dye-bias 
normalization for the Illumina Infinium HumanMethylation450 
platform.
champ_Noob <- preprocessNoob(champ_data$rgSet,offset=15, 
dyeCorr=TRUE, verbose=TRUE)
densityPlot(champ_Noob,sampGroups= champ_Noob@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1),ylim=c(0,4), xlab="Beta", main="Density 
plot champ_Noob data")
mdsPlot(champ_Noob, numPositions=1000, sampNames= 
champ_Noob@phenoData$Sample_Name, sampGroups= champ_Noob@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- champ_Noob")
## Chapter.3 Appendix_2:  test normalisation methods ##
## Performance Metrics ##
#1.  Density plots; to examine QC samples, batch effects and also 
type I vs II distribution z1
    plotBetasByType
#2. MDS / PCA plots: 
# a.possibly with wilcoxon test to check for associations between 
the first few PCs/dimensions and batch variable princomp= function  
# b. ANOVA to check for the proportion of CpGs associated with 
batches?  
#3. Unsupervised hierarchical clustering 
#4. Replicate samples
# a. visually examining density and MDS plots 
# b. Mean absolute difference in M values between replicates- 
may need help with an algorithm for this if I can’t find something 
in a package or supp material   
#5. Diagnostic methods in the wateRmelon package; iDMRs, XCI, 









$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="Raw_preprocess")
densityPlot(Autosomes,sampGroups=Autosomes@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Autosomes_preprocess")
densityPlot(Male_chr,sampGroups= Male_chr@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Male_chr")
densityPlot(Female_chr,sampGroups= Female_chr@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Female_chr")
par(mfrow=c(1,4))
plotBetasByType(Raw_preprocess[,7], main="Raw by probe, all")
plotBetasByType(Autosomes[,7], main="Raw by probe, Autosomes")
plotBetasByType(Male_chr[,7], main="Raw by probe, Male_chr")
plotBetasByType(Female_chr[,7], main="Raw by probe, Female_chr")
# Stratified QN: StratQN
par(mfrow=c(1,4))
densityPlot(getBeta(StratQN),sampGroups=Autosomes@phenoData$Batch, 





Raw_preprocess@phenoData$Batch, pal = rainbow(3), xlim=c(-.
1,1.2),ylim=c(0,3.6), xlab="Beta", main="Stratified QN, all")
plotBetasByType(getBeta(StratQN_all)[,7], type_autosomes, 
main="Stratified QN, all")
# FunNorm:  FunNorm, only have unprocessed all chr together, 
separate?
par(mfrow=c(1,2))
densityPlot(FunNorm,sampGroups= FunNorm@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="FunNorm")
plotBetasByType(FunNorm[,7], main="FunNorm by probe, all")
#SWAN: swan, swan_autosomes, swan_maleChr, swan_femaleChr
par(mfrow=c(1,4))
densityPlot(swan,sampGroups= swan@phenoData$Batch, pal = rainbow(3), 
xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", main="swan")
densityPlot(swan_autosomes,sampGroups= swan_autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="swan_autosomes")
densityPlot(swan_maleChr,sampGroups= swan_maleChr@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="swan_maleChr")
densityPlot(swan_femaleChr,sampGroups= swan_femaleChr@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), 
xlab="Beta", main="Female_chr")
par(mfrow=c(1,4))
plotBetasByType(swan[,7], main="SWAN by probe, all")
plotBetasByType(swan_autosomes[,7], main="SWAN by probe, Autosomes")
plotBetasByType(swan_maleChr[,7], main="SWAN by probe, Male_chr")
plotBetasByType(swan_femaleChr[,7], main="SWAN by probe, 
Female_chr")
# Dasen: Dasen, Dasen_autosomes, Dasen_male, Dasen_female
par(mfrow=c(1,4))
densityPlot(Dasen,sampGroups= Raw_preprocess@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Dasen")
densityPlot(Dasen_autosomes,sampGroups= Autosomes@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Dasen_autosomes")
densityPlot(Dasen_male,sampGroups= Male_chr@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Dasen_male")
densityPlot(Dasen_female,sampGroups= Female_chr@phenoData$Batch, pal 
= rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.6), xlab="Beta", 
main="Dasen_female")
# These last two graphs look really odd, again I think it's an issue 
in calling the probe types
par(mfrow=c(1,4))
plotBetasByType(Dasen[,7], probeType=probeTypes_Dasen , main="Dasen 
by probe, all")
plotBetasByType(Dasen_autosomes[,7], 
probeType=probeTypes_autosomes2 , main="Dasen by probe, Autosomes")
# wont plot the last 2, maybe missing too many sites 
plotBetasByType(Dasen_male[,7], 
probeType=probeTypes_autosomes2_male, main="Dasen by probe, 
Male_chr")
plotBetasByType(Dasen_female[,7], 
probeType=probeTypes_autosomes2_female, main="Dasen by probe, 
Female_chr")
#RUV: BetaRUV_autosomes, BetaRUV_autosomes_optimal, BetaRUV_male, 
BetaRUV_female, BetaRUV_male_optimal, BetaRUV_female_optimal 
par(mfrow=c(1,6))
densityPlot(BetaRUV_autosomes,sampGroups=Autosomes@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Autosomes")
densityPlot(BetaRUV_autosomes_optimal,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Autosomes_Optimal")
densityPlot(BetaRUV_male,sampGroups=Male_chr@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", main="Density 
plot RUV data, Male_chr")
densityPlot(BetaRUV_female,sampGroups=Female_chr@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Female_chr")
densityPlot(BetaRUV_male_optimal,sampGroups=Male_chr@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Male_chr_optimal")
densityPlot(BetaRUV_female,sampGroups=Female_chr@phenoData$Batch, 
pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot RUV data, Female_chr")
par(mfrow=c(1,6))
plotBetasByType(BetaRUV_autosomes[,1], type , main="Autosomes 
BetaRUV by type", cex.legend=.8, legendPos="topright") 
plotBetasByType(BetaRUV_autosomes_optimal[,1], type , 
main="Autosomes_optimal BetaRUV by type", cex.legend=.8, 
legendPos="topright") 
plotBetasByType(BetaRUV_male[,1], type_male , main="Male_chr BetaRUV 
by type", cex.legend=.8, legendPos="topright") 
plotBetasByType(BetaRUV_female[,1], type_female , main="Female_chr 
BetaRUV by type", cex.legend=.8, legendPos="topright") 
plotBetasByType(BetaRUV_male_optimal[,1], type_male , 
main="Male_chr_optimal BetaRUV by type", cex.legend=.8, 
legendPos="topright")
plotBetasByType(BetaRUV_female_optimal[,1], type_female , 





pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 





densityPlot(BMIQ_betas,sampGroups=BMIQ@phenoData$Batch, pal = 
rainbow(3), xlim=c(-.1,1),ylim=c(0,4), xlab="Beta", main="Density 
plot BMIQ data, All chr")





= rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot BetaRUV_limma, Autosomes")
densityPlot(BetaRUV_limma_optimal,sampGroups=Autosomes@phenoData
$Batch, pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,3.5), 
xlab="Beta", main="Density plot BetaRUV_limma_optimal, Autosomes")
par(mfrow=c(1,2))
plotBetasByType(BetaRUV_limma[,1], probeTypes=probeTypes_autosomes2, 







pal = rainbow(3), xlim=c(-.1,1.2),ylim=c(0,20), xlab="Beta", 
main="Density plot Combat, Autosomes")
plotBetasByType(ComBat_autosomes[,1], 




# 2. MDS plots   ###
####################





ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
Raw_preprocess")
mdsPlot(Autosomes, numPositions=1000, sampNames=Autosomes@phenoData
$Sample_Name, sampGroups=Autosomes@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- Raw 
Autosomes")
mdsPlot(Male_chr, numPositions=1000, sampNames=Male_chr@phenoData
$Sample_Name, sampGroups=Male_chr@phenoData$Batch, xlim=c(-16,16), 









mdsPlot(getBeta(StratQN), numPositions=1000, sampNames= 
Autosomes@phenoData$Sample_Name, sampGroups= Autosomes@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- StratQN")
mdsPlot(getBeta(StratQN_all), numPositions=1000, sampNames= 
Raw_preprocess@phenoData$Sample_Name, sampGroups= 
Raw_preprocess@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
StratQN_all")





ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
FunNorm")
# SWAN: swan, swan_autosomes, swan_maleChr, swan_femaleChr
par(mfrow=c(1,4))
mdsPlot(swan, numPositions=1000, sampNames=swan@phenoData
$Sample_Name, sampGroups=swan@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- SWAN")
mdsPlot(swan_autosomes, numPositions=1000, sampNames= 
swan_autosomes@phenoData$Sample_Name, sampGroups= 
swan_autosomes@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
swan_autosomes")
mdsPlot(swan_maleChr, numPositions=1000, sampNames= 
swan_maleChr@phenoData$Sample_Name, sampGroups= 
swan_maleChr@phenoData$Batch, xlim=c(-16,16), 





ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
swan_femaleChr")
# Dasen: Dasen,Dasen_autosomes, Dasen_male, Dasen_female
par(mfrow=c(1,4))
mdsPlot(Dasen, numPositions=1000, sampNames= 
Raw_preprocess@phenoData$Sample_Name, sampGroups= 
Raw_preprocess@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- Dasen")
mdsPlot(Dasen_autosomes, numPositions=1000, sampNames= 
Autosomes@phenoData$Sample_Name, sampGroups= Autosomes@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- Dasen_autosomes")
mdsPlot(Dasen_male, numPositions=1000, sampNames= Male_chr@phenoData
$Sample_Name, sampGroups= Male_chr@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
Dasen_male")
mdsPlot(Dasen_female, numPositions=1000, sampNames= 
Female_chr@phenoData$Sample_Name, sampGroups= Female_chr@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- Dasen_female")
# male and female separate with dasen doesn't work
# RUV: BetaRUV_autosomes, BetaRUV_autosomes_optimal, BetaRUV_male, 
BetaRUV_female, BetaRUV_male_optimal, BetaRUV_female_optimal
par(mfrow=c(1,6))
mdsPlot(BetaRUV_autosomes, numPositions=1000, sampNames= 
Autosomes@phenoData$Sample_Name, sampGroups= Autosomes@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_autosomes")
mdsPlot(BetaRUV_autosomes_optimal, numPositions=1000, sampNames= 
Autosomes@phenoData$Sample_Name, sampGroups= Autosomes@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_autosomes_optimal")
mdsPlot(BetaRUV_male, numPositions=1000, sampNames= 
Male_chr@phenoData$Sample_Name, sampGroups= Male_chr@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_male")
mdsPlot(BetaRUV_female, numPositions=1000, sampNames= 
Female_chr@phenoData$Sample_Name, sampGroups= Female_chr@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_female")
mdsPlot(BetaRUV_male_optimal, numPositions=1000, sampNames= 
Male_chr@phenoData$Sample_Name, sampGroups= Male_chr@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_male_optimal")
mdsPlot(BetaRUV_female_optimal, numPositions=1000, sampNames= 
Female_chr@phenoData$Sample_Name, sampGroups= Female_chr@phenoData
$Batch, xlim=c(-16,16), ylim=c(-7,5),legendNCol=5, legendPos = 
"bottom", main="MDS- BetaRUV_female_optimal")
# QN - lumiQNbetas, need to figure out how to separate sex chr
mdsPlot(lumiQNbetas, numPositions=1000, sampNames= 
methylumi_prepro@phenoData$Sample_Name, sampGroups= 
methylumi_prepro@phenoData$Batch, xlim=c(-16,16), 
ylim=c(-7,5),legendNCol=5, legendPos = "bottom", main="MDS- 
lumiQNbetas")
# BMIQ - BMIQ, need to figure out how to separate sex chr
mdsPlot(BMIQ_betas, numPositions=1000, sampNames= 
methylumi_prepro@phenoData$Sample_Name, sampGroups= 
methylumi_prepro@phenoData$Batch, xlim=c(-16,16), 














match(Raw_Top1000_cpgs, StratQN_M_SD_Top1000_cpgs)  # some do











Combat_StratQN_SD_Top1000_cpgs))  # 730
length(which(Raw_Top1000_cpgs %in% Combat_StratQN_SD_Top1000_cpgs))  
#563
prcomp_Raw_Top1000 <- prcomp(t(Raw_manual_M[Raw_Top1000_cpgs,]))
anova_pc1_Raw1000_Family<- aov(prcomp_Raw_Top1000$x[,1] ~ 
factor(champ_data_mset_corrected@phenoData$Family))
summary(anova_pc1_Raw1000_Family)  # p-val   0.00143 **
prcomp_StratQN_Top1000 <- 
prcomp(t(StratQN_M[StratQN_M_SD_Top1000_cpgs,]))
anova_pc1_StratQN1000_Family <- aov(prcomp_StratQN_Top1000$x[,1] ~ 
factor(champ_data_mset_corrected@phenoData$Family))







summary(anova_pc1_Combat_StratQN1000_Family)  # p-val  0.000795 
# Now use the same method to look at how much clustering is due to 
batch
anova_pc1_Raw1000_Batch <- aov(prcomp_Raw_Top1000$x[,1] ~ 
factor(champ_data_mset_corrected@phenoData$Batch))
summary(anova_pc1_Raw1000_Batch)  # p-val <2e-16 ***  highly sig 
anova_pc1_StratQN1000_Batch <- aov(prcomp_StratQN_Top1000$x[,1] ~ 
factor(champ_data_mset_corrected@phenoData$Batch))




summary(anova_pc1_Combat_StratQN1000_Batch)  # p-val  0.97  NOT 
SIGNIFICANT, this is what expected















rownames(aov_pval_table)= c("Raw", "Qantile Normalisation", 
"Stratified Quantile Normalisation", "BMIQ", "SWAN", "Functional 
Normalisation", "Dasen", "Noob", "RUV", "RUV with limma", "Raw with 






## 3. Unsupervised hierarchial clustering--- takes an excessive 
















hc_StratQNcombat_names <- hclust(dist(t(StratQNcombat_d_names), 
method="euclidean"), method="single")
par(mfrow=c(1,3))
plot(hc_Raw_names, main="Cluster Dendrogram by Batch: 
Raw")
plot(hc_StratQN_names, main="Cluster Dendrogram by Batch: 
Stratified QN") 
plot(hc_StratQNcombat_names, main="Cluster Dendrogram by Batch: 
Stratified QN, ComBat corrected") 
## label by batch
Raw_d_batch <- getM(champ_data_mset_corrected)
colnames(Raw_d_batch) <- champ_data_beta$mset@phenoData$Batch









hc_StratQNcombat_batch <- hclust(dist(t(StratQNcombat_d_batch), 
method="euclidean"), method="single")
par(mfrow=c(3,1))
plot(hc_Raw_batch, main="Cluster Dendrogram by Batch: 
Raw")
plot(hc_StratQN_batch, main="Cluster Dendrogram by Batch: 
Stratified QN") 
plot(hc_StratQNcombat_batch, main="Cluster Dendrogram by Batch: 




## 4. Replicate samples  ##
#############################
# Density plots and MDS to visualise effects of normalisation then 
compare the mean absolute diff in M values between diff replicates
# There are 3 different samples that have technical replicates that 
passed QC:  22-16, 22-17, 72-213
Replicates <- Raw_preprocess[,c(6,27,8,28,31,41,16,18)]
# which batches/plates do they belong to?
Replicates@phenoData$Batch  # [1] 1 2 1 2 3 3 1 1
Replicates@phenoData$Plate  # [1] 1 3 1 3 4 5 2 2
Replicates_Mvals <- getM(Replicates)
colnames(Replicates_Mvals)=Replicates@phenoData$Sample_Name
#[1] "pc22-16"        "PC22-16 (AH9)"  "pc22-17"       
#[4] "PC22-17 (AH10)" "PC22-17a"       "PC22-17b"      
#[7] "pc72-213a"      "pc72-213b"
#  M = logit(Beta) = log( Meth / Unmeth )  This formula has problems 
if either Meth or Unmeth is zero. For this reason, we can use 
betaThreshold to make sure Beta is neither 0 nor 1, before taken the 
logit. What makes sense for the offset and betaThreshold depends 
crucially on how the data was preprocessed. Do not expect the 
default values to be particular good.
# type
How are the values calculated? For getBeta setting type="Illumina" 
sets offset=100 as per Genome Studio. For getM setting type="" 
computes M-values as the logarithm of Meth/Unmeth, otherwise it is 
computed as the logit of getBeta(object).
Replicates_Mvals2 <- getM(Replicates, type="", offset=100, 
betaThreshold=TRUE)
summary(Replicates_Mvals2[,2]) 
# changing these argumenst does nothing to change the number of 
infinite values!!
beta_default  <- getBeta(Replicates)
beta_illumina <- getBeta(Replicates, type="Illumina")
beta_threshold_100 <- getBeta(Replicates, offset=100)
beta_threshold_50 <- getBeta(Replicates, offset=50)
beta_illumina[1:10] # sets offset to 100 as genome studio does
beta_default[1:10]  # these values are slightly higher than illumina 
and include 1.0000, ie no there is no offset and the M-values would 
have issues
beta_threshold_100[1:10] # same as illumina
beta_threshold_50[1:10] # slightly higher values
Mvals_default <-getM(Replicates)  #logit of getBeta(object) 
Mvals_default[1:10]  # this has inf for the 3rd value which was 1 
before
Mvals_methUnmeth <- getM(Replicates, type="")  # logarithm of Meth/
Unmeth
Mvals_methUnmeth[1:10] # same as default, inf at 3
Mvals_threshold <- getM(Replicates, type="", betaThreshold=TRUE) # 
same with or without type
Mvals_threshold[1:10]  # same as default, inf at 3 -- this shouldn't 
be the case since threshold is specified... need to do it manually
# manually 
Mvals_manual <- logit2(beta_default)
Mvals_manual[1:10]  #this is identical to Mvals_default, inf at 3 
Mvals_manual_illumina <- logit2(beta_illumina)  ## use this
Mvals_manual_illumina[1:10]  # slightly lower values, the 3rd value 
is not infinite
Mvals_manual_threshold100 <- logit2(beta_threshold_100)
Mvals_manual_threshold100[1:10] # identical to illumina one
Mvals_manual_threshold50 <- logit2(beta_threshold_50)
Mvals_manual_threshold50[1:10]  #slightly higher than threshold of 
100
# Don't use the default beta values because they contain 1s, use: 
Mvals_manual_illumina
logMethUnmeth <- logit2(getMeth(Replicates) / getUnmeth(Replicates))
logMethUnmeth[1:10]
beta_man <- getMeth(Replicates) / (getMeth(Replicates) + 
getUnmeth(Replicates) + 100)  # maybe I need to keep adjusting the 
offset so it makes the 0s big enough that their log is not -inf?? so 
a sml threshold?   no :(   no it won't make a difference what the 
threshold is if meth is 0 because the numerator will be 0... need to 








length(which(beta_man_M2[,1]==-Inf))  # yesssss this gets rid of the 
negative infinity values but because adding the same number top and 
bottom cancels out it creates + infinite values as beta can now be 
equal to 1. If I add an offset of 50 to the top and 100 to the 
bottom will this affect the value in a biased manner?




length(which(beta_man_M3[,1]==-Inf))  # yes both are length 0 :):):) 
but has it changed values in a biased way.. if I make the difference 
between them very small, say .1
# Use
Replicates_Mvals <- beta_man_M3
# look out for infinite values:  
summary(Replicates_Mvals[,1]) 
#   Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 
# -7.6320 -3.0330  0.8257  0.3039  3.0100 17.6600 
summary(Replicates_Mvals[,2])  
# Min. 1st   Qu.  Median    Mean 3rd Qu.    Max.    
# -7.2020 -2.9490  0.9983  0.3781  3.1330 16.9400
summary(Replicates_Mvals[,3]) 
#   Min.  1st Qu.  Median    Mean 3rd Qu.    Max.    
#   -7.7050 -3.0970  0.9217  0.3675  3.1950 17.9200
summary(Replicates_Mvals[,4])  
#  Min.  1st Qu.  Median    Mean 3rd Qu.    Max.   
#  -7.2920 -3.1900  1.0640  0.3447  3.2780 17.2000 
summary(Replicates_Mvals[,5]) 
#   Min.  1st Qu.  Median    Mean 3rd Qu.    Max.    
#  -8.87800 -3.13200  0.63340  0.08353  2.63400 18.76000   
summary(Replicates_Mvals[,6])  
#    Min. 1st Qu.  Median    Mean 3rd Qu.    Max.    
#   -7.9550 -2.9350  0.7339  0.2195  2.8100 18.1800 
summary(Replicates_Mvals[,7])  
#   Min.  1st Qu.  Median    Mean 3rd Qu.    Max.   
#  -7.3840 -2.8220  0.9293  0.3257  3.0050 17.4500 
summary(Replicates_Mvals[,8])  
#   Min.  1st Qu.  Median    Mean 3rd Qu.    Max.   
#   -7.4520 -2.7940  0.9521  0.3328  3.0040 17.4400  
   



















# 1: "pc22-16"  batch 1, chip 1      
# 2: "PC22-16 (AH9)" batch 2, chip 3
# 3: "pc22-17" batch 1, chip 1
# 4: "PC-17 (AH10)" batch 2, chip 3
# 5: "PC22-17a" batch 3, chip 4
# 6: "PC22-17b" batch 3, chip 5
# 7: "pc72-213a"     batch 1, chip 2
# 8: "pc72-213b"     batch 1, chip 2
# Compare:  
# 1. 22.16 (1 & 2)    diff plate, diff batch (one OS, one here)  
"pc22-16"        "PC22-16 (AH9)"
# 2. 72.213 (7 & 8)   same plate, same batch, different 
sample(array) : Expect to be smallest diff
22.17 (3,4,5,6)  all different plates, 3/4 different 
batches
# 3. 22.17 (3,4)      diff plate, diff batch
# 4. 22.17 (3,5)    diff plate, diff batch
# 5. 22.17 (3,6)   diff plate, diff batch
# 6. 22.17 (4,5)    diff plate, diff batch
# 7. 22.17 (4,6)      diff plate, diff batch
# 8. 22.17 (5,6)    diff plate, same batch  : expect 
middle diff
# 9. (1 & 3) compare diff samples same batch, same plate
#10. (3,7) diff sample, same batch , diff plate
#11. (6,7) diff sample, diff batch, diff plate
#1.
#MeanDiff_22.16=mean(abs(Replicates_Mvals[,1] - Replicates_Mvals[,



































# these should be much bigger differences than the diff between the 
samples but aren't.  THis is preprocessed data so batch effects 
haven't been removed yet, thus makes sense
#1  rep 22.16:  diff plate, diff batch







rownames(table_replicate_medians_rep16) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")
colnames(table_replicate_medians_rep16) <- "Median absolute 
difference between replicates"
write.csv(table_replicate_medians_rep16, file="Replicate.1 Median 
Diffs.csv")
#2  72.213:  same batch, same plate







rownames(table_replicate_medians_rep72.213) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")




#3 22.17a:  diff plate, diff batch







rownames(table_replicate_medians_rep22.17a) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")












rownames(table_replicate_medians_rep22.17b) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")












rownames(table_replicate_medians_rep22.17c) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")












rownames(table_replicate_medians_rep22.17d) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")












rownames(table_replicate_medians_rep22.17e) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")












rownames(table_replicate_medians_rep22.17f) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")













rownames(table_replicate_medians_diffsamp1) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")













rownames(table_replicate_medians_diffsamp2) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")













rownames(table_replicate_medians_diffsamp3) <- c("Raw", "Qantile 
Normalisation", "Stratified Quantile Normalisation", "BMIQ", "SWAN", 
"Functional Normalisation", "Dasen", "Noob", "RUV", "RUV with 
limma", "Raw with ComBat", "Stratified Quantile Normalisation with 
ComBat")





### 5. Dasen metrics ###    
######################
# iDMRs, XCI, 65snps - standard error type measurement for each 
(DMRSE, 1-AUC, GCOSE)
# only iDMRs work on this data
library(wateRmelon)
############
# a) iDMRs:  
# Imprinting differentially methylated regions (iDMRs) are expected 
to be approximately half methylated, as is observed at the 227 
probes in known iDMRs. These functions calculate measures of 
dispersion for the beta values at these CpG sites, 
# Returns a standard error of the mean of betas for all samples and 
iDMR probes (dmrse) or the standard error of the mean for just the 
between sample component (dmrse_row) or between probe(dmrse_col) 
component.
# lower values are better
dmrse_row(Raw_preprocess)  / dmrse_row(Autosomes) 
# 227 iDMR data rows found
# [1] 0.004897683
dmrse_row(Male_chr) / dmrse_row(Female_chr) # don't need all probes 
as autosomes works but can't just do on sex probes 
# 0 iDMR data rows found
dmrse_row(StratQN_betas)    # 0.003342732
dmrse_row(FunNorm_betas)    # 0.005589773
dmrse_row(swan)    # 0.004925195
dmrse_row(swan_autosomes)   # 0.004920393
dmrse_row(Dasen)  # 
0.004927997
dmrse_row(Dasen_autosomes)  # 0.004956462
dmrse_row(BetaRUV_autosomes)   # 0.00422788
dmrse_row(BetaRUV_autosomes_optimal) # 0.00489734  worse than 
default setting
dmrse_row(lumiQNbetas)  # 0.005220801
dmrse_row(BMIQ)  # 
0.006240381
dmrse_row(ComBat_autosomes)  # 0.002518785
# Stratified QN looks to be the best normalisation method. Combat 
batch correction on preprocessed data is the overall best.  
# Try combat on other norm methods if possible
#############
# b) XCI - seabi
# Can only use on the objects normalised with sex CHR or just men
# Calculates an area under ROC curve - based metric for Illumina 
450K data using a t-test for male-female difference as the predictor 
for X-chromosome location of probes. The metric is 1-area so that 
small values indicate good performance,to match our other, standard 
error based metrics gcose and dmrse. Note that this requires both 
male and female samples of known sex and can be slow to compute due 
to running a t-test on every probe.
seabird_Raw<- seabi(getBeta(Raw_preprocess), sex= 
Raw_preprocess@phenoData$Sex, X=as.logical(Annotated@listData
$chr=="chrX")) # takes awhile but computes in the end
#[1] 0.09567028








# c) 65 SNPs:
#There are 65 well-behaved SNP genotyping probes included on the 
array. These each produce a distribution of betas with tight peaks 
for the three possible genotypes, which will be broadened by 
technical variation between samples. The spread of the peaks is thus 
usable as a performance metric.
# genki: A very simple genotype calling by one-dimensional K-means 
clustering is performed on each SNP, and for those SNPs where there 
are three genotypes, the squared deviations are summed for each 
genotype (similar to a standard deviation for each of allele A 
homozygote, heterozygote and allele B homozygote). By default these 
are further divided by the square root of the number of samples to 
get a standard error-like statistic.
# should get: a vector of 3 values for the dispersion of the three 
genotype peaks (AA, AB, BB : low, medium and high beta values)
#gcose - calculate between-sample SNP standard error
genki_Autosomes <- genki(getBeta(Autosomes), 
g=getsnp(rownames(Autosomes)), se=TRUE) 




x <- grep("rs", rownames(y), ignore.case=TRUE,)




### 6. positive controls ###
#########################
# CpGs known to affect methylation, use minfi function 'plotCpg'
# CpG-SNP sites with most significant phenotype-wide correlated cis 
associations - in the brain, fromZhang etc al 2010
library(minfi)
cpgs=c("cg24920358","cg22333868","cg13926569", "cg17749961", 






















row.names(Raw_zhang)  <- gsub("..AH[1-9]+.","",row.names(Raw_zhang))
row.names(Raw_zhang)  <- 
gsub("PC22-17)","PC22-17",row.names(Raw_zhang))
row.names(Raw_zhang)  <- gsub("a","",row.names(Raw_zhang))
row.names(Raw_zhang)  <- gsub("b","",row.names(Raw_zhang))
row.names(Raw_zhang)  <- gsub("pc","PC",row.names(Raw_zhang))







row.names(StratQN_zhang)  <- 
gsub("..AH[1-9]+.","",row.names(StratQN_zhang))
row.names(StratQN_zhang)  <- 
gsub("PC22-17)","PC22-17",row.names(StratQN_zhang))
row.names(StratQN_zhang)  <- gsub("a","",row.names(StratQN_zhang))
row.names(StratQN_zhang)  <- gsub("b","",row.names(StratQN_zhang))
row.names(StratQN_zhang)  <- 
gsub("pc","PC",row.names(StratQN_zhang))




















for (cpg in 1:length(chr)) {
system(paste(c("/Applications/plink-1.07-mac-intel/plink --
noweb --file ~/Documents/GENEPI/prostate/illumina/PCillumina/data --
chr ",chr[cpg]," --from-bp ",pos[cpg]-10^6," --to-bp ",pos[cpg]
+10^6," --recode --out ~/Users/ecazaly/Desktop/R Dec14/NormPaper/
cpg",cpg),collapse=""))
}
#for (cpg in 1:length(chr)) { 
 cpg=4
system(paste(c("/Applications/plink-1.07-mac-intel/plink --
noweb --file /Users/ecazaly/Desktop/R\\ Dec14/NormPaper/
PLINK_PCnoerrors_MAF05/PCnoerrors_MAF05 --chr ",chr[cpg]," --from-bp 
",pos[cpg]-10^6," --to-bp ",pos[cpg]+10^6," --recode --out /Users/
ecazaly/Desktop/R\\ Dec14/NormPaper/cpg",cpg),collapse=""))





























?lm  # figure out where to put kinship as a covariate in model -- 
need to use the GenABEL model to account for kinship

























cpgs <- poss[1:11,4]  # this is where the cpg order gets messed up.  
These are the 10 closest cpgs to "cg01561916" but have unfortunately 
been given the same name as the first bunch of CpGs so when I reran 
the code it messed it up
# oldcpgs: "cg24920358" "cg22333868" "cg13926569" "cg17749961" 




















































# this works for raw now try on other data, ie stratQN and COmBat
#StratQN  





































## There is a big jump in significance!!! 
# Combat_StratQN




















between methylation and SNPs: 
















# this one is in between raw and StratQN, expected as batch and 
family are confounded you may actually be taking out real 
information
********************************************************************
# which were the samples used in this analysis?
rownames(Raw_zhang)[row.names(Raw_zhang) %in% row.names(geno)]
 # [1] "PC11.3"   "PC22.2"   "PC11.4"   "PC22.3"   "PC11.9"   
"PC22.16" 
 # [7] "PC11.147" "PC22.17"  "PC22.21"  "PC22.416" "PC72.4"   
"PC9.1"   
# [13] "PC9.4"    "PC9.12"   "PC9.477"  "PC22.16"  "PC22.17"  
"PC22.17" 
# [19] "PC22.4"   "PC11.180" "PC22.17"  "PC9.338" 




#### Redo plots with KINSHIP and new omni data###
##  Use the association model from the GenABEL package to account 
for kinship.  Then plot as above
# take out the replicate samples:  [,-c(27,28,31,41,16)]
Raw_zhang <- Raw_zhang[-c(27,28,31,41,16),]
StratQN_zhang <- StratQN_zhang[-c(27,28,31,41,16),] 
Combat_StratQN_zhang <- Combat_StratQN_zhang[-c(27,28,31,41,16),] 
# Fix the sample names
rownames(Raw_zhang) <- gsub(".", "_", rownames(Raw_zhang), 
fixed=TRUE)
rownames(Raw_zhang) <- gsub("_3", "_03", rownames(Raw_zhang))
rownames(Raw_zhang) <- gsub("_1", "_01", rownames(Raw_zhang))
rownames(Raw_zhang) <- gsub("_2", "_02", rownames(Raw_zhang))
rownames(Raw_zhang) <- gsub("_4", "_04", rownames(Raw_zhang))
rownames(Raw_zhang) <- gsub("_9", "_09", rownames(Raw_zhang))
rownames(Raw_zhang)[c(6:15,17,19,22:28,30:36,38:47)] <- gsub("_0", 
"_", rownames(Raw_zhang)[c(6:15,17,19,22:28,30:36,38:47)])








Association_2015april/Ass_genetic_input/cutoff_15_final --chr ", 
chr[cpg]," --from-bp ",pos[cpg]-10^6," --to-bp ",pos[cpg]+10^6," --













# match pheno data to genotype  
length(which(cpg4_tfam$V2 %in% rownames(Raw_zhang)))  #39 -- takes 
out 8
Raw_zhang_b <- Raw_zhang[c(which(rownames(Raw_zhang) %in% cpg4_tfam
$V2, arr.ind=TRUE)),]
removed <- Raw_zhang[-c(which(rownames(Raw_zhang) %in% cpg4_tfam$V2, 
arr.ind=TRUE)),]
rows_removed <- rownames(removed)






sex_Raw_zhang <- gsub("M", "1", sex_Raw_zhang)
sex_Raw_zhang <- gsub("F", "0", sex_Raw_zhang)
pheno_Raw_zhang <- cbind(ID_Raw_zhang, sex_Raw_zhang, Raw_zhang)
pheno_Raw_zhang_b <- pheno_Raw_zhang[c(which(rownames(Raw_zhang) %in
% cpg4_tfam$V2, arr.ind=TRUE)),]
write.table(pheno_Raw_zhang_b, file="pheno_Raw_zhang.txt")
remove<- which(!(rownames(pheno_Raw_zhang) %in% 
rownames(pheno_Raw_zhang_b)))
length(remove)
# Now need to make the genotype file match the samples on the array
famID <- matrix(c(49,33,4, 43, 6, 48, 7, 8, 10, 12, 52, 15, 18, 21, 
38, 30, 51, 53, 25, 22, 39, 34, 47, 5, 9, 28, 29, 36, 26, 17, 13, 
45, 27, 11, 37, 14, 31, 50, 44))
# check
length(unique(famID)) # 39









Samples_zhang.txt --chr ", chr[cpg]," --from-bp ", pos[cpg]-10^6," 
--to-bp ",pos[cpg]+10^6," --recode --transpose --out /Users/ecazaly/
Desktop/PhD_Analysis/Association_2015april/Ass_genetic_input/
cpg_b",cpg),collapse=""))




# create gwaa object
gwaa_cpg4=load.gwaa.data(phenofile="pheno_Raw_zhang.txt", 
genofile="Ass_genetic_input/cpg_b4.raw", force=TRUE)
# create kinship coefficient object
kinship <- read.csv("Ass_genetic_input/kinship_coefficient.csv", 
header=TRUE)
# work out which ones I need
Raw_zhang_c <- Raw_zhang_b
rownames(Raw_zhang_c) <- gsub("PC", "PCTAS", rownames(Raw_zhang_c))
rownames(Raw_zhang_c)  <- gsub("_", "-", rownames(Raw_zhang_c) )
kinship$decoded.1 <- gsub("PC22-", "", kinship$decoded.1, 
fixed=TRUE)
kinship$decoded.1<- gsub("PC11-", "",kinship$decoded.1, fixed=TRUE)
kinship$decoded.1<- gsub("PC72-", "", kinship$decoded.1, fixed=TRUE)
kinship$decoded.1<- gsub("PC9-", "", kinship$decoded.1, fixed=TRUE)
kinship$decoded.2 <- gsub("PC22-", "", kinship$decoded.2, 
fixed=TRUE)
kinship$decoded.2 <- gsub("PC11-", "", kinship$decoded.2, 
fixed=TRUE)
kinship$decoded.2 <- gsub("PC72-", "", kinship$decoded.2, 
fixed=TRUE)
kinship$decoded.2 <- gsub("PC9-", "", kinship$decoded.2, fixed=TRUE)
length(which(kinship$decoded.1 %in% rownames(Raw_zhang_c)))  #5654
name=rownames(Meth_B_cg13387643_b)
name <- gsub("PC", "PCTAS", name)
name  <- gsub("_", "-", name )
name <- gsub("-a", "", name)
length(which(kinship$decoded.1 %in% name)))
kinship_1_zhang <- kinship[c(kinship$decoded.1 %in% 
rownames(Raw_zhang_c), arr.ind=TRUE),]
dim(kinship_1_zhang) # 5655   4  good
kinship_2_zhang <- kinship_1_zhang[c(kinship_1_zhang$decoded.2 %in% 
rownames(Raw_zhang_c), arr.ind=TRUE),]
dim(kinship_2_zhang) # 181 4
head(kinship_2_zhang)
kinship_3_zhang <- kinship_2_zhang[-181,c(1,3,4)]
kinship_3_zhang$decoded.1 <- gsub("PCTAS", "PC", kinship_3_zhang
$decoded.1, fixed=TRUE)










# check kinship by Identity-By-State function ibs() in GenABEL
# Create gwaa object with all SNPs, pulling out subjects of interest
library(GenABEL)






# After frequency and genotyping pruning, there are 1616835 SNPs







ibs <- ibs(gwaa_all, weight="freq")
colnames(ibs) <- gsub("_", "-", colnames(ibs))
rownames(ibs) <- gsub("_", "-", rownames(ibs))
# if don't specify weight="freq" then the values are off, with some 
values like 0.781 and others like 1609264.  Identical samples do not 
= 1
# try SNPRelate package
library(SNPRelate)
# Calculate IBD coefficients by KING method of moment.  
snpgdsIBDKING {SNPRelate}



















log10pvps_cpg4=vector()              
for(i in colnames(beta_gwaa_cpg4b@phdata[6])) {
  for(j in colnames(beta_gwaa_cpg4b@gtdata@gtps)){ 
   if(sum(beta_gwaa_cpg4b@gtdata@gtps[j],na.rm=T)==0) {   
  next
  } 
    name[modelnum]= paste(i, j, sep= "/")   
    formula_cpg4=as.formula(paste(beta_gwaa_cpg4b@phdata[i], "~", 
beta_gwaa_cpg4b@gtdata@gtps[j]))
    association_cpg4=polygenic_hglm(formula_cpg4, ibs, 
beta_gwaa_cpg4b)
    coefs_cpg4[modelnum] = summary(association_cpg4$hglm)
$FixCoefMat[2,1]
    pvals_cpg4[modelnum] = summary(association_cpg4$hglm)
$FixCoefMat[2,4]
    log10pvps_cpg4[modelnum]= -1*log10(pvals_cpg4[modelnum])
    modelnum= modelnum + 1
    }
    }
length(which(pvals_cpg4=="NaN"))   #1163
length(pvals_cpg4)    #1661
# so using b-values produces 261 less NaN errors
# Good ones: 498  -- how does this compare to the number of snps in 
the old 370k window?
length(pvals_cpg4)-length(which(pvals_cpg4=="NaN"))
length(beta_gwaa_cpg4b@gtdata@gtps) - length(pvals_cpg4)
# 46 removed due to all 0s
 # something is still not right because the first few are NA but 
worked before..  There is something wrong with the CpG as the loop 
works on other CpGs.  Maybe it is the M-val being negative.  Will 
try on the B-val
 # Warning messages:
# 1: In log(eigen(Sigma, only.values = TRUE)$values) : NaNs produced
# 2: In pt(abs(as.numeric(FixCoefMat[, 3])), object$dfReFe, 
lower.tail = FALSE) :
  # NaNs produced
# 3: In pt(abs(as.numeric(FixCoefMat[, 3])), object$dfReFe, 
lower.tail = FALSE) :
  # NaNs produced




# this seems to work but still get a warning but gives a value not 
NaN 
# Warning message:
# In log(eigen(Sigma, only.values = TRUE)$values) : NaNs produced
# I guess this makes sense as this was the first warning msg above 
and talks about logs which is what the M-values are.  So looks like 
I've sorted the second two and maybe an offset is needed to fix the 
log issue
## when the loop runs on all snps the same 3 errors come up
# so it works on 97 but not 98, whats different
beta_gwaa_cpg4b@gtdata@gtps[,97] #3 x1s
beta_gwaa_cpg4b@gtdata@gtps[,98] # only 2x 1s -- is this below some 
MAF??
beta_gwaa_cpg4b@gtdata@gtps[,9]  # this has heaps of values but the 
loop dpesn't work..
# the coef for this is negative and small and then the p-val is 
NaN..; maybe just need to exclude these ones, see hwo many there are 
 






# seems like a large proportion    
    
# the model doesn't like it when a snp is 0 for everyone, it 
produces NAs and then an error when working out the p-val and messes 
the whole loop up.  The if line says if the column adds up to 0 then 
skip the rest of the loop and go onto the next snp.  Must add 
na.rm=T as some fo the rows have an NA value
# may need to remove monomorphic alleles, ie those that appear in 
only one individual.  see if get an error with this.
     
# Errors being prodiced:  
# Error in GLM.MME(Augy = Augy, AugXZ = AugXZ, starting.delta = 
c(b.hat,  : 
  # GLM.MME diverged! Try different starting values.
# In addition: Warning message:
# In .coef.trunc(qr, .Call(sparseQR_coef, qr, y), drop = TRUE) :
  # sparseQR_coef(): structurally rank deficient case: possibly 
WRONG zeros
# maybe some of the snps come up as all 0s?? try analysis in chunks 
to find culprit







# 96, 97, 98 ok
# 99 error, yes this is where the whole column is 0.  Could just 
mean all are homo, or error. 
# remove 




map <- read.table("Ass_genetic_input/cpg_b4.map", as.is=T)
# cut down map to the 1661 snps that didn't have all 0
name_keep <- gsub("cg17749961/", "", name)
head(map)




























# This it works.  Although it looks like the SNP picked up in the 
previous data is njot on this array or had a NaN value because there 
are now 2 sig SNPs but they are a fair bit further downstream that 
the cpg site.  Which may be good in the fact that the snp would not 
be in the probe body unless it's a reverse probe and even then 
surely its miles and miles away
# try on the normalised and batch corrected data
# Raw_zhang <- Raw_zhang[-c(27,28,31,41,16),]
# StratQN_zhang <- StratQN_zhang[-c(27,28,31,41,16),] 













log10pvps_stratQN=vector()              
for(i in colnames(StratQN_zhang_gwaaB@phdata[6])) {
  for(j in colnames(StratQN_zhang_gwaaB@gtdata@gtps)){ 
   if(sum(StratQN_zhang_gwaaB@gtdata@gtps[j],na.rm=T)==0) {   
  next
  } 
    name_stratQN[modelnum]= paste(i, j, sep= "/")   
    formula_stratQN=as.formula(paste(StratQN_zhang_gwaaB@phdata[i], 
"~", StratQN_zhang_gwaaB@gtdata@gtps[j]))
    association_stratQN=polygenic_hglm(formula_stratQN, ibs, 
StratQN_zhang_gwaaB)
    coefs_stratQN[modelnum] = summary(association_stratQN$hglm)
$FixCoefMat[2,1]
    pvals_stratQN[modelnum] = summary(association_stratQN$hglm)
$FixCoefMat[2,4]
    log10pvps_stratQN[modelnum]= -1*log10(pvals_stratQN[modelnum])
    modelnum= modelnum + 1
    }
    }
length(which(pvals_stratQN=="NaN"))   # this is now 0, as opposed to 
1163.  Must be the offset etc in Strat




































log10pvps_combat=vector()              
for(i in colnames(Combat_zhang_gwaaB@phdata[6])) {  
  for(j in colnames(Combat_zhang_gwaaB@gtdata@gtps)){ 
   
if(sum(Combat_zhang_gwaaB@gtdata@gtps[j],na.rm=T)==0) {   
  next
  } 
    name_combat[modelnum]= paste(i, j, sep= "/")   
    
formula_combat=as.formula(paste(Combat_zhang_gwaaB@phdata[i], "~", 
Combat_zhang_gwaaB@gtdata@gtps[j]))
    association_combat=polygenic_hglm(formula_combat, ibs, 
Combat_zhang_gwaaB)
    coefs_combat[modelnum] = summary(association_combat
$hglm)$FixCoefMat[2,1]
    pvals_combat[modelnum] = summary(association_combat
$hglm)$FixCoefMat[2,4]
    log10pvps_combat[modelnum]= 
-1*log10(pvals_combat[modelnum])
    modelnum= modelnum + 1
    }
    }
length(which(pvals_combat=="NaN"))   # 0
length(pvals_combat)    #1661
length(pvals_combat)-length(which(pvals_combat=="NaN")) #1661
























# also try with the original model with the new OMNI data
# for (i in 1:nsnps) {
# geno <- PPIEgeno[,(i*2+5):(i*2+6)]
# geno <- geno[rowSums(geno=="0")==0,]
# geno <- 
geno[match(row.names(StratQN_zhang),row.names(geno)),]
# als <- levels(factor(unlist(geno)))




# gc <- rowSums(geno==als[1])
# fit = lm(StratQN_zhang[,cpg] ~ gc)
# pv <- summary(fit)$coef[2,4]
# log10pv[i] <- -1*log10(pv)
# }
  for(i in 1:length(Combat_zhang_gwaaB@gtdata@gtps)){ i=1
   if(sum(gwaa10@gtdata@gtps[i],na.rm=T)==0) {   
  next
  }





length(log10pv) # this is giving a pval length of 64779
chr <- c(1,12,10,2,1,17,14,2,19,7)
map <- read.table("Ass_genetic_input/cpg_b4.map", as.is=T)
# cut down map to the 1661 snps that didn't have all 0
name_keep <- gsub("cg17749961/", "", name)
head(map)



























# Use the kinship calculated for a subset of samples 
samples <- c('PC9-1 (AH1)',"PC9-4 (AH2)","PC9-12 (AH4)", "PC9-24 
(AH6)", "PC9-121 (AH7)", "PC9-477 (AH8)", "PC22-16 (AH9)", "PC22-17 
(AH10)", "PC22-210 (AH11)", "PC22-393 (AH12)", "pc11-3", "pc22-2", 
"pc11-4", "pc22-3", "pc11-9", "pc22-16", "pc11-147", "pc22-17", 
"pc22-21", "PC22-468", "pc22-203", "pc22-387", "pc72-136", 
"pc22-416", "pc72-188", "pc72-4", "pc72-77", "pc72-126")






write.csv(meth_dist_raw, file="meth_dist_raw.csv") # use the 


















$Kinship..Coefficient, col=meth_dist_kinship$Family, pch=16, 
ylim=c(200,1000), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Raw Data 
Methylation Distance vs Kinship Coefficient")
legend('topleft', col=1:3, pch=16, legend=levels(meth_dist_kinship
$Family)) 
plot(meth_dist_kinship$Meth.Dist.StratQN..Mval~meth_dist_kinship
$Kinship..Coefficient, col=meth_dist_kinship$Family, pch=16, 
ylim=c(200,1000), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Stratified QN 
Methylation Distance vs Kinship Coefficient")




$Kinship..Coefficient, col=meth_dist_kinship$Family, pch=16, 
ylim=c(200,1000), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Stratified QN, ComBat corrected 
Methylation Distance vs Kinship Coefficient")






ylab='Methylation Distance: M-vals', xlab='Kinship Coefficient 
(absolute Log)', main="Stratified QN, ComBat corrected 
Methylation Distance vs Kinship Coefficient")
legend('topleft', col=1:3, pch=16, legend=levels(meth_dist_kinship
$Family)) 
# Perhaps just look at those closely related as the relationship 




Family_coef <- gsub("Family 9", "3", Family_coef)
Family_coef <- gsub("Family 22", "1", Family_coef)
Family_coef <- gsub("Family 11", "2", Family_coef)
par(mfrow=c(1,3))
plot(close_kinship$Meth.Dist.Raw..Mval~close_kinship
$Kinship..Coefficient, cex=1.5, pch=Family_coef, col=Family_coef, 
ylim=c(200,810), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Methylation Distance vs Kinship 
Coefficient: 
 Raw Data") 
plot(close_kinship$Meth.Dist.StratQN..Mval~close_kinship
$Kinship..Coefficient, cex=1.5,pch=Family_coef, col=Family_coef, 
ylim=c(200,810), ylab='Methylation Distance: M-vals', xlab='Kinship 




$Kinship..Coefficient, cex=1.5, pch=Family_coef, col=Family_coef, 
ylim=c(200,810), ylab='Methylation Distance: M-vals', xlab='Kinship 
Coefficient (absolute Log)', main="Methylation Distance vs Kinship 
Coefficient:
Stratified QN, ComBat corrected")
correlation_Raw <- cor(x=close_kinship$Meth.Dist.Raw..Mval, 
y=close_kinship$Kinship..Coefficient, method="pearson")
# -0.6517868







#### Positive Control 2 :  QQ plots ####
# creat 3 QQ plots looking at methylation vs age, before and after 
normalisation and with Combat
# Run a regression between methylation and age and pull out the p-
value for methylation at a given row.
## For Raw methylation values  ##
rawmeth_age_pv <- function(row) {
  summary(lm(Raw_manual_M_3[row,]~Age_numeric))$coef[2,4]
}
# Test first 100 rows:
pvals <- sapply(1:100,rawmeth_age_pv)
# Obtain p-values for all 
pvals_raw <- sapply(1:nrow(Raw_manual_M_3),rawmeth_age_pv)
## For StratQN ##
StratQN_age_pv <- function(row) {
  summary(lm(StratQN_M_2[row,]~Age_numeric))$coef[2,4]
}
# Test first 100 rows:
pvals_StratQN_test <- sapply(1:100,StratQN_age_pv)
# Obtain p-values for all 
pvals_StratQN <- sapply(1:nrow(StratQN_M_2), StratQN_age_pv)
## For Combat/StratQN ##




# Test first 100 rows:
pvals_CombatStratQN_test <- sapply(1:100, CombatStratQN_age_pv)
# Obtain p-values for all 
pvals_CombatStratQN <- sapply(1:nrow(Combat_StratQN_corrected_M), 
CombatStratQN_age_pv)
#### Then generate expected pvals for each  ####
m=length(pvals_raw) #all 3 have same length
expect.stats=-log10(seq(1/(m+1),m/(m+1),length.out=m))
png("QQplot Raw.png")
qqplot(x=expect.stats, y=-log10(pvals_raw), plot.it=TRUE, xlab = 
"expected -log10(pvalues)", ylab ="observed -log10(pvalues)", 






qqplot(x=expect.stats, y=-log10(pvals_StratQN), plot.it=TRUE, xlab 
="expected -log10(pvalues)", ylab ="observed -log10(pvalues)", 






qqplot(x=expect.stats, y=-log10(pvals_CombatStratQN), plot.it=TRUE, 
xlab = "expected -log10(pvalues)", ylab = "observed -






# these plots show that after normalisation there are a lot more 
sites significantly associated with age.  
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Comparison of pre-processing
methodologies for Illumina 450k
methylation array data in familial analyses
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Abstract
Background: Human methylome mapping in health and disease states has largely relied on Illumina Human
Methylation 450k array (450k array) technology. Accompanying this has been the necessary evolution of analysis
pipelines to facilitate data processing. The majority of these pipelines, however, cater for experimental designs
where matched ‘controls’ or ‘normal’ samples are available. Experimental designs where no appropriate ‘reference’
exists remain challenging. Herein, we use data generated from our study of the inheritance of methylome profiles
in families to evaluate the performance of eight normalisation pre-processing methods. Fifty individual samples
representing four families were interrogated on five 450k array BeadChips. Eight normalisation methods were tested
using qualitative and quantitative metrics, to assess efficacy and suitability.
Results: Stratified quantile normalisation combined with ComBat were consistently found to be the most
appropriate when assessed using density, MDS and cluster plots. This was supported quantitatively by ANOVA on
the first principal component where the effect of batch dropped from p < 0.01 to p = 0.97 after stratified QN and
ComBat. Median absolute differences between replicated samples were the lowest after stratified QN and ComBat
as were the standard error measures on known imprinted regions. Biological information was preserved after
normalisation as indicated by the maintenance of a significant association between a known mQTL and
methylation (p = 1.05e-05).
Conclusions: A strategy combining stratified QN with ComBat is appropriate for use in the analyses when no
reference sample is available but preservation of biological variation is paramount. There is great potential for use
of 450k array data to further our understanding of the methylome in a variety of similar settings. Such advances will
be reliant on the determination of appropriate methodologies for processing these data such as established here.
Keywords: Familial data, 450k, Array, Methylation, Pre-processing pipeline, Normalisation
Background
DNA methylation, the covalent addition of a methyl group
to a cytosine base, usually in a cytosine-guanine pair
(CpG), remains the most widely studied epigenetic modifi-
cation in disease. While around 70 % of CpG dinucleotides
are methylated in mammals, when clustered in groups or
‘islands’ (CGIs) they are generally unmethylated [1]. These
islands occur often at promoter regions, where methylation
has been traditionally associated with transcriptional re-
pression [2]. Less extensively studied, but potentially more
interesting, is the regulatory role of methylation at CpG
shores and within gene bodies, as these regions have been
found to be more variably methylated between tissue types
and in cancer compared to normal tissue [3, 4].
Deepening the complexities surrounding the regulatory
roles of CpG dinucleotides located in regions adjacent to
promoters, ‘shores’ and gene bodies is the knowledge that
sequence variation has a strong influence on methylation.
Gertz et al. [5] examined methylation patterns in a three
generation family and have estimated that genotype
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explains around 80 % of the variation in methylation.
Methylation quantitative trait loci or meQTLs refer to se-
quence variants across the genome driving methylation
patterns [6] and these have been mapped in a variety of
different tissues and at different stages of development in
various organisms [7–10]. Smith et al. [9] have compared
sequence variants influencing methylation patterns across
different human tissues and identified sets of meQTLs
that are tissue specific but also others that are consistent
across different tissue types and indeed across popula-
tions. Further, inherited genetic variants have been linked
to methylation changes observed in disease. Shen et al.
[11] have demonstrated that susceptibility SNPs at the
HNF1B locus in ovarian cancer are associated with altered
methylation and consequent expression of HNF1B. Also,
it has been proposed that at least a proportion of unex-
plained Lynch syndrome cases are likely to be due to epi-
genetic silencing of mismatch repair genes. Indeed, it has
been shown that the inheritance of the c.-27C>A germ-line
variant in the 5′ UTR leads to epigenetic silencing MLH1
in Lynch syndrome [12]. Thus, there is now considerable
interest in mapping inherited methylation changes influen-
cing disease susceptibility and disease course.
Genome-wide epigenetic studies have thus far largely fo-
cused on epigenetic alterations that occur in diseased tis-
sues, where epigenetic changes across the genome are
mapped through comparing ‘normal’ and affected tissues
from the same individual. Indeed, epigenetic drugs, cur-
rently in clinical use, are designed to correct the epigenetic
alterations acquired during disease development [13]. The
assumption being that these acquired epigenetic alterations
are driven by the disease process itself. More recently, it
has been hypothesised that inherited genetic variation can
drive epigenetic alterations and further that these contrib-
ute to disease susceptibility or disease course. To date, the
large majority of genome-wide methylation studies and
consequently the bioinformatic pipelines used to interpret
these data have been designed to compare diseased with
‘normal’ tissue, in order to map epigenetic changes in the
disease tissue itself. This analysis may screen out inherited
epigenetic changes that are evident both in the normal tis-
sue and the diseased tissue of the same affected individual.
There remains a need to explore inter-individual variation
of the epigenome and its contribution to disease. A power-
ful approach to examining the role of inherited variation
drivers of epigenetic change is to examine large families
where inheritance of variation driving epigenetic alter-
ations can be tracked through generations.
A number of challenges exist in the analysis of
genome-wide methylation mapping in samples and these
include technical challenges dealing with batch effects
and the underlying biochemistry employed by the array
methods. This has necessitated the development of nu-
merous pre-processing quality control methods to ensure
reliable, high-quality data generation. As most studies
examining epigenetic profiles have typically examined dif-
ferences between two distinct groups (normal vs tumour
tissue or case vs control), the majority of normalisation
methods for the 450k array are designed for these types of
data, frequently requiring two data groups to normalise
negative and positive control probes or genomic regions.
Such methods are incompatible with pedigree data, which
lack a distinct second group for normalisation. In re-
sponse to the absence of appropriate strategies, we have
developed a pipeline for optimal normalisation and pre-
processing of familial-based methylation array data.
Methods
DNA isolation and preparation
Fifty peripheral blood samples were collected from indi-
viduals representing clusters of densely aggregated cases
of affected men and close relatives from the Tasmanian
Familial Prostate Cancer study. A diagrammatic repre-
sentation of the family pedigrees is shown in Fig. 1, with
disease status indicated. Individuals are of Caucasian
descent, ranging in age from 23 to 89 years. See
Additional file 1: Table S1 for more detailed information
on clinical data and sample handling where available.
DNA was extracted from whole blood using the Nucleon
BACC3 (GE Healthcare) DNA extraction kit, following
the manufacturer’s instructions. DNA was initially quan-
tified on the Nanodrop 8000 (Thermo Scientific) and
samples with a 260:280 ratio of less than 1.80 were fur-
ther purified using the Zymo Clean & Concentrator
(TM)-5 Kit. DNA was then quantified using a Qubit®
Flourometer. One microgram of DNA was bisulphite
converted using the EZ DNA Methylation-Gold (TM)
kit (ZYmo Research), according to the manufacturer’s
instructions. Bisulphite-converted DNA (400 ng) was
then used for analysis of DNA methylation using the
450k array, according to the manufacturer’s instructions.
Data extraction, pre-processing and initial quality control
IDAT files containing the raw intensity signals from red
and green colour channels were generated using Illumi-
na’s iControl software, with all further analysis carried
out in the R environment [14]. A combination of three R
packages, minfi [15], methylumi [16] and ChAMP [17],
were used to load IDAT files into R and perform basic
quality control. Different normalisation methods require
the data to be in different formats which cannot be sub-
sequently modified once loaded into R. As such, a num-
ber of different packages were used to load data, with
the chosen package dependent on the normalisation
method tested. Methylumi was used to read data into R
in the correct format for quantile normalisation in the
lumi R package. The minfi package provides a quality
control report based on inbuilt control probes on the




Fig. 1 (See legend on next page.)
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array (such as staining, hybridization, bisulfite conver-
sion and negative controls) as well as the ability to ex-
clude probes and samples based on probe signal
intensity. Samples failing this initial quality control were
excluded from further analysis. Replicate samples across
batches were included on the beadchips to allow assess-
ment of quality control and technical bias. Of the 50
unique samples and 8 replicates initially interrogated, 45
unique and 5 replicate samples passed quality control
metrics and were used for further analysis. Following
sample quality control, the recommended quality thresh-
olds in ChAMP were employed to exclude poor quality
probes, with a minimum detection p value of 0.05 in
more than one sample removing 6740 probes and a bead
count threshold of <3 in 5 % of samples removing a fur-
ther 478 probes. To account for sex differences in
methylation, driven particularly by dosage compensation
by X-inactivation, probes on the sex chromosomes were
removed prior to normalisation. While ChAMP includes
this option as default when loading data, most packages re-
quire manual separation, normalisation and recombination
of sex chromosomes or their complete manual removal.
Thus, to permit appropriate comparison of normalisation
methods, a homogenous set of loci across all packages was
required; therefore, sex chromosomes were removed at this
stage of analysis and not re-introduced.
Normalisation
Eight normalisation techniques were applied to the
whole dataset, as detailed in Table 1 with each method
evaluating the same samples. The probe subset chosen
for each analysis was selected following the instructions
of each individual normalisation package, which had dif-
ferent requirements. This dictated whether normalisa-
tion methods were compatible and could be used in
conjunction.
Data are presented for each method except RUV, for
which the results were not resolvable using the data gen-
erated in this study. These methods involve various de-
grees of type I and II probe scaling to account for
underlying technical differences between the probe types,
background and dye bias correction and initial between
array batch correction. Depending on the normalisation
method, data was either used in the red/green signal for-
mat (RGset), converted into methylated and unmethylated
values (MethylSet) or converted to β values by the func-
tion β =M/(M +U + 100), where M is the methylated
(See figure on previous page.)
Fig. 1 Selected pedigree clusters from four families from the Tasmanian Familial Prostate Cancer study. Four clusters were chosen from family 9
(a), two from family 11 (b), four from family 22 (c) and five from family 72 (d). Circles represent women and squares men, with individuals affected
by prostate cancer filled in black, those unaffected unfilled and individuals affected by other cancers quarter filled. Samples interrogated on the 450k array are
indicated by a red arrow head. Replicate samples are indicated by square brackets around the sample name, while the batch is indicated underneath the
sample name. Orange stars indicate samples for which good-quality Omni2.5 genotype and 450k methylation data were available
Table 1 Normalisation methods tested. The table includes a
brief description of each method, the relevant R package and
reference for further information
Normalisation method Package Reference
Quantile normalisation
The distributions of probe intensities for
different samples are made identical. Often
used in microarray analysis.
lumi [33]
Stratified quantile normalisation
Probes are stratified by genomic region then
quantile normalised with sex chromosomes
normalised separately when male and female
samples are present. No background
correction, zeros removed by outlier
function. Not recommended for cancer-
normal comparisons or other groups with
global differences.
minfi [15]
Beta-mixture quantile dilation (BMIQ)
Adjusts type II probes to type I distribution.
Recommended for all datasets.
ChAMP [27]
Subset-quantile within array normalisation
(SWAN)
A quantile distribution is created using a
subset of probes, with subsetting based on
the number of CpGs in the probe body.
Separate subsets are created for type I and II
probes. The remaining probes are then
adjusted to the subsets.
minfi [34]
Functional normalisation (FunNorm)
Uses control probes to remove unwanted
technical variation. Also diminishes batch
effects in some datasets. Suitable for use in




Background adjustment and between array
normalisation are performed separately on
type I and II probes.
wateRmelon [20]
Noob
Uses type I probe design to measure non-
specific fluorescence in the opposite colour
channel.
minfi [35]
Remove unwanted variation (RUV)
Previously used with microarray data to
normalise via negative control genes.
Requires distinct groups such as cancer-
normal to normalise on.
RUVnormalize [36]
Batch correction: ComBat
Adjusts for known or unknown batches
using an empirical Bayesian framework.
sva [19]
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signal and U unmethylated. In some normalisation
methods, the offset of 100 is included to regularise scores
when both methylated and unmethylated values are very
low. While the β value is more biologically intuitive (it
ranges from 0 to 1 indicating the proportion of methyla-
tion at that site for the population of cells analysed), it suf-
fers from severe heteroskedasticity at very high or low
values [18]. Logit transforming to anM value removes this
unequal variance. Thus wherever possible, calculations in
this study have been performed on the M values and
transformed back to β values if required for biological in-
terpretation. Eight performance metrics were then used to
compare methods and determine the optimal normalisa-
tion approach for familial datasets. Visual tools such as
density and MDS plots and unsupervised hierarchical
clustering were used to compare the various methods be-
tween all samples and particularly replicate samples. See
Table 2 for a description of each metric.
Table 2 Qualitative and Quantitative metrics used to assess normalisation efficacy. The table includes a brief description of each
metric and which figures describe the results for that method
Method Description Figure
1 Density plot: all samples Bimodal distribution of Beta values as methylated and unmethylated
signals. Each sample is represented by a single line. A batch effect
is indicated when samples performed in the same batch have
a similar distribution.
Fig. 2a, c, e
Additional file 5: Figure S4
Density plot: three groups of
replicate samples
Bimodal distribution of Beta values as methylated and unmethylated
signals. Samples are coloured by replicate group. As each replicate
group contain the same biological information, differences in sample
distribution within groups indicate technical bias.
Additional file 3: Figure S2 (A, C, E)
Density plot: probe I and II
distribution
Bimodal distribution of Beta values as methylated and unmethylated
signals separated by Infinium I and II probe types. Provides information
about probe normalisation which is required for Infinium I and II signals
to be combined in the same analysis.
Fig. 2b, d, f
2 MDS plot: all samples Multidimensional scaling plots show a 2D projection of distances
between samples. For these plots the 1000 most variable sites have
been selected as they are the most biologically relevant for this type
of analysis. Samples cluster by similarity and as such batch effects and
familial clustering can be clearly discerned.
Fig. 3
Additional file 8: Figure S5
MDS plot: three groups of
replicate samples
1000 most variable sites are again selected, with samples coloured
by replicate group. As each replicate group contains the same biological
information, close within group clustering indicates minimal technical
bias while distantly clustered replicate samples indicate heightened
technical bias.
Additional file 3: Figure S2 (B, D, F)
3 ANOVA of the first principal
component for MDS plots
Provides a quantitative value for MDS plots. A lower p value indicates the
clustering is more significantly explained by batch. Ie. a larger p value after
normalisation indicates a reduction in batch effect.
p values displayed on Fig. 3
4 Median absolute differences
between replicate samples
For each replicate group the median M value (log of Beta values) across
all probes was calculated and the absolute difference compared between
replicate groups after various normalisation methods. A smaller absolute
difference indicates improved normalisation as more technical bias
is removed.
Additional file 6: Table S2
5 Imprinted regions:
density plots
227 probes mapping known imprinted hemi-methylated regions can
be used as a standard to measure changes in methylation levels after
normalisation. Density plots have a single distribution peak since there
is roughly 50 % methylation at these sites.
Additional file 4: Figure S3
Differentially methylated region
standard error (DMRSE)
The DMRSE measures how each sample varies from the expected
50 % methylation. Smaller error/deviation from 50 % indicates less
technical bias.
Additional file 1: Table S1
Additional file 4: Figure S3 (A, C, E)
6 Cluster dendrogram Another tool to measure clustering by sample similarity. Samples are
labelled by batch with batch effects clearly seen before normalisation
and diminished after. Red stars indicate replicate samples that are
expected to cluster most closely.
Additional file 2: Figure S1
7 meQTL association Association between methylation at cg17749961 and SNPs in a
2-Mb window.
A significant association is maintained after normalisation and
batch correction.
Additional file 5: Figure S4
8 Epigenome-wide methylation
association with age
QQ plots depicting the association between epigenome-wide
methylation and age.
Plots are performed on raw, normalised and batch-corrected data.
Additional file 9: Figure S6
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Batch correction
Since an obvious batch effect remained after normalisa-
tion, the ComBat function from the sva package [19] was
used to further remove technical bias introduced by inter-
rogating samples on the 450k array in different batches.
Genotype data
DNA from a subset of samples was extracted as described
above and interrogated on Illumina’s HumanOmni2.5-8
Beadchip according to the manufacturer’s instructions.
Quality control was performed with Illumina’s GenomeS-
tudio Software.
Statistical analysis
Eight methods, as described in Table 2, were used to com-
pare the efficacy of the various normalisation methods. In
addition to density and MDS plots, the ANOVA test and
quantitative measures, mean absolute difference between
replicates and the differentially methylated region stand-
ard error (DMRSE) measures were used. Additionally, two
approaches were taken to test the underlying biological in-
formation was preserved between samples; namely, an as-
sociation analysis between genotype and methylation at a
previously identified meQTL and an epigenome-wide as-
sociation analysis with age.
For a qualitative measure to examine effectiveness of be-
tween array normalisation, hierarchical cluster dendrograms
were generated using all probes with the hclust function
using the Euclidean distance between from the default R
package, stats. Cluster dendrograms group samples by dif-
ferences, with similar samples grouping together.
MDS plots were clustered by batch or family; then,
analysis of variance was performed on the first principal
component from a PCA on the 1000 most variable beta
values using the aov and prcomp functions in the stats
core R package. p values are displayed on the MDS plots
in Fig. 2. A lower p value indicates that clustering is
more significantly explained by batch or family, with a
larger p value after normalisation indicating a reduction
in technical bias.
Six replicate sample pairs were used to quantitatively
assess the performance of the normalisation methods, as
one sample from each pair was interrogated on a separ-
ate batch. The median absolute difference between each
pair was calculated by first taking the absolute difference
at each probe between the two replicates and then tak-
ing the median of the differences. A lower median differ-
ence indicates less technical bias, as the samples are
biologically identical.
There are 227 known imprinted regions (iDMRs) on
the 450k array, and these have previously been employed
in analysis packages such as wateRmelon as a quality
control metric [20]. These regions are expected to have
allele-specific methylation and a β value of 0.5, and
therefore deviation from this value can be examined as a
standard error-type measure, denoted DMRSE in the
wateRmelon package. The dmrse_row function was used
to measure dispersion of methylation between samples
for each normalisation method. A lower value indicates
methylation values are more tightly aligned with ex-
pected methylation levels.
While evidence of clustering according to familial rela-
tionships following normalisation correction provides
some confidence that biological integrity of the data is
preserved, to further test the preservation of biologically
relevant information, we examined detectable associa-
tions of known meQTLs in our data. Shoemaker and
colleagues have previously identified 736 CpG sites to be
associated with SNPs in cis [21]. Here, we examined
cg17749961, one of the ten most significant hits re-
ported by Shoemaker et al., in the 22 individuals, for
whom both methylation and genotyping SNP data was
available. Association analysis was performed between
this probe site and SNPs located within a 2-Mb window
adjacent to this site, using linear regression, and assum-
ing an additive disease model. Relatedness was adjusted
for by fitting a linear mixed model on the methylation of
cg17749961 and a kinship matrix, determined by the
identity-by-state function in the GenABEL R package
[22]. The residuals from this model were then used as
the outcome variable in the linear regression model with
SNPs drawn from a 370 K Illumina array. Bonferroni
correction was used to correct for multiple testing error.
To further demonstrate biological information is pre-
served after normalisation and batch correction, the as-
sociation between age and epigenome-wide methylation
was compared for raw data, stratified QN normalised
data and ComBat-corrected stratified QN data. Linear
regression models were fitted with age as the explana-
tory variable and methylation as the outcome variable,
with −log10 p values of the models plotted against
−log10 expected p values as QQ plots.
Results
Evaluation of normalisation methods to address technical
bias
Data generated from whole genome methylation analysis
employing array technology generates an output necessi-
tating application of normalisation methods to correct
for possible bias arising from within and between array
variation. Herein eight different methodologies (Table 1)
were examined and visual and quantitative metrics were
employed to evaluate their comparative performance.
High-quality methylation data was generated for 45
unique and five replicate samples from four families
using the 450k array in three separate batches (see Fig. 1
for further details). A minimum of one sample in each
of the three batches was replicated, providing five
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technical replicates in addition to the three unique sam-
ples on each batch, to permit generation of data from
analysis of the same biological sample. In data lacking
technical bias, replicate samples would be expected to
generate the most similar methylation profiles, while
methylation profiles generated from closely related
individuals should also cluster tightly compared to dis-
tantly or unrelated individuals. However, if technical bias
such as a batch effect has been introduced, this distorts
the profiles and samples no longer cluster by biological





Fig. 2 Multidimensional scaling plots of M values by batch and family. Multidimensional scaling plots for raw (a, b), stratified QN (c, d) and
ComBat stratified QN (e, f) M values. For each plot, the 1000 most variable probes were selected. In a, c and e, numbers represent batches and
are coloured accordingly, with clustering by batch clearly seen in a, to a lesser extent in c and removed in e. In b, d and f, numbers represent
family groups and are coloured accordingly with the clearest clustering present in f after the batch effect has been removed. p values are from an
ANOVA test for significance of batch (a, c and e) or family (b, d and f) on the first principal component from a PCA on the beta values
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Batch effect (between array variation) was examined
and the density distribution plot (Fig. 3a) of the raw β
values from all three batches reveals significant bias. The
greatest contributor to batch effect was the date on
which the BeadChips were processed, with bisulphite
conversion performed on the same day as BeadChip pro-
cessing. Employing a stratified QN (Fig. 3b) and/or
ComBat normalisation (Fig. 3c) dramatically reduced
Fig. 3 Density distribution of β values. Density plot and probe distribution of β values for raw pre-normalisation data (a, b), after stratified QN (c, d)
and with stratified QN and ComBat batch correction (e, f). For density plots (a, c, e), a single line represents a sample, with samples coloured by batch. A
clear batch effect is present in a, lessened in c and removed in e. For the probe distribution (b, d, f), one sample has been chosen with the red dashed
line indicating type I probe distribution, the blue dashed line type II and the solid black line the combined probe distribution. The probe type distribution
is also improved after normalisation, as types I and II are more closely aligned in d and f compared to b
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this observed effect. For between array biases, Fig. 3
shows the density distribution of β values for raw data
samples (A), after stratified QN (C) and after stratified
QN combined with ComBat correction (E). This is par-
ticularly evident when comparing the β value density
plots of three groups of replicate samples (Additional file 2:
Figure S1A, C and E).
Stratified QN also performs best at removing within
array biases as the distribution of probe I and II types
become more uniform (Fig. 3b, d, f ). This bias is driven
by the differing biochemistry of the probes, with type I
employing a single colour channel with a different bead
for methylated and unmethylated DNA and type II con-
taining one bead in two colour channels. The underlying
biology targeted by each probe is confounded by this
technical bias, as type I measures CpG-dense regions
(such as islands) while type II can only tolerate three
CpGs in the length of the probe. As such, type I interro-
gates a greater proportion of unmethylated to methyl-
ated DNA, while type II performs the opposite.
Removing the probe bias is imperative for accurate com-
parisons between these probe types when pooling probe
I and II data, which is necessary for accurate genome-
wide methylation information of both CpG rich and
poor regions.
In contrast, the density plots of β values for other nor-
malisation (SWAN and FunNorm) methods do not im-
prove to the same degree and in some cases greater
variation is introduced (Additional file 3: Figure S2C–G).
For example, a worsening of the batch effect is seen for
SWAN normalisation (Additional file 3: Figure S2D), com-
pared to raw data (Additional file 2: Figure S1A) and the
distribution of methylated and unmethylated signals is
inverted following FunNorm (Additional file 3: Figure S2E).
The second approach employed to examine the per-
formance of the normalisation methods was to generate
multidimensional scaling (MDS) plots. These permitted
the visualisation of the two-dimensional projection of
the differences between samples. For each plot, the 1000
most variable probes were selected, as these represent
the most pertinent biological differences between sam-
ples. M values were used as opposed to β values, the lat-
ter of which have been shown to suffer severe
heteroskedasticity at very high and low values [18].
Again, a strong batch effect is observed in the raw data
(Fig. 2a) as expected and this is removed or significantly
reduced following normalisation using stratified QN
(Fig. 2c) and ComBat (Fig. 2e) corrected data. The
strong batch effect masks the familial relationships in
the raw data; however, following the correction, cluster-
ing according to kinship is clearly evident. Similarly, the
replicate samples (in Additional file 2: Figure S1), which
group disparately in the raw data (A, B), co-locate or
cluster tightly following stratified QN (C, D) and
ComBat (E, F). The MDS plots for each normalisation
method (Additional file 4: Figure S3) also show stratified
QN followed by ComBat to be the most effective
method for removing clustering by batch.
This efficacy of normalisation methods in reducing
clustering of samples by batch was assessed quantita-
tively by ANOVA to test the effect of batch on the first
principal component. The ANOVA was repeated for
each normalisation method, using M values from the top
1000 most variable sites. Consistent with the visualised
MDS plot, the p value was highly significant demonstrat-
ing the significant association of batch in M value in raw
and stratified QN data (p < 0.01) but was not significant
following correction using ComBat (p = 0.97).
For a final qualitative measure to examine effective-
ness of between array normalisation, hierarchical cluster
dendrograms were generated. Application of stratified
QN and ComBat (Additional file 5: Figure S4) again
demonstrated superior normalisation when visualised by
this method; with raw data samples clearly clustering
into three distinct groups (Additional file 5: Figure S4A),
stratified QN resulting in improved clustering (B) while
ComBat batch correction following stratified QN com-
pletely removes the batch effect (C) permitting the de-
sired outcome with related individuals clustering
together in familial groups. Furthermore, replicate sam-
ples cluster more clearly after ComBat normalisation (C,
red stars) indicating removal of batch effects without
perturbing biologically relevant information.
To quantitatively assess the performance of these nor-
malisation methods, the median absolute difference in
M values was calculated for six replicate pairs, with one
sample from each pair interrogated on a separate batch.
With the exception of one pair, stratified QN with Com-
Bat was found to have the lowest absolute median differ-
ence between technical replicate pairs, corresponding to
the highest correlation between replicate pairs (see Add-
itional file 6: Table S2). While others such as SWAN in-
troduced an increase in the error rate relative to the raw
data values.
Finally, standard error measures for imprinted re-
gions were calculated and compared between methods
as described in the statistical analysis section of the
methods. Smaller values indicate lower errors and
more reliable data. A DMRSE of 0.0048 was calcu-
lated for the raw data, with this value increasing with
following normalisations using QN (0.0052), noob
(0.0052) and functional normalisation (0.0056). The
remaining normalisation methods generated reduced
DMSRE values with stratified QN with ComBat batch
correction again producing the smallest error values
at 0.0012. See Additional file 7: Table S3 for a full list
of DMRSE values and Additional file 8: Figure S5 for
the density plots of these probes.
Cazaly et al. Clinical Epigenetics  (2016) 8:75 Page 9 of 14
Increased power for determining true biological
associations
Critical to any normalisation method is the maintenance
of true biological differences between samples. As de-
scribed in the statistical analysis section of the methods,
a previously identified meQTL was selected to perform
association analysis with prior to and following normal-
isation. Following Bonferroni correction, a significant asso-
ciation was detected in the raw data (Fig. 4a, p value =
7.29e-06), increasing markedly after stratified QN (Fig. 4b,
p value = 3.53e-07). After ComBat (C), there was a drop in
significance compared to stratified QN and raw, yet the p
value was still highly significant (p value = 1.05e-05) indicat-
ing preservation of the biological information of interest.
The drop in significance after batch correction may be ex-
plained as confounding between batch and family, which
is removed after ComBat. Ideally, samples would be
randomised across experiments; however, the nature of fa-
milial studies is such that this is not always possible, as
samples are collected at different time points, often across
generations. To maintain maximum power, the inclusion
of all available samples is essential and, therefore, data
processing methods capable of dealing with non-ideal
datasets are required.
Epigenome-wide methylation has long been shown to
drift with age, specifically global hypomethylation and
region-specific hypermethylation are observed [23]. The
association between age and epigenome-wide methylation
was compared for raw data, stratified QN normalised data
and ComBat-corrected stratified QN data to demonstrate
that this biological information was preserved after nor-
malisation and batch correction. After normalisation
(Additional file 9: Figure S6B), there are many more sig-
nificant associations with age than in the raw data (Add-
itional file 9: Figure S6A), indicated by a greater number
of points above the expected line and a much greater
Lambda value (median of observed −log10 p values di-
vided by the median of expected −log10 p values), with an
increase from 0.838 to 1.402. There is another small in-
crease in significance after ComBat batch correction
(Additional file 9: Figure S6C) to 1.448, again indicating
improved strength in testing biological associations.
Discussion
There is currently a plethora of pre-processing methods
and R packages available for analysis of 450k array data,
and comprehensive review articles evaluating their utility
have been published [24–26]. The majority of these are
designed for specific types of sample sets, particularly
those comprised of two distinct groups such as case–
control or cancer-normal with substantial methylation
differences between the two groups. For different data-
sets, such as those from familial studies, which include
complex pedigree structures instead of two distinct
groups, these methods may be ineffective or worse, det-
rimental in that they introduce technical bias, as identi-
fied with selected methods in this paper. To correctly
normalise data, it is critical to choose the most appropri-
ate method; yet there has been little focus on developing
appropriate processing pipelines for familial methylation
array analysis, despite the current interest in inherited
drivers of methylation patterns. Further barriers are the
various format requirements and the lack of integration
to provide a seamless processing pipeline. Here, we have
Fig. 4 Association plot between SNPs and methylation. Association
between methylation at cg17749961 and SNPs in a 2-Mb window.
There is a significant association in the raw data (a, p value = 7.29e-06)
which increases after stratified QN (b, p value = 3.53e-07) and drops
slightly after ComBat correction (c, p value = 1.05e-05)
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tested eight different methods and presented a prelimin-
ary pre-processing pipeline for familial data (depicted in
Fig. 5). This pipeline creates a template to guide and ex-
pedite the analysis of familial datasets, particularly gen-
erated using the 450k array data. Sample size (n = 50) is
a limitation of this study, therefore additional familial
studies would aid in validating the pipeline.
A fundamental requirement for processing methyla-
tion array data is effective adjustment for technical bias,
including batch effects and adjusting for the two-probe
biochemistry of the array. Batch effects may be intro-
duced through bisulphite conversion or downstream
processing or variation in array quality. Various methods
have been developed to adjust for these effects, mostly
involving variations in quantile normalisation, a tech-
nique commonly used in analysis of microarray datasets
to align two different distributions so they result in iden-
tical statistical properties [26–29].
BMIQ and functional normalisation have been advo-
cated as the preferred methods for cancer studies as they
are more specific in design than quantile normalisation
and have been shown to be more effective at removing
unwanted technical bias [27, 29]. However, these
methods work most effectively on case–control or
tumour-normal datasets respectively and to the best of
our knowledge, optimal pre-processing methods for
Fig. 5 Pipeline for familial data processed on the 450k array. Each box indicates a stage of the pipeline including the R package and the data
format required/created in italics
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familial-based data, such as performed here, have not
been reported. Normalisation methods necessarily make
assumptions about data, with the accuracy of these as-
sumptions varying for different datasets. Thus, the same
normalisation method can have a vastly different effect
on different types of data and conversely, as shown here,
different normalisation methods can have vastly different
effects on the same data. It is therefore a key to select
the right normalisation method for the dataset of inter-
est. Of the eight methods tested, stratified QN was con-
sistently identified as the best normalisation method
across all visual and quantitative evaluation metrics for
use in this context. The principle underpinning this nor-
malisation is stratification by genomic region and is thus
ideal for data where the differences between adjacent
genomic loci are maintained. This is in contrast to
tumour-normal tissue datasets where there are large
blocks of dramatically altered methylation patterns
throughout the tumour genome [30]. Again not surpris-
ingly, packages that utilise differences in negative control
methylation patterns between cases and controls such as
FunNorm were not found to be effective on familial
datasets where no ‘normal’ control is available.
The inherent strengths of familial data could be further
exploited by a normalisation technique that accounts for
known relationships between samples. Such a method
could draw on pedigree information to ensure normalisa-
tion has effectively removed technical bias while maintain-
ing known biologically relevant information such as
relatedness and familial clustering by methylation. A diag-
nostic metric accounting for a known relationship could
be used to test the efficacy of pre-processing methods in a
similar manner to the standard error associated with
iDMRs from the wateRmelon package.
It may also be of importance for researchers to con-
sider the undesirable effect of non-specific binding and
the presence of SNPs in the probe body. A study from
the Weksberg lab found around 6 % of probes on the
array cross-hybridised to non-targeted genomic regions
[31]. They have catalogued these probes and suggest re-
moving them prior to downstream analysis. Their study
also demonstrates that SNPs in the probe body can
interfere with probe binding, altering the methylation
signal at around 14 % of sites. Illumina recommends all
probes containing a SNP within 10 bp of the interro-
gated CpG site ought to be removed, while others sug-
gest the ‘probe effect’ continues to the entire 50-bp
length of the probe [31, 32]. The removal of all such
probes would be undesirable for studies examining the
effect of genotype on methylation, as evidence suggests
the vast majority of these SNPs occur either at the CpG
site itself (meSNPs) or close by [32].
To overcome this issue, Zhi and colleagues suggest an
elegant approach to examine the effect of meSNPs on
methylation without the potential bias introduced by
SNPs altering probe binding [32]. The type II probes
contain only one bead type for both methylated and
unmethylated sites of interest, with the methylation sta-
tus of the loci designated by the addition of a different
coloured nucleotide (red or green) at the single base ex-
tension. As type II probes terminate one base pair before
the cytosine of the CpG dinucleotide, a mutation at the
cytosine itself would not affect probe binding. As such,
probes without SNPs in the probe body but present at
the single base extension can reliably be used to examine
the effect of meSNPs on methylation, a very useful tech-
nique for examining the effect of inherited variation on
methylation patterns.
Conclusions
Preservation of the biological integrity of information
from methylation array data is imperative and requires ap-
propriate pre-processing to minimise technical errors,
which will be dictated by the type of data. Stratified QN in
combination with ComBat batch correction performed
the best of those methods tested for normalising familial
data interrogated on 450k array. This method was ob-
served to remove technical biases while maintaining bio-
logically relevant information; allowing true biological
differences and similarities to inform our search for the
role of methylation patterns driving disease processes. The
workflow presented in this paper (highlighted in Fig. 5)
provides a streamlined methodology to pre-process famil-
ial data and may also be instructive for other datasets in-
cluding longitudinal studies where the same individuals
are repeatedly measured over time.
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Additional file 1: Table S1. Clinical data and sample extraction and
storage information. (DOCX 20 kb)
Additional file 2: Figure S1. Hierarchical cluster dendrogram for raw,
stratified QN and ComBat-corrected data. Samples are clustered by
similarity and labelled by batch. Raw data samples (A) clearly cluster into
three distinct batches while stratified QN (B) partially adjusts clustering by
batch and stratified QN combined with ComBat considerably diminishes
the batch effect (C). Red stars indicate replicate samples which cluster
more clearly in (C), indicating removal of batch effects. (PDF 449 kb)
Additional file 3: Figure S2. Density distribution of β values and
multidimensional scaling plots of M values for replicate samples. Density
(A, C, E) and MDS (B, D, F) plots of three replicate sample groups for raw
(A, B), stratified QN (C, D) and stratified QN ComBat-corrected (E, F) data.
For all plots, samples are coloured by batch 1–3 as labelled. Density plots
show the distribution of β values, which become more uniform after stratified
QN (C) and stratified QN plus ComBat (E). MDS plots show clustering of the
1000 most variable sites by M value, highlighting the decreasing variance
between replicate groups after stratified QN and ComBat (F). (PDF 7387 kb)
Additional file 4: Figure S3. Density distribution of β values for
imprinted differentially methylated regions. Density plots for raw (A),
stratified QN (C) and stratified QN with ComBat (E) for 227 probes
mapping known imprinted differentially methylated regions. Each line
represents a sample, with samples coloured by batch. As methylation at
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these loci is allele-specific there is a single density distribution rather than
the bimodal distribution seen in Additional file 3: Figure S2. The standard
error-type measure (DMRSE) diminishes with Stratified QN and ComBat,
indicating more reliable data. B, D and F show the Infinium I and II probe
distributions, which becomes more uniform with stratified QN and
ComBat. (PDF 4133 kb)
Additional file 5: Figure S4. Density distribution of β values for all
normalisation methods. Density plots of β values for various normalisation
methods: raw pre-normalisation data (A), quantile normalisation (B), BMIQ
(C), SWAN (D), FunNorm (E), Dasen (F), noob (G), stratified QN (H), raw with
ComBat correction (I) and stratified QN with ComBat correction (J). A single
line represents a sample with samples coloured by batch. The batch effect
present in the raw data (A) remains after the majority of normalisation
methods with Dasen (F) and stratified QN (H) showing the most uniform
distributions. Some methods such as quantile normalisation (B) and
FunNorm (E) flip the methylated and unmethylated signal distribution.
ComBat is effective at removing batch effects in both raw (I) and normalised
(J) data, with the best outcome seen with stratified QN with ComBat batch
correction (J). (PDF 260 kb)
Additional file 6: Table S2. Median absolute difference between
technical replicate pairs. (DOCX 14 kb)
Additional file 7: Table S3. Standard error measures for imprinted
differentially methylated regions for the various normalisation methods.
(DOCX 13 kb)
Additional file 8: Figure S5. Multidimensional scaling plots of M values
by batch for all normalisation methods. Multidimensional scaling plots for
raw (A), quantile normalisation (B), BMIQ (C), SWAN (D), FunNorm (E),
Dasen (F), noob (G), stratified QN (H), raw with ComBat correction (I) and
stratified QN with ComBat correction (J). For each plot, the 1000 most
variable probes were selected. Batches are numbered and coloured, with
clustering by batch clearly seen in the raw data (A) and removed to
varying degrees with different normalisation methods. ComBat correction
following stratified QN provides optimal batch correction removal as the
samples no longer cluster according to batch. (PDF 559 kb)
Additional file 9: Figure S6. QQ plots for the association of age and
epigenome-wide methylation. QQ plots with −log10 p values from the
linear model of methylation and age plotted against expected −log10
p values. Raw data (A), data normalised by stratified QN (B) and data
normalised by stratified QN then corrected with ComBat (C). (PDF 85 kb)
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Appendix	  4.1	  Linkage	  regions	  with	  the	  highest	  LOD	  scores	  previously	  identified	  through	  the	  
SNP Chr Position LOD	  Score SNP Chr Position LOD	  Score SNP Chr Position LOD	  Score
RS2600776 2 237263622 3.09 RS4714457 6 41485970 2.26 RS1722791 15 21503831 2.17
RS2600793 2 237269550 3.25 RS814836 6 41497306 2.2 RS1524842 15 21505342 2.43
RS7585432 2 237291473 3.44 RS814839 6 41502190 2.2 RS1717839 15 21525066 2.36
RS975919 2 237293119 3.44 RS13219238 6 41506909 2.16 RS11632341 15 21540364 2.36
RS10929183 2 237293840 3.61 RS13196762 6 41512003 2.22 RS1628195 15 21551731 2.41
RS7556982 2 237308938 3.67 RS766389 6 41514764 2.08 RS824205 15 21559164 2.27
RS13419340 2 237325521 3.67 RS11962670 6 41520542 2.04 RS8182040 15 21569096 2.25
RS1549869 2 237335771 3.7 RS9381065 6 41522528 2.02 RS1722842 15 21582049 2.38
RS999031 2 237355157 3.58 RS912881 6 41523715 2.02 RS12439817 15 21582093 2.41
RS1897464 2 237363415 3.61 RS1970923 6 41525198 1.98 RS7181322 15 21583164 3.16
RS934397 2 237371678 3.61 RS9357362 6 41541193 2.02 RS940595 15 21589360 3.13
RS1344762 2 237373226 3.73 RS2496635 6 41542795 2.11 RS8038234 15 21597810 3.13
RS10929194 2 237385373 3.73 RS7762551 6 41545237 2.35 RS824211 15 21598281 3.16
RS13000320 2 237388433 3.73 RS728825 6 41551451 2.43 RS7180295 15 21601351 3.01
RS1368202 2 237395901 3.85 RS728826 6 41551593 2.58 RS2352765 15 21606718 3.01
RS10166334 2 237405247 3.91 RS2477831 6 41551667 2.58 RS844033 15 21609833 3.01
RS1000007 2 237416793 3.88 RS10947972 6 41554327 2.58 RS824162 15 21609981 2.99
RS7565608 2 237425567 4.03 RS4714468 6 41560974 2.58 RS1524845 15 21612590 3.04
RS11694315 2 237435644 4.03 RS2496637 6 41563034 2.35 RS824167 15 21614609 3.01
RS3888913 2 237444863 3.41 RS721313 6 41563275 2.31 RS2177077 15 21618739 3.01
RS30105 2 237459284 3.43 RS3800282 6 41568265 2.35 RS8031166 15 21633826 2.68
RS6737351 2 237464699 3.52 RS6913778 6 41572879 2.44 RS11633486 15 21639815 2.68
RS10169105 2 237470609 3.37 RS6907558 6 41575838 2.59 RS8038712 15 21647999 2.65
Tasmanian	  Familial	  Prostate	  Cancer	  Study	  
RS12463648 2 237475305 3.37 RS2495232 6 41582705 2.77 RS1459958 15 21649687 2.45
RS4663682 2 237481662 3.37 RS2495233 6 41583425 2.77 RS10519445 15 21657901 2.47
RS7603272 2 237486328 3.48 RS2477842 6 41597419 2.85 RS4778341 15 21663374 2.47
RS7581699 2 237496143 3.48 RS2496652 6 41612104 2.95 RS1459985 15 21668350 2.47
RS10929201 2 237497105 3.6 RS4714484 6 41639201 2.95 RS2883186 15 21680981 2.21
RS729454 2 237516077 3.65 RS913074 6 41646523 3.1 RS4778346 15 21686776 2.11
RS1435847 2 237527888 3.56 RS4714487 6 41655290 3.07
RS7600637 2 237538697 3.45 RS13362583 6 41671135 3.07
RS2701323 2 237550613 3.28 RS913075 6 41676884 2.91
RS4663691 2 237565291 3.25 RS9381084 6 41678328 2.75
RS2701336 2 237571642 3.2 RS9369298 6 41684618 2.75
RS4663692 2 237573371 3.14 RS2842639 6 41690967 2.75 SNP Chr Position LOD	  Score
RS755512 2 237575821 3.12 RS6928533 6 41701974 2.8 RS738092 22 19190931 3.03
RS2573718 2 237582343 3.2 RS1973920 6 41711172 2.77 RS7291930 22 19206509 4.64
RS2318131 2 237598705 3.14 RS2495229 6 41713808 2.73 RS1110462 22 19211385 4.6
RS7591958 2 237608324 3.12 RS2268408 6 41718697 2.77 RS5995708 22 19217080 4.47
RS7576705 2 237612027 3.14 RS2842658 6 41727028 2.89 RS7292126 22 19226926 4.47
RS7597414 2 237622493 3.26 RS4714501 6 41727341 2.94 RS886319 22 19233410 4.51
RS7589198 2 237632354 3.21 RS2230088 6 41729249 2.97 RS177421 22 19243757 4.51
RS12620999 2 237701106 3.18 RS2143678 6 41731011 2.67 RS165674 22 19258809 4.6
RS10172321 2 237730202 3.35 RS1474762 6 41735030 2.56 RS361646 22 19277274 4.8
RS6714237 2 237734087 3.32 RS1474761 6 41735041 2.68 RS165626 22 19284760 4.7
RS7599969 2 237734970 3.32 RS4714503 6 41741250 2.63 RS552823 22 19286906 3.87
RS12613316 2 237740231 3.18 RS6458234 6 41746737 2.46 RS561595 22 19290707 3.9
RS4527163 2 237765225 3.15 RS1011101 6 41751364 2.12 RS680548 22 19295555 3.87
RS4663242 2 237767644 3.15 RS1883816 6 41752419 2.14 RS473304 22 19297450 3.64











1 cg13387643 10 33.80 51 cg19300401 18 20.91
2 cg20592836 44 30.25 52 cg05161773 18 20.68
3 cg25203245 37 28.94 53 cg23052585 29 20.67
4 cg13928473 18 28.86 54 cg18618432 28 20.59
5 cg15083522 42 28.34 55 cg11251367 9 20.42
6 cg03075889 27 27.84 56 cg25543264 36 20.29
7 cg07414487 66 27.73 57 cg11585022 34 20.28
8 cg05792312 10 27.68 58 cg18527716 25 19.70
9 cg09281805 10 27.00 59 cg02113055 33 19.63
10 cg08146865 42 26.84 60 cg18572898 138 19.57
11 cg10724632 20 26.55 61 cg09993319 9 19.40
12 cg09084244 31 26.38 62 cg18709904 29 19.26
13 cg21927991 20 26.25 63 cg18088486 29 19.05
14 cg25013753 15 26.25 64 cg04610028 14 18.94
15 cg08210706 24 25.90 65 cg22851875 12 18.85
16 cg16490124 29 25.56 66 cg05338731 33 18.81
17 cg19393008 23 25.53 67 cg12551908 20 18.80
18 cg20205188 12 25.39 68 cg26128129 8 18.64
19 cg05809586 22 25.11 69 cg07686394 29 18.61
20 cg17723206 11 24.96 70 cg04028540 9 18.48
21 cg23098789 6 24.48 71 cg05059349 24 17.93
22 cg04145681 46 24.42 72 cg27341708 29 17.10
23 cg27481428 23 24.24 73 cg05509228 9 16.97
24 cg23681001 17 24.23 74 cg12186981 36 16.95
Appendix	  4.2	  Significant	  me-­‐QTL	  Associations	  for	  the	  Variable	  Methylation	  Approach	  using	  
25 cg07240846 7 24.10 75 cg25593194 37 16.73
26 cg06330797 14 23.95 76 cg09533869 14 16.57
27 cg00231519 27 23.87 77 cg06032337 59 16.29
28 cg26705599 11 23.81 78 cg02658043 18 16.26
29 cg19360212 27 23.77 79 cg21498547 8 15.76
30 cg00257789 32 23.74 80 cg17056069 12 15.69
31 cg18828306 24 23.73 81 cg02533724 8 15.52
32 cg18624102 29 23.64 82 cg00345083 12 15.03
33 cg25674027 32 23.39 83 cg16748433 26 14.23
34 cg04998327 13 23.33 84 cg20536971 27 14.03
35 cg10530344 20 22.90 85 cg26365090 6 12.53
36 cg06318935 25 22.73 86 cg12195446 19 12.48
37 cg05134736 12 22.59 87 cg17662493 31 12.33
38 cg22274273 9 22.58 88 cg08238375 45 12.04
39 cg01127608 4 22.29 89 cg14797147 15 11.59
40 cg15567368 1 22.03 90 cg13232075 20 11.50
41 cg02978201 19 22.00 91 cg10507965 13 10.84
42 cg15765638 12 21.88 92 cg07501029 7 10.56
43 cg01341801 31 21.53 93 cg20086657 28 10.09
44 cg01891583 12 21.53 94 cg00704664 9 9.69
45 cg24009806 8 21.48 95 cg03796003 11 9.43
46 cg16791832 13 21.35 96 cg24925741 9 8.04
47 cg09856996 5 21.34 97 cg03224005 14 7.98
48 cg12342501 15 21.30 98 cg26642774 8 7.76
49 cg02890259 23 21.18 99 cg25465065 26 6.85
50 cg12657416 13 21.02 100 cg09289202 11 6.21
Mean	  Number	  of	  Significant	  hits:	  21.94
Mean	  log	  p-­‐value:	  22.06











1 cg20592836 44 30.25 49 cg13885788 7 19.76
2 cg25203245 37 28.94 50 cg18527716 25 19.70
3 cg15083522 42 28.34 51 cg02113055 33 19.63
4 cg07414487 66 27.73 52 cg18572898 138 19.57
5 cg02464073 9 27.35 53 cg08049519 35 19.55
6 cg08146865 42 26.84 54 cg09993319 9 19.40
7 cg10724632 20 26.55 55 cg00474373 7 19.39
8 cg23698271 7 26.33 56 cg18709904 29 19.26
9 cg21927991 20 26.25 57 cg18088486 29 19.05
10 cg06464078 22 25.81 58 cg04610028 14 18.94
11 cg16490124 29 25.56 59 cg05338731 33 18.81
12 cg19393008 23 25.53 60 cg07686394 29 18.61
13 cg17723206 11 24.96 61 cg05059349 24 17.93
14 cg24801230 57 24.70 62 cg27341708 29 17.10
15 cg23098789 6 24.48 63 cg07498088 42 16.99
16 cg04145681 46 24.42 64 cg12186981 36 16.95
17 cg27481428 23 24.24 65 cg04131969 19 16.73
18 cg23681001 17 24.23 66 cg09533869 14 16.57
19 cg07240846 7 24.10 67 cg06032337 59 16.29
20 cg06330797 14 23.95 68 cg02658043 18 16.26
21 cg26705599 11 23.81 69 cg24534774 35 16.22
22 cg19360212 27 23.77 70 cg21498547 8 15.76
23 cg00257789 32 23.74 71 cg17056069 12 15.69
24 cg18828306 24 23.73 72 cg04627110 59 15.61
25 cg25674027 32 23.39 73 cg02533724 8 15.52
26 cg04998327 13 23.33 74 cg10140678 12 14.62
27 cg10530344 20 22.90 75 cg25755428 6 14.43
28 cg06318935 25 22.73 76 cg16748433 26 14.23
29 cg22274273 9 22.58 77 cg04657146 1 13.44
30 cg01127608 4 22.29 78 cg23603995 26 13.25
31 cg04003990 15 22.03 79 cg03075889 21 13.16
32 cg15567368 1 22.03 80 cg26365090 6 12.53
33 cg16963093 3 22.00 81 cg12195446 19 12.48
34 cg21463262 7 21.92 82 cg17662493 31 12.33
35 cg05331763 10 21.83 83 cg14797147 15 11.59
36 cg01891583 12 21.53 84 cg07501029 7 10.56
37 cg16791832 13 21.35 85 cg20086657 28 10.09
38 cg09856996 5 21.34 86 cg00704664 9 9.69
39 cg12342501 15 21.30 87 cg03796003 11 9.43
40 cg02890259 23 21.18 88 cg27126508 13 9.03
41 cg12657416 13 21.02 89 cg24925741 9 8.04
42 cg19300401 18 20.91 90 cg03224005 14 7.98
43 cg05161773 18 20.68 91 cg11607219 22 7.75
44 cg23052585 29 20.67 92 cg25465065 26 6.85
45 cg18618432 28 20.59 93 cg02100397 2 6.73
46 cg05111645 115 20.46 94 cg09289202 11 6.21
47 cg11251367 9 20.42 95 cg21550016 30 5.86
48 cg10528424 4 20.26 96 cg01201512 13 5.64
Mean	  Number	  of	  Significant	  hits:	  22.77
Mean	  log	  p-­‐value:	  18.9
Chr Genomic	  Position CpG	  Name
1 chr15 24125985 cg12151888
2 chr6 41407766 cg26223899
3 chr15 24043142 cg26261358
4 chr6 41383225 cg10863737
5 chr6 41528198 cg03036702
6 chr2 237992612 cg16995742
B)	  Risk	  Loci	  identified	  through	  published	  familial	  prostate	  cancer	  studies
Chr Genomic	  Position CpG	  Name
1 chr1 235292369 cg16490124
2 chr1 241800323 cg03964373
3 chr1 240620177 cg11251367
4 chr1 233089275 cg00069771
5 chr1 233518998 cg16675926
6 chr1 232086152 cg23209941
7 chr1 231820076 cg07134368
8 chr1 242002464 cg24361198
C)	  Risk	  Loci	  identified	  through	  published	  prostate	  cancer	  GWAS	  
Chr Genomic	  Position CpG	  Name
1 chr8 128079561 cg11123619
2 chr19 51362954 cg04741880
3 chr2 121684535 cg26075039
4 chr10 101910498 cg20720056
5 chr1 154839813 cg06221963
6 chr1 154839909 cg09359103
7 chr6 6543402 cg23069046
8 chr6 153455993 cg02956194
9 chr6 41528198 cg03036702
10 chr5 1298644 cg12474444
11 chr8 143751801 cg24634471
12 chr8 143757498 cg04035553
13 chr8 143751796 cg10596483
14 chr19 51336166 cg14773235
15 chr12 47353065 cg18468917
16 chr1 117487269 cg16060930
Appendix	  4.4	  The	  most	  significant	  associations	  from	  the	  risk	  loci	  approach
A)	  Risk	  loci	  identified	  through	  the	  Tasmanian	  Familial	  Prostate	  Cancer	  Study	  
17 chr6 32186049 cg00366603
18 chr6 32188822 cg10158182
19 chr6 32202844 cg17239008
20 chr6 32186244 cg17351927
21 chr6 32415210 cg06281714
22 chr5 1325588 cg06550200
23 chr10 100167465 cg26690318
24 chr10 126700684 cg14375985
25 chr10 126686762 cg09349613
26 chr20 62387416 cg13301327
27 chr20 61660810 cg08564027
28 chr11 2211939 cg19586845
29 chr11 2243973 cg01452169
30 chr11 2222912 cg07146321
31 chr11 2212225 cg08241307
32 chr1 38180356 cg06437931
33 chr2 238410067 cg14271023
34 chr2 238380390 cg14458575
35 chr2 238392110 cg16989719






Variable Methylation Approach to Identify meQTLs    
 1. Identify most variable CpGs  
2. Draw SNPs in 250kb surrounds   
3. Perform association analysis in windows     
4. Sort and organise most significant associations   
 
#############################################################
# Methods of determining the most variable CpG sites between 
individuals
load("/Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_meth_input/R_workspaces_scripts_Meth/Methylation.RData") # load 
clean data
# use the object Meth_M which contains normalised and batch 
corrected M values (logit of Beta values) for 47 samples at 467263 
CpG sites.  M values are used to determine which CpGs are the most 
variable as this measure is less vulnerable to heteroskedasticity 
than  Beta values. Once CpG sites are identified, Beta values can 
then be used for more biologically interpretable plots
## Initial Comparison of variability methods ##
# check the difference between using M and Beta values in the SD 
approach
length(which(rownames(Top100_SD_M) %in% rownames(Top100_SD))) # 71 
cross over 
# check which aren't in overlap and see what plots look like, some 
look messy 




## Top 100/500 variable by 95% reference range, only sbe SNPs, no 
probe SNPs
quantile_95_M_sbeSNP <- apply(Meth_M_sbeSNP,1, quantile, 
probs=c(0, .025, 0.5, 0.975, 1))
range_95_M_sbeSNP <- as.matrix(quantile_95_M_sbeSNP[4,]-
quantile_95_M_sbeSNP[2,])




# check the difference between different methods
length(which(rownames(Top100_SD) %in% rownames(Top100_range_M))) # 
51, 51% 
length(which(rownames(Top100_SD_M) %in% rownames(Top100_range_M))) # 
67, 67%
length(which(rownames(Top500_SD_M) %in% rownames(Top500_range_M))) # 
407, 81%
length(which(rownames(Top100_SD_Meth_M_sbeSNP) %in% 
rownames(Top100_range_M_sbeSNP))) # 73, 73%
length(which(rownames(Top500_SD_Meth_M_sbeSNP) %in% 
rownames(Top500_range_M_sbeSNP))) # 428, 86%
# check the difference between CpGs with a SNP at the sbe and the 
ones without taking this into account
length(which(rownames(Top100_SD_M) %in% 
rownames(Top100_SD_Meth_M_sbeSNP))) # 80, 80%
length(which(rownames(Top500_SD_M) %in% 
rownames(Top500_SD_Meth_M_sbeSNP))) # 396, 79%
length(which(rownames(Top100_range_M) %in% 
rownames(Top100_range_M_sbeSNP))) # 90, 90%  # these have the 
greatest overlap
length(which(rownames(Top500_range_M) %in% 
rownames(Top500_range_M_sbeSNP))) # 415, 83%
# Thus, the range is better at pulling out the sbe SNPs rather than 
SD, especially in the most variable sites (Top100) where its 10% 
more than the Top500
# write a csv with 4 columns listing 100s/500s and the overlap 
between
Tops_100 <- cbind(rownames(Top100_SD_M), rownames(Top100_range_M), 
rownames(Top100_SD_Meth_M_sbeSNP), rownames(Top100_range_M_sbeSNP))




Tops_500 <- cbind(rownames(Top500_SD_M), rownames(Top500_range_M), 
rownames(Top500_SD_Meth_M_sbeSNP), rownames(Top500_range_M_sbeSNP))




### Chose M over Beta values due to heteroskedasticity, chose a 
combination of SD and 95%-range to give wider coverage and chose a 
combination of only sbe SNP CpGs (SD) and CpGs unfiltered for sbe 
SNPs (95%-range) ###
############################
## 1. Standard Deviation  ##
############################
# Prioritise the CpGs that are TypeII and have a SNP at the sbe as 
methylation at these sites are the most likely to be affected by 
SNPs but those SNPs will not affect the pribe binding.  Also check 
for SNPs in probe body as these may affect the binding of the probe
load("/Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_meth_input/R_workspaces_scripts_Meth/Methylation.RData")
# Which are type II probes?
typeII <- Annotated_meth[which(Annotated_meth$Type=="II"),]
dim(typeII)  #336539     33
# Which of these have a SNP at the sbe?
typeII_sbeSNP <- typeII[which(!(typeII$SBE_rs=="NA")),]
dim(typeII_sbeSNP)  #7049   33
#What are the CpG names for these sites?
names_typeII_sbeSNP <- rownames(typeII_sbeSNP)
length(names_typeII_sbeSNP)  #7049




# Which are the most variable between samples by Standard Deviation?
# First, get the CpG names and ensure they match the Meth_M info
length(which(names_typeII_sbeSNP %in% rownames(Meth_M)))  #only 
6920, other 69 may be control probes
keep_typeII_sbeSNP <- typeII_sbeSNP[which(names_typeII_sbeSNP %in% 
rownames(Meth_M)),]






identical(rownames(keep_typeII_sbeSNP), keep_names_typeII_sbeSNP)  
#TRUE, good
# Pull out these CpGs from the Meth_M data
Meth_M_sbeSNP <- Meth_M[keep_names_typeII_sbeSNP,]
dim(Meth_M_sbeSNP)  # 6920   47
identical(keep_names_typeII_sbeSNP,rownames(Meth_M_sbeSNP))  #TRUE







pheno=Meth_info@phenoData@data$Family, measure="beta", ylim= c(0,1))
# the pheno is wrong here, need to match up with the correct data 
frame but for these purposes it doesn't matter as I don't currently 
care how they segregate, just as long as there are 3 groups
# Also have plotted as B than M as this is more biologically 
interpretable 
# These look quite variable.  There are some that appear randomly 
vriable though, ie. may need to perfect the kmeans cluster method to 
get three nice clusters rather than just random variation




top100sbeSNP$Type  # yes all II
top100sbeSNP$pos
top100sbeSNP$chr  # yes all diff chr




identical(rownames(top100Meth_M), rownames(top100sbeSNP)) # TRUE
# Subset Meth_B for biologically relevant values and to use in the 
assoication model if the top100Meth_M does not work as has been a 
problem in the past because low values generate NaNs
top100Meth_B <- Meth_B[rownames(Top100_SD_Meth_M_sbeSNP),]
# Use top100sbeSNP as the object for annotation info and 
top100Meth_M or top100Meth_B as the actual methylation data for the 
model
########################
## 2. K-means Cluster ##
########################
# This method was not as efficient as SD or 95%-range as it requires 
extensive optimisation of the parameters for within and between sum 
of squares so clusters are generated in three regions. For example 
adjustment of within ss cut offs indicate which samples are to be 
included in the cluster and adjustment of between ss indicates the 
distance between clusters, optinmally clustered in three distinct 
groups, not random variation across the possible beta value range of 
0:1.  If not performed in parallel the function is also 
computationally slow and requires the data to be broken into to 
chunks 
# for examples trying a totss >1 and withinss <0.15 was much more 
effective than default metrics but still required further 
optimisation for similar efficacy as SD or 95%-range






  betweenSS1[modelnum]=if(cluster$totss>1 && cluster$withinss<0.15) 
cluster$betweenss/cluster$totss else "NA"
  modelnum= modelnum +1 }
############################
## 3. 95%-reference range ##
############################
# The difference between the most and least methylated individuals, 
among 95% of the individuals forming the central distribution of 
methylation values.  This approach is less sensitive to outliers 
than the full range and more readily interpretable than SD
dim(Meth_M) # [1] 467263     47
quantile(Meth_M[1,], probs=c(0, .025, 0.5, 0.975, 1))  # Test the 
quantile function on one CpG site, dividing the distribution into 
quintiles and selecting the lower 2.5% and upper 97.5% as the 2nd 
and 4th quantiles
      # 0%     2.5%      50%    97.5%     100% 
# 2.096701 2.211459 2.819828 3.769314 3.914120 
quantile_95_M <- apply(Meth_M,1, quantile, probs=c(0, .025, 0.5, 
0.975, 1))  # apply to all CpG sites
range_95_M <- as.matrix(quantile_95_M[4,]-quantile_95_M[2,]) # 
calculate the 95%-range for each CpG site by subtracting the 2nd 
quantile from the 4th
ord_range_95 <- range_95_M[order(range_95_M, decreasing=TRUE),] # 
order the 95% range in decreasing order so those CpGs with the 
greatest range are first
Top100_range_M <- as.matrix(ord_range_95_M[1:100]) # select the 
first 100 CpG sites with the greatest 95%-range
Top500_range_M <- as.matrix(ord_range_95_M[1:500]) # select the 
first 500 CpG sites with the greatest 95%-range
## Top 100/500 variable by 95% reference range, only sbe SNPs, no 
probe SNPs
quantile_95_M_sbeSNP <- apply(Meth_M_sbeSNP,1, quantile, 
probs=c(0, .025, 0.5, 0.975, 1))
range_95_M_sbeSNP <- as.matrix(quantile_95_M_sbeSNP[4,]-
quantile_95_M_sbeSNP[2,])





rownames(Top100_range_M_sbeSNP))) # 90, 90%
# Do association analysis for Top100_range_M because 90/100 of them 
were sbe SNPs so wanted to know what the other 10 looked like, ie do 
they have lower log p-vals like I suspect
# Use Top100_range_M in the model, if Beta values are required used 
the CpG names from this object to pull the correct Beta values
#########################
## Perform Association ##
#########################
## Data required for both analysis ##
# a) Selecting samples
colnames(top100Meth_M)  # good quality samples on methylation array
 # [1] "PC11.3"   "PC22.2"   "PC11.4"   "PC22.3"   "PC11.9"  
 # [6] "PC22.16"  "PC11.147" "PC22.17"  "PC22.21"  "PC22.468"
# [11] "PC22.203" "PC22.387" "PC72.136" "PC22.416" "PC72.188"
# [16] "PC72.4"   "PC72.213" "PC72.77"  "PC72.126" "PC9.1"   
# [21] "PC9.4"    "PC9.12"   "PC9.24"   "PC9.121"  "PC9.477" 
# [26] "PC22.210" "PC22.393" "PC22.414" "PC22.4"   "PC22.162"
# [31] "PC22.195" "PC11.415" "PC22.418" "PC11.234" "PC22.476"
# [36] "PC11.180" "PC72.03"  "PC22.388" "PC9.338"  "PC22.386"
# [41] "PC9.357"  "PC22.274" "PC9.129"  "PC72.106" "PC9.29"  
# [46] "PC72.187" "PC9.286" 
# create a text file with these samples so they can be pulled from 
the plink file
# Create a fam file with all the samples from the genotyping data 
then match these to the ones that have methylation data.  NB, have 
used the position of the first variable CpG site plus 1Mb to make it 
fast as I don't need all the information.
system("/Applications/plink-1.07-mac-intel/plink --noweb --bfile /
Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Ass_genetic_input/cutoff_15_final --chr 1 --from-bp 33292126 --to-bp 
34292126 --transpose --recode --out /Users/ecazaly/Desktop/
PhD_Analysis/Association_2015april/Perform_Ass/Top100variable/
geno_sampleNames") 
# Use the .tfam file generated by this command to look at samples
geno_samples <- read.table("geno_sampleNames.tfam")  # sample names 
are V2 column. There are 51 samples
# change the format of methylation names so they can be compared
topVariable_samples <-  colnames(top100Meth_M)
topVariable_samples <- gsub(".", "_",topVariable_samples, fixed=T)
topVariable_samples[20] <- gsub("_1", "_01",topVariable_samples[20], 
fixed=T)
topVariable_samples[2] <- gsub("_2", "_02",topVariable_samples[2], 
fixed=T)
topVariable_samples[c(1,4)] <- gsub("_3", 
"_03",topVariable_samples[c(1,4)], fixed=T)
topVariable_samples[c(3,16,21,29)] <- gsub("_4", 
"_04",topVariable_samples[c(3,16,21,29)], fixed=T)
topVariable_samples[5] <- gsub("_9", "_09",topVariable_samples[5], 
fixed=TRUE)
topVariable_samples[16] <- gsub("04","04_a", 
topVariable_samples[16], fixed=TRUE) 





# match the two sample files to see which to keep
length(geno_samples$V2)  #51
length(meth_samplesNames$V2) #47
length(which(geno_samples$V2 %in% meth_samplesNames$V2)) #39, agrees 
with previous scripts
# create new text file with just these names to pull out desired 
samples from plink
keep_sampleNames <- geno_samples[which(geno_samples$V2 %in% 
meth_samplesNames$V2),]
# make sure keep V1 as this is the family ID.  I didn't put a proper 
family ID in the genotyping file so it's just a number 1-51 
write.table(keep_sampleNames[,1:2], col.names=FALSE, 
row.names=FALSE, quote=FALSE, file="keep_samples.txt")
# b) creating a kinship coefficient matrix to include how samples 
are related in the association model 
# Use the ibs (identity by state) function from the GenABEL package. 
Here I've created the ibs_no object by choosing "no" for the weight 
argument in the ibs function, this allows direct IBS computaitons.  
I tested an alternative method, "weight=freq" which takes into 
account allelic frequency assuming HWE but this method was not 
sucessful in the association model, possibly because the assumption 
did not hold for my familial data where the allelic frequencies may 






ibs_no <- ibs(gwaa_all_omni, weight="no") 
colnames(ibs_no) <- gsub("_", "-", colnames(ibs_no))
rownames(ibs_no) <- gsub("_", "-", rownames(ibs_no))
####################################
## 1. Standard Deviation Method  ##
###################################
# Use top 100 variable as determined by SD with no probe SNPs and 
all sbe SNPs in Type II probes
# Export genotype data from PLINK and create R object with 250Kb 
window, 125Kb (50^3) either side (tested 200kb/400kb/500kb/1Mb, 
there was only 1-5 snps in the 200Kb-400Kb for the first cpg but 
increasing to 2MB gave 704 SNPs in the 1st Cpg window but some other 













keep_samples.txt --chr ", chr[cpg]," --from-bp ",pos[cpg]-50^3," --
to-bp ",pos[cpg]+50^3," --recode --transpose --out /Users/ecazaly/
Desktop/PhD_Analysis/Association_2015april/Perform_Ass/
Top100variable/",cpgNames[cpg]),collapse=""))
} # Files should be in .tped and .tmap format for the GenABEL R 
package;  add in --transpose line 













# Create phenotype file from 'top100Meth_B' data.  Tried 
top100Meth_M but this fails in the model
colnames(top100Meth_B) <- topVariable_samples
length(which(colnames(top100Meth_B) %in% keep_sampleNames$V2))






































for(i in colnames(gwaa@phdata[(cpgInfo[cpg,4])+2])) {
  for(j in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[j], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(i, j, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[i], "~", 
gwaa@gtdata@gtps[j]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum= modelnum + 1
    }} 





keep_samples.txt --chr ", cpgInfo[cpg,1]," --from-bp ",cpgInfo[cpg,
2]-50^3," --to-bp ",cpgInfo[cpg,2]+50^3," --recode --out /Users/
ecazaly/Desktop/PhD_Analysis/Association_2015april/Perform_Ass/
Top100variable/", cpgInfo[cpg,3], sep=""))
 # don't transpose to get .map file  
map <- read.table(paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100variable/",cpgInfo[cpg,
3],".map",sep=""), as.is=T)  
# cut down map to the snps that have pvals
name_keep <- gsub(paste(cpgInfo[cpg,3], "/", sep=""),"", name, 
fixed=TRUE)
map_b <- map[c(which(name_keep %in% map$V2)),]

















+1.2,"adjusted p-value",font=3, cex=0.4, col="red")
text(map_b[nsnps,4]*10^-6-0.033, 35, paste("Significant 
associations: ", length(which(log10pvps> -1*log10(0.05/nsnps))), 
spe=""), cex=0.6)
dev.off()    







cpgInfo[cpg,3], ".csv", sep="")) 
}    





import.list <- llply(filenames, read.csv, header=T)
details_all <- matrix(nrow=100, ncol=3)
library(reshape)
details_all <- merge_recurse(import.list)










MAF <- top100sbeSNP[,"SBE_maf"] # for these it is the same as  
top100sbeSNP[,"CpG_maf"]
identical(top100sbeSNP[,"SBE_maf"], top100sbeSNP[,"CpG_maf"])  #TRUE








rs_onOMNI_100 <- conversion[conversion$RsID %in% CPG_detail_100[,
7],]
for(i in rownames(CPG_detail_100)){ 
CPG_detail_100[i,9] <- if(CPG_detail_100[i,7] %in% 





## 2. 95%-range Method ##
#########################






identical(rownames(Annotated_range), cpgNames_range)  #TRUE
identical(rownames(Meth_M_100range), cpgNames_range)  #TRUE
chr_range <- Annotated_range$chr
chr_range <- as.integer(gsub("chr", "", chr_range))
pos_range <- Annotated_range$pos
cpgNumber_range <- 1:length(chr_range)










keep_samples.txt --chr ", chr_range[cpg]," --from-bp 















# Create phenotype file, try with Meth_M 
Meth_M_100range
# select only the samples that have geno data for
colnames(Meth_M_100range) <- colnames(top100Meth_B)
length(which(colnames(Meth_M_100range) %in% keep_sampleNames$V2)) 
















# the association model did not work with these M-values as the 
pheno input, try with Beta values and see if that works
Meth_B_100range <- Meth_B[cpgNames_range,]
colnames(Meth_B_100range) <- colnames(top100Meth_B)









































for(i in colnames(gwaa@phdata[(cpgInfo_range[cpg,4])+2])) {
  for(j in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[j], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(i, j, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[i], "~", 
gwaa@gtdata@gtps[j]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum= modelnum + 1
    }} 
# plot 




keep_samples.txt --chr ", cpgInfo_range[cpg,1]," --from-bp 




 # don't transpose to get .map file  
map <- read.table(paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/Top100_range/", cpgInfo_range[cpg,
3],".map",sep=""), as.is=T)  
# cut down map to the snps that have pvals
name_keep <- gsub(paste(cpgInfo_range[cpg,3], "/", sep=""),"", name, 
fixed=TRUE)
map_b <- map[c(which(name_keep %in% map$V2)),]




















+1.2,"adjusted p-value",font=3, cex=0.4, col="red")
text(map_b[nsnps,4]*10^-6-0.033, 35, paste("Significant 
associations: ", length(which(log10pvps> -1*log10(0.05/nsnps))), 
spe=""), cex=0.6)








Hits_range/", cpgInfo_range[cpg,3], ".csv", sep="")) 
}    





import.list <- llply(filenames, read.csv, header=T)
details_all_range <- matrix(nrow=100, ncol=3)
library(reshape)
details_all_range <- merge_recurse(import.list)





#get info on the hits
range_sigHits_annotated <- Annotated_meth[details_all_range
$CpG_Name,]
dim(range_sigHits_annotated)  # [1] 98  33
# 96 sig hits from the 98 ass that worked, 85 of these are >10log 
pval
# check these for CpG_rs
range_10log <- details_all_range[which(details_all_range
$Highest_pval>=10),]
dim(range_10log)  #85  3
range_10log_cpgs <- range_10log$CpG_Name
range_10log_annotated <- Annotated_meth[range_10log_cpgs, 
c(1,2,4,9,12,14,15,16,17,18,19,24,28,29,33)]
range_10log_annotated$CpG_rs  # all but 4 have CpG_rs
length(which(!(is.na(range_10log_annotated$CpG_rs))))  #81
length(which(!(is.na(range_sigHits_annotated$CpG_rs))))  #90 







# write range signifcant hits to a csv with annotaion details and 












# Use the csv files with genome annotations and log p-vals to 
prioritise CpGs for validation and further follow up. 
###############################################################
##  Prostate Cancer Risk Loci Approach to Identify meQ 3QTLs ##
###############################################################
# generate prostate cancer rick genomic windows to examine the 
association between SNPs in the region and methylation 
# For our linkage regions and GWAS, a 50KB window was taken around 
the hit SNP.  For published linkage regions a sliding window 
approach was used as described below
# Sliding windows were created by selecting a core region of 30KB 
with an additional 10KB either side which overlaps with wondows 
either side. This size window was chosen as (Smith et al 2014, Zhi 
et al 2013) have found 15KB/10KB to be average distance for 
association, this gives a little extra incase.  Larger windows were 
not chosen as (Luijk et al 2015) have suggested that windows of 
hundreds of KB are much too large due to high FDR, they suggest 
10-50KB.  These windows are much less than the 250KB windows used in 
the methylation approach as that method examines only one CpG per 
window and thus has a lower number of tests and FDR.
# if ROI are greater than 50KB then take a few 50KB windows with an 
overlap of 10KB each side, if less than 50KB then take whole region 








## Data required for all analysis ##
# the same files/R objects generated for the methylation apparoach 
were used to:
# a) Select samples
# b) Kinship coefficient matrix
####################################################################
#########################
## 1. Familial Prostate Cancer risk regions identified in our lab 
through linkage analysis ##
####################################################################
#########################
# In a familial prostate cancer linkage analysis performed in our 
lab (REFERENCE), 4 regions with high LOD scores were identified as 
possible prostate cancer risk regions. Within these regions 143 SNPs 
were identified (ask Nick about exactly how he did this) on four 
chromosomes (2,6,15,22)





PCrisk_list$Liesel_LinkageROI_List # look at genes
genes_Leisel <- annotated_genes[which(annotated_genes
$UCSC_RefGene_Name %in% PCrisk_list$Liesel_LinkageROI_List),] 
dim(genes_Leisel)
# [1] 1428   33    
genes_Leisel$UCSC_RefGene_Name  # gene names, there are duplicates 
as some genes have more than one cpg
genes_Leisel$Name  # these are the cpg sites
# pull these from Meth_B
genes_Leisel_Meth_B <- Meth_B[which(rownames(Meth_B) %in% 
genes_Leisel$Name),]
dim(genes_Leisel_Meth_B)






$Liesel_LinkageROI_List) # 1428 
# any of these CpGs in the TopVariable?
which(genes_Leisel$Name %in% rownames(top100sbeSNP))  #1:  1298
# Top 500 ?
which(rownames(Top500_SD_Meth_M_sbeSNP) %in% genes_Leisel$Name) # 
same 1 1298 / 71
Top500_SD_Meth_M_sbeSNP[71,]
genes_Leisel[1298,]
# this is cg20205188 the one that was pulled out at the top of the 
script, no more by looking at top 500.
# what about looking at CpGs within the region.. may not necessarily 
be associated with the gene..
# but also positions themselves 
chrAll_risk$chr
chrAll_risk$pos # maybe pull cpgs within range?








colnames(leisel) <- c("snp", "chr", "pos", "LOD")
leisel$start_50KB <- leisel$pos-25000
leisel$end_50KB <- leisel$pos+25000
leisel$end_50KB - leisel$start_50KB # check
leisel$chr <- as.numeric(gsub("chr", "", leisel$chr, fixed=T))







keep_samples.txt --chr ", leisel$chr[i]," --from-bp ", leisel





















keep_samples.txt --chr ", leisel$chr[i]," --from-bp ", leisel









$chr[i] & Annotated_meth$pos <leisel$end_50KB[i] & Annotated_meth
$pos >leisel$start_50KB[i]),])
cpgs_leisel <- cpgs_leisel[which(cpgs_leisel %in% 
rownames(Meth_B))]
Meth_B_leisel <- data.frame(Meth_B[cpgs_leisel,])
Meth_B_leisel <- if(length(cpgs_leisel)==1) 
t(Meth_B_leisel) else Meth_B_leisel
colnames(Meth_B_leisel) <- topVariable_samples




keep_leisel <- if(length(cpgs_leisel)==1) t(keep_leisel) 
else keep_leisel
rownames(keep_leisel) <- if(length(cpgs_leisel)==1) 
cpgs_leisel else rownames(keep_leisel)







dim(keep_leisel) # 39 1






















rownames(gwaa@gtdata@gtps))           
name=vector()   
coefs=vector()
pvals=vector() 
log10pvps=vector()   
Number_Sig_Hits=vector() 
Highest_pval=vector() 
modelnum=1   
for(cpg in colnames(gwaa@phdata[-c(1,2)])) { 
  for(snp in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[snp], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(cpg, snp, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[cpg], "~", 
gwaa@gtdata@gtps[snp]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum=modelnum+1






nsnps  <- ncol(gwaa@gtdata@gtps) 










hits_leisel_detailed <- data.frame(window_name, nsnps, nCPGs, 





as.character(leisel$snp[i]),".csv", collapse=""))  
}
# this gives 53 files, the amount with stringent sig hits





import.list <- llply(filenames, read.csv, header=T)









# A lot of repetition in the CpGs because of the overlapping sliding 
window and this spreadsheet also lists the significant hits of each 
SNP with a CpG so that the most significant one can be determined.  
IN the methylation approach, only the ..
####################################################################
###########################
## 2. Prostate Cancer risk regions identified in published studies 
through linkage analysis  ##
####################################################################
###########################
# A list of 32 prostate cancer risk linkage regions from published 
familial studies was generated on OMIM (www.ncbi.nlm.nih.gov/omim).  
These regions were already annotated to the hg19 genome build so it 













# Create data frame with the new windows:  50KB total 
linkage_windows_50KB <- data.frame(linkage_region$Region_Identifier, 
linkage_region$hg19_chr, linkage_region$range, linkage_region
$start-10000, linkage_region$end+10000)
colnames(linkage_windows_50KB) <- c("window_name", "chr", 
"ROI_range", "window_start", "window_end")
linkage_windows_50KB$window_range <- (linkage_windows_50KB
$window_start - linkage_windows_50KB$window_end)*-1 




# do the first and second window manually then the thirs onwards in 
a loop.  For the largest region of 44000000 bp there should be 
44000000/40000 = 1100 windows? it's not too worrying that there are 
a lot as long as there are not too many significant hits, just need 






first_window_start[i] <- if(linkage_region$range[i]< 30000) 
linkage_region$start[i] - ((50000-linkage_region$range[i])/2) else 
linkage_region$start[i]-10000
first_window_end[i] <- if(linkage_region$range[i]< 30000) 
linkage_region$start[i] + ((50000-linkage_region$range[i])/2) + 
linkage_region$range[i] else linkage_region$start[i]+40000 #then the 
next window starts 10kb in of that end
first_window_range[i] <- first_window_end[i] -first_window_start[i] 
}
first_window <- data.frame(linkage_region$Region_Identifier, 
rep(1,32), linkage_region$range, linkage_region$hg19_chr, 
first_window_start, first_window_end, first_window_range)
colnames(first_window) <- c("ROI", "windows_window", "ROI_range", 
"chr", "windows_start", "windows_end", "windows_range")
# Keep creating these windows until all regions are broken down to 






second_window_start[i] <- if(linkage_region$range[i]> 30000) 
first_window_end[i]-10000 else NA
second_window_end[i] <- if(linkage_region$range[i]> 30000) 
(first_window_end[i]+ 40000) else NA
second_window_range[i] <- if(is.na(second_window_end[i])) NA else 
second_window_end[i] - second_window_start[i] }
second_window <- data.frame(linkage_region$Region_Identifier, 
rep(2,32), linkage_region$range, linkage_region$hg19_chr, 
second_window_start, second_window_end, second_window_range)
colnames(second_window) <- c("ROI", "windows_window", "ROI_range", 
"chr", "windows_start", "windows_end", "windows_range")
# how do you know when to stop the windows? for the 3rd if original 
ROI >60 ? that covers 2 x30 unique windows plus overlap?  just keep 





third_window_start[i] <- if(!(is.na(second_window_range[i])) & 
linkage_region$range[i]> 60000) second_window_end[i]-10000 else NA
third_window_end[i] <- if(linkage_region$range[i]> 60000) 
(second_window_end[i]+ 40000) else NA
third_window_range[i] <- if(is.na(third_window_end[i])) NA else 
third_window_end[i] - third_window_start[i] 
}
third_window <- data.frame(linkage_region$Region_Identifier, 
rep(3,32), linkage_region$range, linkage_region$hg19_chr, 
third_window_start, third_window_end, third_window_range)
colnames(third_window) <-c("ROI", "windows_window", "ROI_range", 





fourth_window_start[i] <- if(!(is.na(third_window_range[i])) & 
linkage_region$range[i]> 90000) third_window_end[i]-10000 else NA
fourth_window_end[i] <- if(linkage_region$range[i]> 90000) 
(third_window_end[i]+ 40000) else NA
fourth_window_range[i] <- if(is.na(fourth_window_end[i])) NA else 
fourth_window_end[i] - fourth_window_start[i] 
}
fourth_window <- data.frame(linkage_region$Region_Identifier, 
rep(4,32), linkage_region$range, linkage_region$hg19_chr, 
fourth_window_start, fourth_window_end, fourth_window_range)
colnames(fourth_window) <- c("ROI", "windows_window", "ROI_range", 
"chr", "windows_start", "windows_end", "windows_range")
# write the first few windows in a csv, check, then combine first 
two with others
oneTo4 <- rbind(first_window, second_window, third_window, 
fourth_window)




# loop the remaining windows (start from the 3rd window, can then 




linkage_region$Region_Identifier[1] <- gsub("1", "01", 
linkage_region$Region_Identifier[1], fixed=T)
linkage_region$Region_Identifier[2] <- gsub("2", "02", 
linkage_region$Region_Identifier[2], fixed=T)
linkage_region$Region_Identifier[3] <- gsub("3", "03", 
linkage_region$Region_Identifier[3], fixed=T)
linkage_region$Region_Identifier[4] <- gsub("4", "04", 
linkage_region$Region_Identifier[4], fixed=T)
linkage_region$Region_Identifier[5] <- gsub("5", "05", 
linkage_region$Region_Identifier[5], fixed=T)
linkage_region$Region_Identifier[6] <- gsub("6", "06", 
linkage_region$Region_Identifier[6], fixed=T)
linkage_region$Region_Identifier[7] <- gsub("7", "07", 
linkage_region$Region_Identifier[7], fixed=T)
linkage_region$Region_Identifier[8] <- gsub("8", "08", 
linkage_region$Region_Identifier[8], fixed=T)









for(i in 1:32){ 
for(j in 1:35200){ 
windows_start[j] <- if(linkage_region$range[i]> 30000*j) 
linkage_region$start[i]+30000+40000*j else NA
windows_end[j] <- if(linkage_region$range[i]> 30000*j) 
(linkage_region$start[i]+30000+40000*j)+50000 else NA
windows_end[j] <- if(!(is.na(windows_end[j])) & windows_start[j] < 
linkage_region$end[i]) windows_end[j] else NA
windows_range[j] <- if(is.na(windows_end[j])) NA else windows_end[j] 
- windows_start[j]

















# This works. Then combine the oneTo4 and order by ROI, 
windows_window, check then remove then manual 3&4 windows
# Needed to change window.1 etc to just 1,2,3... because when it 




import.list <- llply(filenames, read.csv, header=T)
library(reshape)
windows_all <- merge_recurse(import.list)
dim(windows_all) # 5797    8
head(windows_all)
windows_all[1:20,1:6]
# order by ROI, window
windows_all <- windows_all[with(windows_all, order(windows_all$ROI, 
windows_all$windows_window)),]
# remove duplicate windows
windows_all$X <- paste(windows_all$ROI, "_", windows_all
$windows_window, sep="")
dim(windows_all)-dim(windows_all[unique(windows_all$X),]) # should 

































foreach(i=1:length(windows_all2$ROI_window)) %dopar% { #
system(paste(c("/opt/apps/plink-1.07-x86_64/plink --noweb --bfile /
home/ecazaly/Data/Aug2015_onwards/Ass_genetic_input/cutoff_15_final 
--keep /home/ecazaly/Data/Aug2015_onwards/Ass_genetic_input/
keep_samples.txt --chr ", windows_all2$chr[i]," --from-bp ", 
windows_all2$windows_start[i]," --to-bp ", 
windows_all2$windows_end[i]," --recode --transpose --out /home/
ecazaly/Data/Aug2015_onwards/Ass_genetic_input/windows/", 
as.character(windows_all2$ROI_window[i])),collapse=""))









system(paste(c("/opt/apps/plink-1.07-x86_64/plink --noweb --bfile /
home/ecazaly/Data/Aug2015_onwards/Ass_genetic_input/cutoff_15_final 
--keep /home/ecazaly/Data/Aug2015_onwards/Ass_genetic_input/
keep_samples.txt --chr ", windows_all2$chr[i]," --from-bp ", 
windows_all2$windows_start[i]," --to-bp ", 





Annotated_meth$pos <windows_all2$windows_end[i] & Annotated_meth$pos 
>windows_all2$windows_start[i]),])
# if(length(cpgs_genomic)<=1) { next  # no cpgs in the 
window
# }
cpgs_genomic <- cpgs_genomic[which(cpgs_genomic %in% 
rownames(Meth_B))]
Meth_B_genomic <- data.frame(Meth_B[cpgs_genomic,])
Meth_B_genomic <- if(length(cpgs_genomic)==1) 
t(Meth_B_genomic) else Meth_B_genomic
colnames(Meth_B_genomic) <- topVariable_samples




keep_genomic <- if(length(cpgs_genomic)==1) t(keep_genomic) 
else keep_genomic
rownames(keep_genomic) <- if(length(cpgs_genomic)==1) 
cpgs_genomic else rownames(keep_genomic)








pheno <- cbind(ID, sex, t(keep_genomic))
write.table(pheno, file=paste("/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/windows/Phenos/





pheno_",windows_all2$ROI_window[i], ".txt", sep=""), 
genofile=paste("/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/windows/", 








rownames(gwaa@gtdata@gtps))           
name=vector()   
coefs=vector()
pvals=vector() 
log10pvps=vector()   
Number_Sig_Hits=vector() 
Highest_pval=vector() 
modelnum=1   
for(cpg in colnames(gwaa@phdata[-c(1:2)])) {  
  for(snp in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[snp], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(cpg, snp, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[cpg], "~", 
gwaa@gtdata@gtps[snp]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum=modelnum+1
    }}
# plot, will not plot at this stage, just generate significant hit 
data




collapse=""), as.is=T)  
# cut down map to the snps that have pvals
# name_keep <- gsub(paste(colnames(gwaa@phdata[,-c(1:2)]), "/", 
sep="")[i], "", name, fixed=TRUE) 
# map_b <- map[c(which(name_keep %in% map$V2)),] 
# should correct by /ntests not /nsnps but see if any are sig first 
because may use Simes procedure rather than Bonferroni to correct if 
some look possibly sig
nsnps  <- ncol(gwaa@gtdata@gtps) 
nCPGs <-  ncol(gwaa@phdata[-c(1:2)])











  } 
  




import.list <- llply(filenames, read.csv, header=T)
Hits_all_linkage <- matrix(nrow=2061, ncol=7)
library(reshape)
Hits_all_linkage_a <- 
Hits_all_linkage_b <- merge_recurse(import.list)  # still too big
colnames(Hits_all_linkage) <- c("window_name", "nsnps", "nCPGs", 




# There are too many for the memory to handle.  Need to be more 
stingent with the cut offs for significance, or the ones I choose to 
bind.  Choose those with just log10 pvals >10 as for familial 
associations




pheno_",windows_all2$ROI_window[i], ".txt", sep=""), 
genofile=paste("/home/ecazaly/Data/Aug2015_onwards/
Ass_genetic_input/windows/", 








rownames(gwaa@gtdata@gtps))           
name=vector()   
coefs=vector()
pvals=vector() 
log10pvps=vector()   
Number_Sig_Hits=vector() 
Highest_pval=vector() 
modelnum=1   
for(cpg in colnames(gwaa@phdata[-c(1:2)])) {  
  for(snp in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[snp], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(cpg, snp, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[cpg], "~", 
gwaa@gtdata@gtps[snp]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum=modelnum+1
    }}
nsnps  <- ncol(gwaa@gtdata@gtps) 











hits_linkage_detailed <- data.frame(window_name, nsnps, nCPGs, 
ntests, Number_Sig_Hits, Number_Sig_Hits_stringent, Highest_pval, 
stringent_cpgs, stringent_log_pvals)
if (log10pvps[which(log10pvps>-1*log10(0.05/ntests))] <= 10) 
write.csv(hits_linkage_detailed, file=paste("/home/ecazaly/Data/
Aug2015_onwards/Ass_genetic_input/hits/Detailed_hits_", 
as.character(windows_all2$ROI_window[i]),".csv", collapse="")) # 
Create excel files for just the ones with log pvals >10
  } 
# The code works but not the if line as it writes csvs for hits with 
lower log pvals than 10. I've upped the CPUs to 35 from 25, should 
only take a few hours





import.list <- llply(filenames, read.csv, header=T)




dim(Detail_hits_all_linkage) # 573  10  The proportion with 
significant hits is a lot less than the other methods, therefore not 
an issue with FDRs??











# which have stringent pval hits?
hits_linkage_cpgs <- gsub("/..+", "", hits_linkage$stringent_cpgs)
length(hits_linkage_cpgs) #573
length(unique(hits_linkage_cpgs))  # 228, most out of all three but 
not too huge considering how many started with
hits_linkage_cpgs_unique <- hits_linkage_cpgs[which(!
(duplicated(hits_linkage_cpgs)))]






# only 16, so much smaller proportion than the other 2  (6/13, 
30/131)
hits_linkage_cpgs_rs$CpG_rs
# are any of these the original rs picked up in previous studies? 
can't look at for this as it's regions but can with other two.  None 
in the other two.   but could be in LD, look further into the 
locations/proximites
rownames(hits_linkage_cpgs_rs)  
# what proportion of sig pvals and >10 log pvals were these?
# 16/228 for sig hits.  
 # [1] "cg16490124" "cg03964373" "cg11251367"
 # [4] "cg00069771" "cg16675926" "cg23209941"
 # [7] "cg07134368" "cg01021334" "cg00382740"
# [10] "cg20267322" "cg03224005" "cg04910228"
# [13] "cg13081429" "cg03272499" "cg24412204"
# [16] "cg02262873"
# 8/228 had log pvals >10 these are probably the most interesting.  








# the one that doesn't had quite a high log pval of 19.942  
"cg24361198"
Annotated_meth_hits_linkage["cg24361198",]
# no probe SNPs, OpenSea, type II, chr1:242002464, quite far at the 
end of q arm of chr1
# check genes within 1500 bases, as 450k annotation doesn't give any 
there shouldn't be anything
242002464-1500   # chr1: 242000964
242002464+1500   # chr1: 242003964
# UCSC tell you if that CpG site has previously been found to be 
methylated, unmethylated, partially methylated
# out of 6 diff cell lines 5 were methylated and 1 was unmethylated 
in HepG2 (liver carcinoma cell line)





# "cg16490124" "cg11251367" "cg03224005"
# these all have CpG_rs
rownames(Annotated_meth_hits_linkage[which(hits_linkage_cpgs_unique 
%in% cpgInfo_range$cpgNames_range),]) %in% 





#[1] "cg16490124" "cg11251367" "cg00069771" "cg23209941" 
"cg03224005"  
# these don't overlap with the gwas ones
rownames(Annotated_meth_hits_linkage[which(hits_linkage_cpgs_unique 
%in% cpgInfo_range_500$cpgNames_range_500),]) %in% 
rownames(hits_linkage_cpgs_rs)  #[1] TRUE TRUE TRUE TRUE TRUE
# not overly surprising since 90/100 range were CpG_rs.. what about 
500 proportion?
# what about overlap with Standard Deviation
length(which(hits_linkage_cpgs_unique %in% rownames(Top100_SD_M))) 
#3, the same ones
rownames(Annotated_meth_hits_linkage[which(hits_linkage_cpgs_unique 
%in% rownames(Top100_SD_M)),])
[1] "cg16490124" "cg11251367" "cg03224005"
length(which(hits_linkage_cpgs_unique %in% rownames(Top500_SD_M))) 
#4 same as above but missing one
rownames(Annotated_meth_hits_linkage[which(hits_linkage_cpgs_unique 
%in% rownames(Top500_SD_M)),])
[1] "cg16490124" "cg11251367" "cg00069771" "cg03224005"
# save all the proportions to /Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Perform_Ass/proportions.xlsx
# Follow up the 8 CpGs with >10 log pvals, ie. check what genes 
they're near and for the 7 that are CpG_rs if that snp has been 
linked to disease risk etc
linkage_FollowUp_cpgs <- c("cg16490124", "cg03964373", "cg11251367", 
"cg00069771", "cg16675926", "cg23209941", "cg07134368", 
"cg24361198")
linkage_FollowUp <- Annotated_meth[linkage_FollowUp_cpgs, 
c(1,2,4,9,12,14,15,16,17,18,19,24,28,29,33)]
# All on chr1.  They are all from ROI_8  230700000-243700000 Look 




# check any overlap with previously annotated variability by SD for 
CpG_rs
linkage_FollowUp_cpgs  %in% rownames(top100sbeSNP) # two are
linkage_FollowUp_cpgs[which(linkage_FollowUp_cpgs  %in% 
rownames(top100sbeSNP))]
[1] "cg16490124" "cg11251367"
# excel doc with gene info found at:
/Users/ecazaly/Desktop/PhD_Analysis/Association_2015april/
Perform_Ass/Top100variable/CPG_detail_long.xlsx
 save(linkage_FollowUp_cpgs, linkage_FollowUp, hits_linkage, 
Annotated_meth_hits_linkage, hits_linkage_cpgs_rs, cpgInfo_range, 













# GWAS published PC risk loci generated from GWAS Catalog, then 
generated windows of 25KB either side of risk SNP to create a 50KB 
window of interest to perform association
# A list of 320 prostate cancer risk SNPs from published GWAS 
studies was generated using the GWAS catalogue (https://
www.ebi.ac.uk/gwas/).  63 duplicate SNPs from multiple studies were 
removed, along with 1 SNP with no information on UCSC, leaving 256 





dim(gwas_catalog)  # 320 variants, 33 data info columns
# column 22 "SNPs" has the rs numbers
# column 13 has the position as per genome build h38
gwas_catalog_lessINFO <- gwas_catalog[,c(11,12,13,22)]







# when I put this into SNP nexus only got 254 back under "Genomic 
Coordinates and External Links" and 
# 494 under "Consequences on UCSC"
# Checked which were unique rs names:
length(unique(gwas_catalog_lessINFO$SNPs))  #[1] 257, still 3 more 
than turned up in SNP nexus..
# but #25 is NA so that takes it down to 256
length(gwas_catalog_lessINFO$SNPs)  # [1] 320









duplicated(unique_gwas$SNPs) # all FALSE





# As these SNPs have been annotated to the latest genome build hg38, 
I ran them through SNP nexus, to generate hg19 annotations so that 
they can be compared to 450K data and other other PC risk info.  
# Again got 254 out so went through ths excel file to find the two 
missing ones, they are rs115457135 and rs11530697
# rs115457135 has now been 'merged' with rs7767188, replaced on 
excel spreadsheet and looked up position
#  rs11530697 has now been 'merged' with rs3129859 , replaced on 
excel spreadsheet and looked up position 










# added to All_PCrisk_info spreadsheet




dim(gwas) # 256 11
gwas <- gwas[,c(8,9,10)]
colnames(gwas) <- c("snp", "chr", "pos")
gwas$start_50KB <- gwas$pos-25000
gwas$end_50KB <- gwas$pos+25000
gwas$end_50KB - gwas$start_50KB # check
gwas$chr <- as.numeric(gsub("chr", "", gwas$chr, fixed=T))
# remove those on the X chr, I have no meth data for these
length(which(!(is.na(gwas$chr)))) #242 
length(which(is.na(gwas$chr))) #14
gwas <- gwas[which(!(is.na(gwas$chr))),] 
dim(gwas) # 242 5
gwas$snp







keep_samples.txt --chr ", gwas$chr[snp]," --from-bp ", gwas


















keep_samples.txt --chr ", gwas$chr[i]," --from-bp ", gwas





# make pheno file
cpgs_genomic <- rownames(Annotated_meth[which(Annotated_chr==gwas
$chr[i] & Annotated_meth$pos <gwas$end_50KB[i] & Annotated_meth$pos 
>gwas$start_50KB[i]),])
# if(length(cpgs_genomic)<=1) { next  # no cpgs in the window
# }
cpgs_genomic <- cpgs_genomic[which(cpgs_genomic %in% 
rownames(Meth_B))]
Meth_B_genomic <- data.frame(Meth_B[cpgs_genomic,])
Meth_B_genomic <- if(length(cpgs_genomic)==1) t(Meth_B_genomic) else 
Meth_B_genomic
colnames(Meth_B_genomic) <- topVariable_samples




keep_genomic <- if(length(cpgs_genomic)==1) t(keep_genomic) else 
keep_genomic
rownames(keep_genomic) <- if(length(cpgs_genomic)==1) cpgs_genomic 
else rownames(keep_genomic)







dim(keep_genomic) # 39 1




windows_gwas/pheno_",as.character(gwas$snp[i]), ".txt", sep=""), 
quote=FALSE)
# Perform association















rownames(gwaa@gtdata@gtps))           
name=vector()   
coefs=vector()
pvals=vector() 
log10pvps=vector()   
Number_Sig_Hits=vector() 
Highest_pval=vector() 
modelnum=1   
for(cpg in colnames(gwaa@phdata[-c(1,2)])) {  
  for(snp in colnames(gwaa@gtdata@gtps)){   
  if(sum(gwaa@gtdata@gtps[snp], na.rm=T)<1) { 
  next  }
   name[modelnum]= paste(cpg, snp, sep= "/")     
    formula=as.formula(paste(gwaa@phdata[cpg], "~", 
gwaa@gtdata@gtps[snp]))
    association=polygenic_hglm(formula, ibs_no, gwaa)
    coefs[modelnum]= summary(association$hglm)$FixCoefMat[2,1]
    pvals[modelnum]= summary(association$hglm)$FixCoefMat[2,4]
    log10pvps[modelnum]= -1*log10(pvals[modelnum])
    modelnum=modelnum+1
    }}  
nsnps  <- ncol(gwaa@gtdata@gtps) 












hits_gwas_detailed <- data.frame(window_name, nsnps, nCPGs, ntests, 





$snp[i]),".csv", collapse=""))  
}
# there are 79





import.list <- llply(filenames, read.csv, header=T)








# These associations have one CpG with multiple SNPs, pull all the 







hits_gwas_cpgs <- gsub("/..+", "", hits_gwas$stringent_cpgs)
length(hits_gwas_cpgs) #745
length(unique(hits_gwas_cpgs))  # 131, so 131 separate CpGs
hits_gwas_cpgs_unique <- hits_gwas_cpgs[which(!
(duplicated(hits_gwas_cpgs)))]
# ones with log pval >10
hits_gwas_10plus <- hits_gwas[hits_gwas$stringent_log_pvals >=10,]
dim(hits_gwas_10plus) #155
hits_gwas_cpgs_10plus <- gsub("/..+", "", hits_gwas_10plus
$stringent_cpgs)
length(unique(hits_gwas_cpgs_10plus))  # 36, only 36 separate CpGs 
with a log10 pval >10
 # [1] "cg11123619" "cg04741880" "cg26075039" "cg20720056" 
"cg06221963"
 # [6] "cg09359103" "cg23069046" "cg02956194" "cg03036702" 
"cg12474444"
# [11] "cg24634471" "cg04035553" "cg10596483" "cg14773235" 
"cg18468917"
# [16] "cg16060930" "cg00366603" "cg10158182" "cg17239008" 
"cg17351927"
# [21] "cg06281714" "cg06550200" "cg26690318" "cg14375985" 
"cg09349613"
# [26] "cg13301327" "cg08564027" "cg19586845" "cg01452169" 
"cg07146321"
# [31] "cg08241307" "cg06437931" "cg14271023" "cg14458575" 
"cg16989719"
# [36] "cg13284789"






dim(Annotated_meth_hits_gwas_10plus ) #36, 33




# 22 33, so 22 out of the 36 unique CpGs with a log10 >10 have a 
CpG_rs
gwas_cpgs_rs_10plus$CpG_rs
 # [1] "rs75324250"  "rs45588133"  "rs112225149" "rs4919427"   
"rs6920276"  
 # [6] "rs672341"    "rs4714482"   "rs3888705"   "rs7485236"   
"rs56209138" 
# [11] "rs3134797"   "rs8192585"   "rs438475"    "rs28895028"  
"rs12763379" 
# [16] "rs72830824"  "rs72828989"  "rs11696871"  "rs12292212"  
"rs57606101" 
# [21] "rs35847523"  "rs4508746"
#  Follow up the 36 with >10pvals, ie. follow up 22 with a CpG_rs 
and 14 that do not have CpG_rs
gwas_FollowUp_cpgs <- unique(hits_gwas_cpgs_10plus)





# 6 have probe_rs sites and some are Type I probes with CpG_rs that 
are not sbe_rs. Remove these as can't be sure the signal is not an 
artifact 
# Are any of these the original rs picked up in previous studies?
which(hits_gwas_cpgs_rs$CpG_rs %in% hits_gwas$window_name) # none
# what is the overlap with top[100 and top500] 95%-range variable 
CpG sites?
length(which(hits_gwas_cpgs_unique %in% cpgInfo_range





[1] "cg02956194" "cg24634471" "cg10596483"
[4] "cg00366603" "cg26690318" "cg13301327"
# Overlap with Standard Deviation?
length(which(hits_gwas_cpgs_unique %in% rownames(Top100_SD_M))) #0
length(which(hits_gwas_cpgs_unique %in% rownames(Top500_SD_M))) #6
rownames(Annotated_meth_hits_gwas[which(hits_gwas_cpgs_unique %in% 
rownames(Top500_SD_M)),])
[1] "cg02956194" "cg24634471" "cg10596483" "cg00366603"
[5] "cg26690318" "cg13301327"
# identical to 95%-range as above
# Create PNGs showing associations
# need to be specific with which cpg against all snps to get n(cpg) 
plots
for(CPG in 1:ncol(gwaa@phdata[,-c(1:2)])){  # 
png(filename=paste("/Users/ecazaly/Desktop/PhD_Analysis/
Association_2015april/Ass_genetic_input/Genetic_riskLoci/
PNGs_gwas/", colnames(gwaa@phdata[,-c(1:2)])[CPG],".png", sep=""), 
pointsize=12,units="mm",width=137.6,height=137.6*2/3,res=800)
par(family="serif")
par(mar=c(4,4,3,0.5))   






title(main=list(paste("Association between ", 







+1.2,"adjusted p-value",font=3, cex=0.4, col="red")
text(map_b[nsnps,4]*10^-6-0.033, 35, paste("Significant 






dev.off()    
}














1 PC1-­‐03 Familial M Affected 82
2 PC2-­‐01 Familial M Affected 52
3 PC2-­‐02 Familial M Affected 53
4 PC2-­‐03 Familial M Affected 58
5 PC4-­‐01 Familial M Affected 74
6 PC9-­‐01 Familial M Affected 64
7 PC9-­‐04 Familial M Affected 65
8 PC9-­‐12 Familial M Affected 72
9 PC9-­‐121 Familial M Unaffected 48
10 PC9-­‐129 Familial F NA 61
11 PC9-­‐24 Familial F NA 45
12 PC9-­‐286 Familial M Unaffected 47
13 PC9-­‐338 Familial M Affected 63
14 PC9-­‐357 Familial M Unaffected 42
15 PC9-­‐532 Familial M Affected 71
62
16 PC11-­‐03 Familial M Affected 89
17 PC11-­‐04 Familial M Affected 73
18 PC11-­‐09 Familial M Affected 83
19 PC11-­‐147 Familial M Affected 61
20 PC11-­‐180 Familial M Unaffected 42
21 PC11-­‐234 Familial M Unaffected 55
PC11	  Median	  Age	  at	  Collection: 67
22 PC22-­‐03 Familial M Affected 74
23 PC22-­‐04 Familial M Affected 62
24 PC22-­‐16 Familial M Affected 76
25 PC22-­‐162 Familial M Unaffected 56
26 PC22-­‐17 Familial M Affected 63
27 PC22-­‐203 Familial M Affected 75
28 PC22-­‐21 Familial M Affected 70
29 PC22-­‐210 Familial F NA 73
30 PC22-­‐274 Familial M Unaffected 45
31 PC22-­‐387 Familial M Affected 79
32 PC22-­‐388 Familial M Unaffected 73
33 PC22-­‐393 Familial F NA 44
PC9	  Median	  Age	  at	  Collection:
Apendix	  5.1	  Samples	  for	  which	  good	  quality	  bisulphite	  sequencing	  data	  was	  generated
34 PC22-­‐414 Familial F NA 66
35 PC22-­‐416 Familial M Affected 61
36 PC22-­‐418 Familial M Unaffected 54
37 PC22-­‐468 Familial M Affected 69
38 PC22-­‐476 Familial M Unaffected 36
66
39 PC27-­‐01 Familial M Affected 64
40 PC72-­‐01 Familial M Affected 71
41 PC72-­‐02 Familial M Affected 85
42 PC72-­‐03 Familial M Affected 70
43 PC72-­‐04 Familial M Affected 78
44 PC72-­‐106 Familial M Unaffected 46
45 PC72-­‐126 Familial M Affected 49
46 PC72-­‐187 Familial F NA 41
47 PC72-­‐188 Familial M Other	  Cancer 23
48 PC72-­‐77 Familial M Affected 75
70
49 PC75-­‐01 Familial M Affected 65
50 DVA1690 Case/Control M Unaffected 70
51 DVA1694 Case/Control M Unaffected 68
52 DVA1695 Case/Control M Unaffected 70
53 DVA1696 Case/Control M Unaffected 68
54 DVA1703 Case/Control M Unaffected 71
55 DVA1704 Case/Control M Unaffected 68
56 DVA1705 Case/Control M Unaffected 70
57 DVA1710 Case/Control M Unaffected 67
58 DVA1711 Case/Control M Unaffected 69
59 DVA1718 Case/Control M Unaffected 67
60 DVA1720 Case/Control M Unaffected 69
61 DVA1723 Case/Control M Unaffected 67
62 DVA1725 Case/Control M Unaffected 70
63 DVA1728 Case/Control M Unaffected 67
64 DVA1729 Case/Control M Unaffected 68
65 DVA1730 Case/Control M Unaffected 70
66 DVA1732 Case/Control M Unaffected 68
67 DVA1735 Case/Control M Unaffected 69
68 DVA1737 Case/Control M Unaffected 69
69 DVA1739 Case/Control M Unaffected 70
70 DVA1743 Case/Control M Unaffected 68
PC72	  Median	  Age	  at	  Collection:
PC22	  Median	  Age	  at	  Collection:
71 DVA1744 Case/Control M Unaffected 69
72 DVA1745 Case/Control M Unaffected 70
73 DVA1746 Case/Control M Unaffected 67
74 DVA1747 Case/Control M Unaffected 68
75 DVA1748 Case/Control M Unaffected 70
76 DVA1749 Case/Control M Unaffected 71
77 DVA505 Case/Control M Unaffected 67
78 DVA552 Case/Control M Unaffected 67
79 DVA566 Case/Control M Unaffected 70
80 DVA576 Case/Control M Unaffected 68
81 DVA599 Case/Control M Unaffected 70
Control	  Median	  Age	  at	  Collection: 69
Median	  age	  of	  affected	  individuals: 71
Median	  age	  of	  unaffected	  individuals: 69
*	  Age	  at	  DNA	  collection	  in	  years
Organge	  highlighting:	  37	  samples	  with	  good	  quality





Gene	   CpG rs chr Position 	  Size
1 CASZ1_a cg13387643 rs284310 1 10737562 930
2 CASZ1_b cg13387643 rs284310 1 10737562 913
3 CDK2AP1 cg09084244 rs1109559 12 123757860 1102
4 MCC cg08238375 rs4705795 5 112483149 1058
5 TP53INP2	   cg20592836 rs2378256 20 33292126 1217
6 ITGB2 cg02464073 rs1721 21 46349496 1217
7 RPS6KA2 cg06330797 rs7357046 6 167195910 1230
8 USP7_a cg01891583 rs2304466 16 8995926 817
9 USP7_b cg01891583 rs2304466 16 8995926 822
10 S	  EPT9	   cg05161773 rs426439 17 75378036 1183
11 MGMT	   cg09993319 rs7898151 10 131529435 945
12 FOXP4 cg03036702 rs4714482 6 41528198 958
13 ARHGAP22 cg25013753 rs1051508 10 49654342 1109
14 C10orf46 cg00231519 rs36101953 10 120516119 946
15 AJAP1_a cg00345083 rs7517857 1 4725584 735
16 AJAP1_b cg00345083 rs7517857 1 4725584 864
17 NME6 cg08146865 rs3197223 3 48335857 751
18 ZFAT	   cg21927991 rs5025124 8 135494242 1110
19 NSMCE4A	   cg19360212 rs11200296 10 123731471 1296
20 FOXK2_a cg05331763 rs79974293 17 80535367 905
21 FOXK2_b cg05331763 rs79974293 17 80535367 880
22 FMN2	   cg11251367 rs12403072 1 240620177 1180
23 TOX2 cg26365090 rs11700304 20 42574362 1201
24 SMC1B	   cg17662493 rs6006744 22 45806309 1060
25 PRM1_a cg02978201 rs737008 16 11374865 680
26 PRM1_b cg02978201 rs737008 16 11374865 785
27 RAB11B_a cg04610028 rs2967607 19 8464538 782
28 RAB11B_b cg04610028 rs2967607 19 8464538 865
29 STK25 cg09289202 rs6757649 2 242443982 1000
Appendix	  5.2	  Primers	  for	  bisulphite	  sequencing






























Appendix	  5.3	  Optimal	  PCR	  conditions	  for	  meQTL	  regions
Gene	   CpG Chr* Position Size Temp** Q	  solution Cycles Amplified
1 CASZ1_a cg13387643 1 10737562 930 58 None 40 Yes
2 CASZ1_b cg13387643 1 10737562 913 62 	  0.5uL 40 Yes
3 MCC cg08238375 5 112483149 1058 56 None 40 Yes
4 S	  EPT9	   cg05161773 17 75378036 1183 58 None 45 Yes
5 AJAP1_a cg00345083 1 4725584 735 58 None 40 Yes
6 AJAP1_b cg00345083 1 4725584 864 61 	  0.5uL 40 Yes
7 ZFAT	   cg21927991 8 135494242 1110 61 	  0.5uL 45 Yes
8 SMC1B	   cg17662493 22 45806309 1060 56 	  0.5uL 45 Yes
9 PRM1_a cg02978201 16 11374865 680 58 None 40 Yes
10 PRM1_b cg02978201 16 11374865 785 58 None 40 Yes
11 NME6 cg08146865 3 48335857 751 61 	  0.5uL 45 Yes
12 FOXP4 cg03036702 6 41528198 958 62 	  0.5uL 45 Yes
13 C10orf46 cg00231519 10 120516119 946 60 	  0.5uL 45 Yes
14 RPS6KA2 cg06330797 6 167195910 1230 60 	  0.5uL 45 Yes
15 MGMT	   cg09993319 10 131529435 945 62 	  0.5uL 45 Yes
16 STK25 cg09289202 242443982 1000 62 	  0.5uL 45 Yes
17 ARHGAP22 cg25013753 10 49654342 1109 60 	  0.5uL 45 Yes
18 USP7_a cg01891583 16 8995926 817 54 None 40 Yes
19 FOXK2_b cg05331763 17 80535367 880 62 None 45 Yes
20 RAB11B_a cg04610028 19 8464538 782 62 	  0.5uL 40 Yes
21 USP7_b cg01891583 16 8995926 822 60 	  0.5uL 45 No
22 FOXK2_a cg05331763 17 80535367 905 60 	  0.5uL 45 No
23 RAB11B_b cg04610028 19 8464538 865 56 	  0.5uL 45 No
24 ITGB2 cg02464073 21 46349496 1217 60 	  0.5uL 45 No
25 NSMCE4A	   cg19360212 10 123731471 1296 55 	  0.5uL 45 No
26 TP53INP2	   cg20592836 20 33292126 1217 55 	  0.5uL 45 No
27 TOX2 cg26365090 20 42574362 1201 54 	  0.5uL 45 No
28 FMN2	   cg11251367 1 240620177 1180 58 	  0.5uL 45 No
29 CDK2AP1 cg09084244 12 123757860 1102 60 	  0.5uL 45 No
*	  Chromosome
**	  Reaction	  Temperature
# Quality Control Pipeline for Bisulphite Sequencing data: 
Based on the Epigenesis guide http://www.epigenesys.eu/images/
stories/protocols/pdf/20120720103700_p57.pdf  
# Key steps: 
# 1. QC
# 2. Alignment
# 3. Extract Methylation data
# 4. Load Data in R
# 5. Perform QC with BiSeq







./fastqc ~/Emma_home/BiSeq_wd/WD/*fastq.gz --o ~/Emma_home/
BiSeq_wd/WD/FastQC_output
# Quality and Adapter trimming:  Trim Galore 
# This works on paired-end files, so both files per sample at 
the same time.  Default: removes base calls with Phred score 
20 or lower, removes Illumina adapter sequence form 3’ end, 
removes sequences shorter than 20bp
cd ~/Emma_home/BiSeq_wd/trim_galore_zip
./trim_galore --paired --trim1 ~/Emma_home/BiSeq_wd/WD/
*.fastq.gz --o ~/Emma_home/BiSeq_wd/test_2 --path_to_cutadapt 
~/Emma_home/BiSeq_wd/cutadapt-1.9.1/bin/cutadapt
# Generate a FastQC report for each trimmed read 
cd /gd/apps/FastQC-11.4
./fastqc ~/Emma_home/BiSeq_wd/test_2/*.fq.gz --o ~/Emma_home/
BiSeq_wd/FastQC_trimmed
2. Alignment to bisulphite reference:  Bismark
# Requires a working version of Perl, Bowtie2 and samtools 
# Sequencing data needs to be FastA format, either .fa 
or .fasta
# download reference genome from Ensemble:  http://
asia.ensembl.org/info/data/ftp/index.html/   
# Genome build Hg19
# Path to UCSC reference genome:  /gd/Genome_Reference/gatk-
bundle/hg19/ucsc.hg19.fasta
# Copied over to my folder
cd /gd/apps/bowtie2-2.2.6
module load bowtie2 
cd ~/Emma_home/BiSeq_wd/bismark_v0.15.0
chmod +x bismark
chmod +x bismark_genome_preparation  




# Align the genome, use --multicore to process in parallel
./bismark --multicore 10 -n 1 ~/Emma_home/BiSeq_wd/Alignment/
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# Creates two files (BAM and txt report file) for each of the 
96 samples 
3. Extract Methylation data
cd ~/Emma_home/BiSeq_wd/bismark_v0.15.0
chmod +x bismark_methylation_extractor  # makes this command 











# Use the --comprehensive command so that it combines the 4 
reads
./bismark_methylation_extractor -s --comprehensive ~/
Emma_home/BiSeq_wd/Alignment/alignment_output/
*.fq.gz_bismark_bt2_pe.bam -p --no_overlap --o ~/Emma_home/
BiSeq_wd/extracted_meth_comp
# Use bismark2bedGraph to get the required .cov files for R
chmod +x bismark2bedGraph
cd ~/Emma_home/BiSeq_wd/bismark_v0.15.0













./bismark2bedGraph --output PC9-29.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC9-29_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt









./bismark2bedGraph --output PC4-01.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC4-01_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt









./bismark2bedGraph --output PC1-03.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC1-03_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt





























./bismark2bedGraph --output PC2-03.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC2-03_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt





./bismark2bedGraph --output PC2-01.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC2-01_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt




./bismark2bedGraph --output PC9-01.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC9-01_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt





./bismark2bedGraph --output DVA552.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA552_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt































./bismark2bedGraph --output PC9-04.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC9-04_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt







































./bismark2bedGraph --output DVA599.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA599_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt









./bismark2bedGraph --output DVA505.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA505_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt





























































./bismark2bedGraph --output NTC.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_NTC_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt

























./bismark2bedGraph --output DVA566.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA566_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt

































./bismark2bedGraph --output DVA711.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA711_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output DVA720.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA720_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt
./bismark2bedGraph --output PC9-24.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC9-24_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt





./bismark2bedGraph --output PC2-02.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC2-02_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt








./bismark2bedGraph --output PC9-12.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_PC9-12_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt




./bismark2bedGraph --output DVA576.bedGraph --dir ~/Emma_home/
BiSeq_wd/R/CpG_context ~/Emma_home/BiSeq_wd/R/CpG_context/
CpG_context_DVA576_L001_R1_001_val_1.fq.gz_bismark_bt2_pe.txt

















































## 4. Load Data in R ##
#######################
library(BiSeq)
sample_sheet <- read.csv("SampleSheet_2.csv", header=T)  
sample_names <- as.character(sample_sheet$Sample_ID) 
# load all files
files <- list.files("~/Emma_home/BiSeq_wd/R/cov_files/")
file_path <- paste("~/Emma_home/BiSeq_wd/R/cov_files/", files, 
sep="")
biseqRaw <- readBismark(file_path, colData=sample_names) 
biseqRel <- rawToRel(biseqRaw) # create relative data
##############################
## 5. Perform QC with BiSeq ##
##############################
# Subset object to contain only regions of interest
# Currently 104,302 CpGs, many off target regions as final 
regions of interest only 678
regions <- read.csv("/Users/ecazaly/Desktop/Thesis/Results/
Chapter_5/MiSeq/My_analysis/BiSeq_regions_r.csv")





range(covered_cpgs) #[1]  43 389 # before 
removing off-target 118, 14375
median(covered_cpgs) #303  #old 1164
mean(covered_cpgs) #[1] 289 # before removing off-
target 1670
median <- covStats_regions$Median_coverage
range(median) #[1] 2 1472 # before removing 
off-target 2 67





units="mm", width=250, height=250*2/3, res=900)
covBoxplots(biseq_regions, col="cornflowerblue", las=2)
dev.off()
# Set QC thresholds for samples dependant on:
# 1. Median_coverage: median of the coverage of the CpG 






# now remove any that do not have a min coverage of 10 
covStats_samples_100$Median_coverage










pointsize=12, units="mm", width=250, height=250*2/3, res=900)
covBoxplots(clean_raw, col="cornflowerblue", las=2, 
main="Coverage per sample: clean data")
dev.off()
# Set QC thresholds for CpGs:
# 1. Remove CpGs if row medians = 0
# 2. Remove CpGs if row medians = 1







clean5 <- clean4[-which(rowMedians(methLevel(clean4_rel), 
na.rm=T)==0),]
#253 sites, 88 samples
clean5_rel <- rawToRel(clean5)
length_nan_5 <- function(row) {
length(which(is.nan(methLevel(clean5_rel)[row,])))
}
number_nans_5 <- sapply(1:nrow(clean5_rel), length_nan_5)
length(which(number_nans_5>75.6))  # 5
clean_raw5_90nan <- clean5[-which(number_nans_5>75.6),]
dim(clean_raw5_90nan) #248, 88  
clean_rel5_90nan <- rawToRel(clean_raw5_90nan)
# Analysis Pipeline for Bisulphite Sequencing data in R 
####################################################################
####################################################
# Key steps: 
# 1. Validate 450k data
# 2. Examine genotype-methylation association




## 1. Validate 450k data ##
###########################
# This was performed on raw data not cleaned because I wanted to 
include as many CpGs as possible when validating
# use the biseq_regions object generated in the above section
methLevel(bsRel_keyCpg)  
length(methLevel(bsRel_keyCpg))  #1248 (96x13), this includes the 
NTC + 95 samples
# remove NTC
bsRel_keyCpg2 <- bsRel_keyCpg[,-34]
length(methLevel(bsRel_keyCpg2))  #1235 (95x13)
length(which(is.nan(methLevel(bsRel_keyCpg2)))) #199  16%





## 2. Examine genotype-methylation association ##
#################################################
# Methylation Landscape Plots in 37 samples from the familial study 
with both methylation and genotype array data. These were the 
samples analysed for meQTL analysis in Chapter.4 An additional 2 
samples were removed from the analysis in this chapter as the 
bisulphite sequencing data was of poor quality
# 1. Group samples into 3 groups based on genotype at the CpG of 
interest
# 2. Within each group take the median methylation at each CpG site. 
# 3. Plot these three medians across all CpGs in the region using a 
different colour for each genotype
# 4. Is there a pattern between genotype and methylation?
# not present on Omni2.5 (8): FOXK2 (rs79974293), CASZ1 (rs284310), 
SEPT9 (rs426439), MGMT (rs7898151), MCC (rs4705795), FOXP4 
(rs4714482), C10orf46 (rs36101953), RAB11 (rs2967607)
# present on Omni2.5 (5): NME6 (rs3197223) , AJAP (rs7517857), USP7 
(kgp9608995), PRM1 (rs737008), ITGB2 (rs1721)
###  Regions with CpG-SNP present on Omni2.5  ###















NME6_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
NME6_detail$row.name),]
NME6_rel <- rawToRel(NME6_raw)
**** have to remove the poor quality samples ****
rownames(ibs_no) %in% colnames(NME6_raw)  # 3 False
NME6_gwaa <- gwaa_all_omni[which(rownames(ibs_no) %in% 
colnames(NME6_raw)),which(colnames(gwaa_all_omni@gtdata)=="rs319722
3")]
NME6_genotype <- as.genotype.gwaa.data(NME6_gwaa) 
dim(NME6_genotype)

















length(NME6_GA)  #13, 1 less
length(NME6_GG)  #14, 1 less
# check this against general populaiton frequencies?
NME6_AA_meth <- methLevel(NME6_rel_samples_ord)[, NME6_AA]
dim(NME6_AA_meth)
NME6_AA_medians <- rowMedians(NME6_AA_meth, na.rm=T)
NME6_GA_meth <- methLevel(NME6_rel_samples_ord)[, NME6_GA]
NME6_GA_medians <- rowMedians(NME6_GA_meth, na.rm=T)
NME6_GG_meth <- methLevel(NME6_rel_samples_ord)[, NME6_GG]
NME6_GG_medians <- rowMedians(NME6_GG_meth, na.rm=T)




# no longer NaNs but there are still some 1s/0s
library(gplots)
png(filename="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/NME6_landscape.png", pointsize=12, units="mm", 
width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif") 
plot(start(ranges(NME6_rel_samples_ord))*10^-6, NME6_AA_medians, 
type="o", pch=15, col="dark green", bg="dark green", xlab="", 
ylab="", main="Median Methylation by Genotype NME6
cg08146865 / rs3197223", ylim=c(0, 1.05))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)






legend(48.335843,1.11, legend="CpG-SNP: UTR in open sea", 
col="black", bty="n", cex=0.8)
legend(x=48.3356, y=0.3, pch=17, col="cornflower blue", bty="n", 
legend="GG (14)") 
legend(x=48.3356, y=0.2, pch=15, col="dark green", bty="n", 
legend="AA (10)") 
legend(x=48.3356, y=0.1, pch=16, col="hotpink", bty="n", legend="GA 
(13)") 
dev.off()
### AJAP (rs7517857) ###
AJAP_detail<- regions[which(regions$Gene=="AJAP1_a_b"),]
AJAP_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
AJAP_detail$row.name),]
AJAP_rel <- rawToRel(AJAP_raw)
AJAP_gwaa <- gwaa_all_omni[which(rownames(ibs_no) %in% 
colnames(AJAP_raw)),which(colnames(gwaa_all_omni@gtdata)=="rs751785
7")]
AJAP_genotype <- as.genotype.gwaa.data(AJAP_gwaa) 
which(colnames(AJAP_rel) %in% rownames(AJAP_genotype))
AJAP_rel_samples <- AJAP_rel[,which(colnames(AJAP_rel) %in% 
rownames(AJAP_genotype))]
colnames(AJAP_rel_samples)







# work out the median methylation level per genotype
AJAP_genotype$sample <- rownames(AJAP_genotype)
AJAP_AA <- AJAP_genotype$sample[which(AJAP_genotype$rs7517857 =="A/
A")]
AJAP_GA <- AJAP_genotype$sample[which(AJAP_genotype$rs7517857 =="A/
G")]
AJAP_GG <- AJAP_genotype$sample[which(AJAP_genotype$rs7517857 =="G/
G")]
length(AJAP_AA)  #11 now 10
length(AJAP_GA)  #17 now 16
length(AJAP_GG)  #11 now 10
AJAP_AA_meth <- methLevel(AJAP_rel_samples_ord)[, AJAP_AA]
dim(AJAP_AA_meth)
AJAP_AA_medians <- rowMedians(AJAP_AA_meth, na.rm=T)
AJAP_GA_meth <- methLevel(AJAP_rel_samples_ord)[, AJAP_GA]
AJAP_GA_medians <- rowMedians(AJAP_GA_meth, na.rm=T)
AJAP_GG_meth <- methLevel(AJAP_rel_samples_ord)[, AJAP_GG]









type="o", pch=15, col="dark green", bg="green", xlab="", ylab="", 
main="Median Methylation by Genotype AJAP
cg00345083 / rs7517857")
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)






legend(4.72513,1.062, legend="CpG-SNP: intronic in CpG shore", 
col="black", bty="n", cex=0.8)
legend(x=4.72485, y=0.3, pch=17, col="cornflower blue", bty="n", 
legend="GG (10)") 
legend(x=4.72485, y=0.2, pch=15, col="dark green", bty="n", 
legend="AA (10)") 
legend(x=4.72485, y=0.1, pch=16, col="hotpink", bty="n", legend="GA 
(16)") 
dev.off()
### USP7 (kgp9608995), cg01891583, 8995926 ###
USP7_detail <- regions[which(regions$Gene=="USP7_a"),]
USP7_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
USP7_detail$row.name),]
USP7_rel <- rawToRel(USP7_raw)
USP7_gwaa <- gwaa_all_omni[which(rownames(ibs_no) %in% 
colnames(USP7_raw)),which(colnames(gwaa_all_omni@gtdata)=="kgp96089
95")]
USP7_genotype <- as.genotype.gwaa.data(USP7_gwaa) 
which(colnames(USP7_rel) %in% rownames(USP7_genotype))
USP7_rel_samples <- USP7_rel[,which(colnames(USP7_rel) %in% 
rownames(USP7_genotype))]
colnames(USP7_rel_samples)








USP7_AA <- USP7_genotype$sample[which(USP7_genotype$kgp9608995 =="A/
A")]
USP7_GA <- USP7_genotype$sample[which(USP7_genotype$kgp9608995 =="A/
G")]
USP7_GG <- USP7_genotype$sample[which(USP7_genotype$kgp9608995 =="G/
G")]
length(USP7_AA)  #14 now 13
length(USP7_GA)  #20 now 19
length(USP7_GG)  #4
USP7_AA_meth <- methLevel(USP7_rel_samples_ord)[, USP7_AA]
dim(USP7_AA_meth)
USP7_AA_medians <- rowMedians(USP7_AA_meth, na.rm=T)
USP7_GA_meth <- methLevel(USP7_rel_samples_ord)[, USP7_GA]
USP7_GA_medians <- rowMedians(USP7_GA_meth, na.rm=T)
USP7_GG_meth <- methLevel(USP7_rel_samples_ord)[, USP7_GG]





Genotype_methylation/USP7_landscape.png", pointsize=12, units="mm", 
width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif") 
plot(start(ranges(USP7_rel_samples_ord))*10^-6, USP7_AA_medians, 
type="o", pch=15, col="green", bg="green", xlab="", ylab="", 
main="Median Methylation by Genotype USP7
cg01891583 / kgp9608995", ylim=c(0, 1.06))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)





abline(v= 8995926*10^-6, col="black", lwd=1)
legend(8.99574,1.12, legend="CpG-SNP: intronic in open sea", 
col="black", bty="n", cex=0.8)
legend(x=8.99533, y=0.3, pch=17, col="cornflower blue", bty="n", 
legend="GG (14)") 
legend(x=8.99533, y=0.2, pch=15, col="dark green", bty="n", 
legend="AA (10)") 
legend(x=8.99533, y=0.1, pch=16, col="hotpink", bty="n", legend="GA 
(13)") 
dev.off()
### PRM1 (rs737008), cg02978201, 11374865 ###
PRM1_detail <- regions[which(regions$Gene=="PRM1_a_b"),]
PRM1_raw <- clean_raw_90nan[which(rownames(clean_raw_90nan) %in% 
PRM1_detail$row.name),]
PRM1_rel <- rawToRel(PRM1_raw)
PRM1_gwaa <- gwaa_all_omni[which(rownames(ibs_no) %in% 
colnames(PRM1_raw)),which(colnames(gwaa_all_omni@gtdata)=="rs737008
")]
PRM1_genotype <- as.genotype.gwaa.data(PRM1_gwaa) 
which(colnames(PRM1_rel) %in% rownames(PRM1_genotype))
PRM1_rel_samples <- PRM1_rel[,which(colnames(PRM1_rel) %in% 
rownames(PRM1_genotype))]
colnames(PRM1_rel_samples)








PRM1_AA <- PRM1_genotype$sample[which(PRM1_genotype$rs737008 =="A/
A")]
PRM1_CA <- PRM1_genotype$sample[which(PRM1_genotype$rs737008 =="A/
C")]
PRM1_CC <- PRM1_genotype$sample[which(PRM1_genotype$rs737008 =="C/
C")]
length(PRM1_AA)  #20, 19 now
length(PRM1_CA)  #17, 15 now
length(PRM1_CC)  #2
PRM1_AA_meth <- methLevel(PRM1_rel_samples_ord)[, PRM1_AA]
dim(PRM1_AA_meth)
PRM1_AA_medians <- rowMedians(PRM1_AA_meth, na.rm=T)
PRM1_CA_meth <- methLevel(PRM1_rel_samples_ord)[, PRM1_CA]
PRM1_CA_medians <- rowMedians(PRM1_CA_meth, na.rm=T)
PRM1_CC_meth <- methLevel(PRM1_rel_samples_ord)[, PRM1_CC]





Genotype_methylation/PRM1_landscape.png", pointsize=12, units="mm", 
width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif") 
plot(start(ranges(PRM1_rel_samples_ord))*10^-6, PRM1_AA_medians, 
type="o", pch=15, col="dark green", bg="green", xlab="", ylab="", 
ylim=c(0, 1.06), main="Median Methylation by Genotype PRM1
cg02978201 / rs737008")
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)





abline(v= 11374865*10^-6, col="black", lwd=1)
legend(11.37483,1.12, legend="CpG-SNP: coding (synonymous in open 
sea)", col="black", bty="n", cex=0.8)
legend(x=11.37425, y=0.3, pch=17, col="cornflower blue", bty="n", 
legend="CC (2)") 
legend(x=11.37425, y=0.2, pch=15, col="dark green", bty="n", 
legend="AA (19)") 
legend(x=11.37425, y=0.1, pch=16, col="hotpink", bty="n", legend="CA 
(15)") 
dev.off()
### ITGB2 (rs1721), cg02464073 ###
ITGB2_detail <- regions[which(regions$Gene=="ITGB2"),]
ITGB2_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
ITGB2_detail$row.name),]
ITGB2_rel <- rawToRel(ITGB2_raw)
ITGB2_gwaa <- gwaa_all_omni[which(rownames(ibs_no) %in% 
colnames(ITGB2_raw)),which(colnames(gwaa_all_omni@gtdata)=="rs1721"
)]
ITGB2_genotype <- as.genotype.gwaa.data(ITGB2_gwaa) 
which(colnames(ITGB2_rel) %in% rownames(ITGB2_genotype))
ITGB2_rel_samples <- ITGB2_rel[,which(colnames(ITGB2_rel) %in% 
rownames(ITGB2_genotype))]
colnames(ITGB2_rel_samples)








ITGB2_AA <- ITGB2_genotype$sample[which(ITGB2_genotype$rs1721 =="A/
A")]
ITGB2_GA <- ITGB2_genotype$sample[which(ITGB2_genotype$rs1721 =="A/
G")]
ITGB2_GG <- ITGB2_genotype$sample[which(ITGB2_genotype$rs1721 =="G/
G")]
length(ITGB2_AA)  #2, now 1
length(ITGB2_GA)  #24, now 23
length(ITGB2_GG)  #12, now 11
ITGB2_AA_meth <- methLevel(ITGB2_rel_samples_ord)[, ITGB2_AA]
dim(ITGB2_AA_meth)
ITGB2_AA_medians <- ITGB2_AA_meth # only 1 change to meth value 
instead of rowMedians
ITGB2_GA_meth <- methLevel(ITGB2_rel_samples_ord)[, ITGB2_GA]
ITGB2_GA_medians <- rowMedians(ITGB2_GA_meth, na.rm=T)
ITGB2_GG_meth <- methLevel(ITGB2_rel_samples_ord)[, ITGB2_GG]






units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif") 
plot(start(ranges(ITGB2_rel_samples_ord))*10^-6, ITGB2_AA_medians, 
type="o", pch=15, col="dark green", bg="green", xlab="", ylab="", 
main="Median Methylation by Genotype ITGB2
cg02464073 / rs1721", ylim=c(0, 1.06))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(ITGB2_rel_samples_ord))*10^-6, type="o", 
ITGB2_GA_medians, pch=16, col="hotpink")
points(start(ranges(ITGB2_rel_samples_ord))*10^-6, type="o",  
ITGB2_GG_medians, pch=17, col="cornflowerblue")
abline(v= 46349496*10^-6, col="black", lwd=1)
legend(46.349475,1.12, legend="CpG-SNP: UTR in CpG shore", 
col="black", bty="n", cex=0.8)
legend(x=46.34929, y=0.3, pch=17, col="cornflower blue", bty="n", 
legend="GG (11)") 
legend(x=46.34929, y=0.2, pch=15, col="dark green", bty="n", 
legend="AA (1)") 
legend(x=46.34929, y=0.1, pch=16, col="hotpink", bty="n", legend="GA 
(23)") 
dev.off()
###  Regions without CpG-SNP on Omni2.5  ###
# CASZ1
CASZ1_detail <- regions[which(regions$Gene=="CASZ1_a_b"),]
CASZ1_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
CASZ1_detail$row.name),]
CASZ1_rel <- rawToRel(CASZ1_raw)
# genotype at kpg1150744   or rs284307
casz1_gwaa <- 
gwaa_all_omni[,which(colnames(gwaa_all_omni@gtdata)=="rs284307")]
casz1_genotype <- as.genotype.gwaa.data(casz1_gwaa) 
# need to convert kpg1150744 to rs
# casz1_gwaa2 <- 
gwaa_all_omni[,which(colnames(gwaa_all_omni@gtdata)=="kpg1150744")]




casz1_GA <- casz1_genotype$sample[which(casz1_genotype$rs284307 
=="A/G")]






CASZ1_rel_samples <- CASZ1_rel[,which(colnames(CASZ1_rel) %in% 
rownames(casz1_genotype))]
colnames(CASZ1_rel_samples)






#FALSE, 2 geno samples not having seq data
which(!(rownames(casz1_genotype) %in% 
colnames(CASZ1_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
casz1_geno <- casz1_genotype[which(casz1_genotype$sample %in% 
colnames(CASZ1_rel_samples_ord)),]
identical(colnames(CASZ1_rel_samples_ord), rownames(casz1_geno))  
#TRUE
casz1_AA <- casz1_geno$sample[which(casz1_geno$rs284307=="A/A")]
casz1_GA <- casz1_geno$sample[which(casz1_geno$rs284307 =="A/G")]




CASZ1_AA_meth <- methLevel(CASZ1_rel_samples_ord)[, casz1_AA]
CASZ1_AA_medians <- rowMedians(CASZ1_AA_meth, na.rm=T)
CASZ1_GA_meth <- methLevel(CASZ1_rel_samples_ord)[, casz1_GA]
CASZ1_GA_medians <- rowMedians(CASZ1_GA_meth, na.rm=T)
CASZ1_GG_meth <- methLevel(CASZ1_rel_samples_ord)[, casz1_GG]




units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(CASZ1_rel_samples_ord))*10^-6, CASZ1_AA_medians, 
type="b", pch=15, col="cornflower blue", bg="green", xlab="", 
ylab="", main="Median Methylation by Genotype CASZ1", ylim=c(0, 
1.06))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(CASZ1_rel_samples_ord))*10^-6, type="b", 




legend(10.73731,1.12, legend="CpG-SNP: intronic in open sea", 
col="black", bty="n", cex=0.8)
legend(x=10.7369, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (9)") #AA
legend(x=10.7369, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (15)") #GA
legend(x=10.7369, y=0.1, pch=17, col="hotpink", bty="n", legend="GG 
(13)") #GG
dev.off()
# C10orf46:   cg00231519 / rs36101953 / chr10:120516119
# rs10886296: 120522232 - 120516119  #6113
# rs4319431: 120515182 - 120516119  # -937
# Use rs4319431 genotype as this is ~1kb away and the LD plot 
indicates in LD with CpG-SNP
which(colnames(gwaa_all_omni@gtdata)=="rs4319431") # [1] 987672
C10orf46_gwaa <- 
gwaa_all_omni[,which(colnames(gwaa_all_omni@gtdata)=="rs4319431")]











# there's 39 but should only be 37 as 2 biseq are bad quality. 
Perform below to eliminate and get geno data in right format
C10orf46_detail <- regions[which(regions$Gene=="C10orf46"),]
C10orf46_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) 
%in% C10orf46_detail$row.name),]
C10orf46_rel <- rawToRel(C10orf46_raw)
which(colnames(C10orf46_rel) %in% rownames(C10orf46_genotype))  #37
C10orf46_rel_samples <- C10orf46_rel[,which(colnames(C10orf46_rel) 
%in% rownames(C10orf46_genotype))]
colnames(C10orf46_rel_samples)










# 16 (PC9-477), 23 (PC9-29)




C10orf46_AA <- C10orf46_geno$sample[which(C10orf46_geno$rs4319431 
=="A/A")]
C10orf46_GA <- C10orf46_geno$sample[which(C10orf46_geno$rs4319431 
=="A/G")]
C10orf46_GG <- C10orf46_geno$sample[which(C10orf46_geno$rs4319431 
=="G/G")]
length(C10orf46_AA)  # 5
length(C10orf46_GA)  # 9
length(C10orf46_GG)  # 23
C10orf46_AA_meth <- methLevel(C10orf46_rel_samples_ord)[, 
C10orf46_AA]
C10orf46_AA_medians <- rowMedians(C10orf46_AA_meth, na.rm=T)
C10orf46_GA_meth <- methLevel(C10orf46_rel_samples_ord)[, 
C10orf46_GA]
C10orf46_GA_medians <- rowMedians(C10orf46_GA_meth, na.rm=T)
C10orf46_GG_meth <- methLevel(C10orf46_rel_samples_ord)[, 
C10orf46_GG]
C10orf46_GG_medians <- rowMedians(C10orf46_GG_meth, na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/from_LD/C10orf46_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(C10orf46_rel_samples_ord))*10^-6, 
C10orf46_AA_medians, type="b", pch=15, col="cornflower blue", 
bg="green", xlab="", ylab="", main="Median Methylation by Genotype 
C10orf46
 cg00231519 / rs36101953", ylim=c(0,1.07))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(C10orf46_rel_samples_ord))*10^-6, type="b", 




legend(120.51587, 1.12, legend="CpG-SNP: intronic in CpG shore", 
col="black", bty="n", cex=0.8)
legend(x=120.5155, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (5)") #AA
legend(x=120.5155, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (9)") #GA
legend(x=120.5155, y=0.1, pch=17, col="hotpink", bty="n", legend="GG 
(23)") #GG
dev.off()
# RAB11: cg04610028 / rs2967607 / chr19:8464538 / intronic in CpG 
shore
conversion[which(conversion$Name=="kgp6405269"),] #rs2913970  
8464653 - 8464538 = 115
conversion[which(conversion$Name=="kgp9275677"),] #rs2913971  
8463460 - 8464538 = -1078
# Use genotype at kgp6405269 as this is ~100b away and the LD plot 












length(RAB11_AA)  # 2
length(RAB11_GA)  # 11
length(RAB11_GG)  # 26
RAB11_detail <- regions[which(regions$Gene=="RAB11_a"),]
RAB11_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
RAB11_detail$row.name),]
RAB11_rel <- rawToRel(RAB11_raw)
which(colnames(RAB11_rel) %in% rownames(RAB11_genotype))  #37
RAB11_rel_samples <- RAB11_rel[,which(colnames(RAB11_rel) %in% 
rownames(RAB11_genotype))]
colnames(RAB11_rel_samples)






#FALSE, 2 geno samples not having seq data
which(!(rownames(RAB11_genotype) %in% 
colnames(RAB11_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
RAB11_geno <- RAB11_genotype[which(RAB11_genotype$sample %in% 
colnames(RAB11_rel_samples_ord)),]
identical(colnames(RAB11_rel_samples_ord), rownames(RAB11_geno))  
#TRUE
RAB11_AA <- RAB11_geno$sample[which(RAB11_geno$kgp6405269 =="A/A")]
RAB11_GA <- RAB11_geno$sample[which(RAB11_geno$kgp6405269 =="A/G")]
RAB11_GG <- RAB11_geno$sample[which(RAB11_geno$kgp6405269 =="G/G")]
length(RAB11_AA)  # 2
length(RAB11_GA)  # 10
length(RAB11_GG)  # 25
RAB11_AA_meth <- methLevel(RAB11_rel_samples_ord)[, RAB11_AA]
RAB11_AA_medians <- rowMedians(RAB11_AA_meth, na.rm=T)
RAB11_GA_meth <- methLevel(RAB11_rel_samples_ord)[, RAB11_GA]
RAB11_GA_medians <- rowMedians(RAB11_GA_meth, na.rm=T)
RAB11_GG_meth <- methLevel(RAB11_rel_samples_ord)[, RAB11_GG]
RAB11_GG_medians <- rowMedians(RAB11_GG_meth, na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/from_LD/RAB11_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(RAB11_rel_samples_ord))*10^-6, RAB11_AA_medians, 
type="b", pch=15, col="cornflower blue", bg="green", xlab="", 
ylab="", main="Median Methylation by Genotype RAB11
cg04610028 / rs2967607", ylim=c(0,1.07))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(RAB11_rel_samples_ord))*10^-6, type="b", 




legend(8.46432, 1.13, legend="CpG-SNP: intronic in CpG shore", 
col="black", bty="n", cex=0.8)
legend(x=8.463937, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (2)") #AA
legend(x=8.463937, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (10)") #GA
legend(x=8.463937, y=0.1, pch=17, col="hotpink", bty="n", legend="GG 
(25)") #GG
dev.off()
# SEPT9: cg05161773 / rs426439 / chr17:75378036
conversion[which(conversion$Name=="kgp9468443"),]  #rs67129266
75381103 - 75378036 = 3067
conversion[which(conversion$Name=="kgp9643238"),]  #rs312828   
75373938 - 75378036 = -4098
# Use genotype at kgp9468443 as this is ~3kb away and the LD plot 




SEPT9_genotype <- as.genotype.gwaa.data(SEPT9_gwaa) 
SEPT9_genotype$sample <- rownames(SEPT9_genotype)
SEPT9_AA <- SEPT9_genotype$sample[which(SEPT9_genotype$kgp9468443 
=="A/A")]
SEPT9_GA <- SEPT9_genotype$sample[which(SEPT9_genotype$kgp9468443 
=="A/G")]





# there's 39 but should only be 37 as 2 biseq are bad quality. 
Perform below to eliminate and get geno data in right format
SEPT9_detail <- regions[which(regions$Gene=="SEPT_9"),]
SEPT9_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
SEPT9_detail$row.name),]
SEPT9_rel <- rawToRel(SEPT9_raw)
which(colnames(SEPT9_rel) %in% rownames(SEPT9_genotype))  #37
SEPT9_rel_samples <- SEPT9_rel[,which(colnames(SEPT9_rel) %in% 
rownames(SEPT9_genotype))]
colnames(SEPT9_rel_samples)






#FALSE, 2 geno samples not having seq data
which(!(rownames(SEPT9_genotype) %in% 
colnames(SEPT9_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
SEPT9_geno <- SEPT9_genotype[which(SEPT9_genotype$sample %in% 
colnames(SEPT9_rel_samples_ord)),]
identical(colnames(SEPT9_rel_samples_ord), rownames(SEPT9_geno))  
#TRUE
SEPT9_AA <- SEPT9_geno$sample[which(SEPT9_geno$kgp9468443 =="A/A")]
SEPT9_GA <- SEPT9_geno$sample[which(SEPT9_geno$kgp9468443 =="A/G")]




SEPT9_AA_meth <- methLevel(SEPT9_rel_samples_ord)[, SEPT9_AA]
SEPT9_AA_medians <- rowMedians(SEPT9_AA_meth, na.rm=T)
SEPT9_GA_meth <- methLevel(SEPT9_rel_samples_ord)[, SEPT9_GA]
SEPT9_GA_medians <- rowMedians(SEPT9_GA_meth, na.rm=T)
SEPT9_GG_meth <- methLevel(SEPT9_rel_samples_ord)[, SEPT9_GG]
SEPT9_GG_medians <- rowMedians(SEPT9_GG_meth, na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/from_LD/SEPT9_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(SEPT9_rel_samples_ord))*10^-6, SEPT9_AA_medians, 
type="b", pch=15, col="cornflower blue", bg="green", xlab="", 
ylab="", main="Median Methylation by Genotype SEPT9
cg05161773 / rs426439", ylim=c(0,1.07))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(SEPT9_rel_samples_ord))*10^-6, type="b", 




legend(75.378020, 1.13, legend="CpG-SNP: intronic in open sea", 
col="black", bty="n", cex=0.8)
legend(x=75.3776, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (16)") #AA
legend(x= 75.3776, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (12)") #GA
legend(x= 75.3776, y=0.1, pch=17, col="hotpink", bty="n", legend="GG 
(9)") #GG
dev.off()
# MGMT:  cg09993319 / rs7898151 / chr10:131529435 / intronic in open 
sea
conversion[which(conversion$Name=="kgp8599981"),] #rs12571103    
131530307 - 131529435 = 872
# Use genotype at as this is ~1kb away. However this may not be in 
LD with CpG-SNP as haplotype block right on the site where the 




MGMT_genotype <- as.genotype.gwaa.data(MGMT_gwaa) 
MGMT_genotype$sample <- rownames(MGMT_genotype)
MGMT_AA <- MGMT_genotype$sample[which(MGMT_genotype$kgp8599981 =="A/
A")]
MGMT_GA <- MGMT_genotype$sample[which(MGMT_genotype$kgp8599981 =="A/
G")]





# there's 39 but should only be 37 as 2 biseq are bad quality. 
Perform below to eliminate and get geno data in right format
MGMT_detail <- regions[which(regions$Gene=="MGMT"),]
MGMT_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
MGMT_detail$row.name),]
MGMT_rel <- rawToRel(MGMT_raw)
which(colnames(MGMT_rel) %in% rownames(MGMT_genotype))  #37
MGMT_rel_samples <- MGMT_rel[,which(colnames(MGMT_rel) %in% 
rownames(MGMT_genotype))]
colnames(MGMT_rel_samples)






#FALSE, 2 geno samples not having seq data
which(!(rownames(MGMT_genotype) %in% 
colnames(MGMT_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
MGMT_geno <- MGMT_genotype[which(MGMT_genotype$sample %in% 
colnames(MGMT_rel_samples_ord)),]
identical(colnames(MGMT_rel_samples_ord), rownames(MGMT_geno))  
#TRUE
MGMT_AA <- MGMT_geno$sample[which(MGMT_geno$kgp8599981 =="A/A")]
MGMT_GA <- MGMT_geno$sample[which(MGMT_geno$kgp8599981 =="A/G")]




MGMT_AA_meth <- methLevel(MGMT_rel_samples_ord)[, MGMT_AA]
MGMT_AA_medians <- rowMedians(MGMT_AA_meth, na.rm=T)
MGMT_GA_meth <- methLevel(MGMT_rel_samples_ord)[, MGMT_GA]
MGMT_GA_medians <- rowMedians(MGMT_GA_meth, na.rm=T)
MGMT_GG_meth <- methLevel(MGMT_rel_samples_ord)[, MGMT_GG]
MGMT_GG_medians <- rowMedians(MGMT_GG_meth, na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/from_LD/MGMT_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(MGMT_rel_samples_ord))*10^-6, MGMT_AA_medians, 
type="b", pch=15, col="cornflower blue", bg="green", xlab="", 
ylab="", main="Median Methylation by Genotype MGMT
cg09993319 / rs7898151", ylim=c(0,1.07))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(MGMT_rel_samples_ord))*10^-6, type="b", 




legend(131529420*10^-6, 1.12, legend="CpG-SNP: intronic in open 
sea", col="black", bty="n", cex=0.8)
legend(x= 131.52948, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (3)") #AA
legend(x= 131.52948, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (18)") #GA
legend(x= 131.52948, y=0.1, pch=17, col="hotpink", bty="n", 
legend="GG (16)") #GG
dev.off()
# MCC: cg08238375 / rs4705795 / chr5:112483149  / intronic in open 
sea
conversion[which(conversion$Name=="kgp1825521"),]  #rs57297544  
112482136  - 112483149 = -1013
# 112482033 -  112483149 = -1116
# 112483604 -  112483149 = 455 rs2416305
# Use genotype at rs2416305 as this is ~.5 kb away and the LD plot 




MCC_genotype <- as.genotype.gwaa.data(MCC_gwaa) 
MCC_genotype$sample <- rownames(MCC_genotype)
MCC_AA <- MCC_genotype$sample[which(MCC_genotype$rs2416305 =="A/A")]
MCC_GA <- MCC_genotype$sample[which(MCC_genotype$rs2416305 =="A/G")]




# there's 39 but should only be 37 as 2 biseq are bad quality. 
Perform below to eliminate and get geno data in right format
MCC_detail <- regions[which(regions$Gene=="MCC"),]
MCC_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
MCC_detail$row.name),]
MCC_rel <- rawToRel(MCC_raw)
which(colnames(MCC_rel) %in% rownames(MCC_genotype))  #37
MCC_rel_samples <- MCC_rel[,which(colnames(MCC_rel) %in% 
rownames(MCC_genotype))]
colnames(MCC_rel_samples)






#FALSE, 2 geno samples not having seq data
which(!(rownames(MCC_genotype) %in% colnames(MCC_rel_samples_ord)))
# 16 (PC9-477), 23 (PC9-29)
MCC_geno <- MCC_genotype[which(MCC_genotype$sample %in% 
colnames(MCC_rel_samples_ord)),]
identical(colnames(MCC_rel_samples_ord), rownames(MCC_geno))  #TRUE
MCC_AA <- MCC_geno$sample[which(MCC_geno$rs2416305 =="A/A")]
MCC_GA <- MCC_geno$sample[which(MCC_geno$rs2416305 =="A/G")]
MCC_GG <- MCC_geno$sample[which(MCC_geno$rs2416305 =="G/G")]
length(MCC_AA)  # 27
length(MCC_GA)  # 10 
length(MCC_GG)  # 0  only genotype to have 0 so far
MCC_AA_meth <- methLevel(MCC_rel_samples_ord)[, MCC_AA]
MCC_AA_medians <- rowMedians(MCC_AA_meth, na.rm=T)
MCC_GA_meth <- methLevel(MCC_rel_samples_ord)[, MCC_GA]
MCC_GA_medians <- rowMedians(MCC_GA_meth, na.rm=T)
MCC_GG_meth <- methLevel(MCC_rel_samples_ord)[, MCC_GG]
MCC_GG_medians <- rowMedians(MCC_GG_meth, na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
Genotype_methylation/from_LD/MCC_landscape.png", pointsize=12, 
units="mm", width=200, height=250, res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1, family="serif")
plot(start(ranges(MCC_rel_samples_ord))*10^-6, MCC_AA_medians, 
type="b", pch=15, col="cornflower blue", bg="green", xlab="", 
ylab="", main="Median Methylation by Genotype MCC
cg08238375 / rs4705795", ylim=c(0,1.07))
title(ylab="Median Methylation", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(start(ranges(MCC_rel_samples_ord))*10^-6, type="b", 




legend(112.48314, 1.12, legend="CpG-SNP: intronic in open sea", 
col="black", bty="n", cex=0.8)
legend(x=112.48323, y=0.3, pch=15, col="cornflower blue", bty="n", 
legend="AA (27)") #AA
legend(x=112.48323, y=0.2, pch=16, col="dark green", bty="n", 
legend="GA (10)") #GA




## 3. Examine methylation levels between cancer/control groups ##
#################################################################
# Methylation Landscape Plots --> colour methylation values by case/
control status 
# Clean data generated in above section
clean_raw5_90nan
clean_rel5_90nan
cancer <- clean_raw5_90nan[, which(clean_raw5_90nan@colData
$Disease=="A")] 
# 248, 31
control <- clean_raw5_90nan[, which(clean_raw5_90nan@colData
$Disease=="DVA_control")]
# 248, 32
# subset this data by meQTL region
AJAP_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
AJAP_detail$row.name),]
AJAP_rel <- rawToRel(AJAP_raw)
CASZ1_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
CASZ1_detail$row.name),]
CASZ1_rel <- rawToRel(CASZ1_raw)
NME6_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
NME6_detail$row.name),]
NME6_rel <- rawToRel(NME6_raw)
MCC_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
MCC_detail$row.name),]
MCC_rel <- rawToRel(MCC_raw)
C10orf46_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) 
%in% C10orf46_detail$row.name),]
C10orf46_rel <- rawToRel(C10orf46_raw)
MGMT_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
MGMT_detail$row.name),]
MGMT_rel <- rawToRel(MGMT_raw)
USP7_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
USP7_detail$row.name),]
USP7_rel <- rawToRel(USP7_raw)
PRM1_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
PRM1_detail$row.name),]
PRM1_rel <- rawToRel(PRM1_raw)
FOXK2_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
FOXK2_detail$row.name),]
FOXK2_rel <- rawToRel(FOXK2_raw)
SEPT9_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
SEPT9_detail$row.name),]
SEPT9_rel <- rawToRel(SEPT9_raw)
RAB11_raw <- clean_raw5_90nan[which(rownames(clean_raw5_90nan) %in% 
RAB11_detail$row.name),]
RAB11_rel <- rawToRel(RAB11_raw)




median_AJAP_cancer <- rowMedians(methLevel(AJAP_rel[, 
which(AJAP_rel@colData$Disease=="A")]), na.rm=T)
median_AJAP_control <- rowMedians(methLevel(AJAP_rel[, 
which(AJAP_rel@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/
AJAP_cancer.png", pointsize=12, units="mm", width=200, height=250, 
res=400)
par(mfrow=c(2,1), mar=c(5,3.3,4,1)+0.1)  #c(bottom, left, top, 
right), default is c(5, 4, 4, 2) + 0.1.
plot(rep(start(ranges(AJAP_rel))*10^-6,ncol(cancer)), 
methLevel(AJAP_rel[, which(AJAP_rel@colData$Disease=="A")]), 
type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="AJAP: 
Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(AJAP_rel))*10^-6, ncol(control)), 
methLevel(AJAP_rel[, which(AJAP_rel@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(AJAP_rel))*10^-6), median_AJAP_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at AJAP by cancer 
status")
points(rep(start(ranges(AJAP_rel))*10^-6), median_AJAP_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=4725584*10^-6, col="black", lwd=1.5)
legend(x=(4725584*10^-6)-0.00004, y=1.16, legend="CpG-SNP: intronic 
in CpG Shore", bty="n", cex=.8)
legend(x=(start(ranges(AJAP_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(AJAP_rel))[1]*10^-6)-0.00006, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(AJAP_rel))*10^-6), median_AJAP_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", main="AJAP: 
Median Methylation per Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(AJAP_rel))*10^-6), median_AJAP_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=4725584*10^-6, col="black", lwd=1.5)
legend(x=(4725584*10^-6)-0.00004, y=1.16, legend="CpG-SNP; intronic 
in CpG Shore", bty="n", cex=.8)
legend(x=(start(ranges(AJAP_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(AJAP_rel))[1]*10^-6)-0.00006, y=1.17, pch=17, 









type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="CASZ1: Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(CASZ1_rel))*10^-6, ncol(control)), 
methLevel(CASZ1_rel[, which(CASZ1_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(CASZ1_rel))*10^-6), median_CASZ1_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at CASZ1 by cancer 
status")
points(rep(start(ranges(CASZ1_rel))*10^-6), median_CASZ1_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=10737562*10^-6, col="black", lwd=1)
legend(x=(10737562*10^-6)-0.00027, y=1.16, legend="CpG-SNP; intronic 
in open sea", bty="n", cex=.8)
legend(x=(start(ranges(CASZ1_rel))[1]*10^-6)+0.0001,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(CASZ1_rel))[1]*10^-6)-0.000009, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
median_CASZ1_cancer <- rowMedians(methLevel(CASZ1_rel[, 
which(CASZ1_raw@colData$Disease=="A")]), na.rm=T)
median_CASZ1_control <- rowMedians(methLevel(CASZ1_rel[, 
which(CASZ1_raw@colData$Disease=="DVA_control")]), na.rm=T)
plot(rep(start(ranges(CASZ1_rel))*10^-6), median_CASZ1_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="CASZ1: Median Methylation per Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(CASZ1_rel))*10^-6), median_CASZ1_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=10737562*10^-6, col="black", lwd=1)
legend(x=(10737562*10^-6)-0.00027, y=1.16, legend="CpG-SNP; intronic 
in open sea", bty="n", cex=.8)
legend(x=(start(ranges(CASZ1_rel))[1]*10^-6)+0.0001,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(CASZ1_rel))[1]*10^-6)-0.000009, y=1.17, 




median_PRM1_cancer <- rowMedians(methLevel(PRM1_rel[, 
which(PRM1_raw@colData$Disease=="A")]), na.rm=T)
median_PRM1_control <- rowMedians(methLevel(PRM1_rel[, 
which(PRM1_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/





type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="PRM1: 
Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(PRM1_rel))*10^-6, ncol(control)), 
methLevel(PRM1_rel[, which(PRM1_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(PRM1_rel))*10^-6), median_PRM1_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at PRM1 by cancer 
status", ylim=c(0,1.1))
points(rep(start(ranges(PRM1_rel))*10^-6), median_PRM1_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=11374865*10^-6, col="black", lwd=1)
legend(x=(11374865*10^-6)+0.000006, y=1.16, legend="CpG-SNP: coding 
(synonymous) in open sea", bty="n", cex=.8)
legend(x=(start(ranges(PRM1_rel))[1]*10^-6)+0.00014,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(PRM1_rel))[1]*10^-6)-0.00002, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(PRM1_rel))*10^-6), median_PRM1_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", main="PRM1: 
Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(PRM1_rel))*10^-6), median_PRM1_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=11374865*10^-6, col="black", lwd=1)
legend(x=(11374865*10^-6)+0.000006, y=1.16, legend="CpG-SNP: coding 
(synonymous) in open sea", bty="n", cex=.8)
legend(x=(start(ranges(PRM1_rel))[1]*10^-6)+0.00014,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(PRM1_rel))[1]*10^-6)-0.00002, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
dev.off()
# USP7  
median_USP7_cancer <- rowMedians(methLevel(USP7_rel[, 
which(USP7_raw@colData$Disease=="A")]), na.rm=T)
median_USP7_control <- rowMedians(methLevel(USP7_rel[, 
which(USP7_raw@colData$Disease=="DVA_control")]), na.rm=T)
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type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="USP7: 
Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(USP7_rel))*10^-6, ncol(control)), 
methLevel(USP7_rel[, which(USP7_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(USP7_rel))*10^-6), median_USP7_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at USP7 by cancer 
status")
points(rep(start(ranges(USP7_rel))*10^-6), median_USP7_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=8995926*10^-6, col="black", lwd=1)
legend(x=(8995926*10^-6)-0.00025, y=1.16, legend="CpG-SNP: 
intragenic in open sea", bty="n", cex=.8)
legend(x=(start(ranges(USP7_rel))[1]*10^-6)+0.0001,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(USP7_rel))[1]*10^-6)-0.00001, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(USP7_rel))*10^-6), median_USP7_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", main="USP7: 
Median Methylation per Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(USP7_rel))*10^-6), median_USP7_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=8995926*10^-6, col="black", lwd=1)
legend(x=(8995926*10^-6)-0.00025, y=1.16, legend="CpG-SNP: 
intragenic in open sea", bty="n", cex=.8)
legend(x=(start(ranges(USP7_rel))[1]*10^-6)+0.0001,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(USP7_rel))[1]*10^-6)-0.00001, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
dev.off()
# FOXK2
median_FOXK2_cancer <- rowMedians(methLevel(FOXK2_rel[, 
which(FOXK2_raw@colData$Disease=="A")]), na.rm=T)
median_FOXK2_control <- rowMedians(methLevel(FOXK2_rel[, 
which(FOXK2_raw@colData$Disease=="DVA_control")]), na.rm=T)
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type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="FOXK2: Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(FOXK2_rel))*10^-6, ncol(control)), 
methLevel(FOXK2_rel[, which(FOXK2_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=80535367*10^-6, col="black", lwd=1)
legend(x=(80535367*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in CpG shore", bty="n", cex=.8)
points(rep(start(ranges(FOXK2_rel))*10^-6), median_FOXK2_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at FOXK2 by cancer 
status", ylim=c(0,1.1))
points(rep(start(ranges(FOXK2_rel))*10^-6), median_FOXK2_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(FOXK2_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(FOXK2_rel))[1]*10^-6)+0.00003, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(FOXK2_rel))*10^-6), median_FOXK2_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="ITBG2: Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(FOXK2_rel))*10^-6), median_FOXK2_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=80535367*10^-6, col="black", lwd=1)
legend(x=(80535367*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in CpG shore", bty="n", cex=.8)
legend(x=(start(ranges(FOXK2_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(FOXK2_rel))[1]*10^-6)+0.00003, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
# NME6
median_NME6_cancer <- rowMedians(methLevel(NME6_rel[, 
which(NME6_raw@colData$Disease=="A")]), na.rm=T)
median_NME6_control <- rowMedians(methLevel(NME6_rel[, 
which(NME6_raw@colData$Disease=="DVA_control")]), na.rm=T)
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type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="NME6: 
Individual Methylation Level", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(NME6_rel))*10^-6, ncol(control)), 
methLevel(NME6_rel[, which(NME6_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(NME6_rel))*10^-6), median_NME6_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Position (Mb)", 
ylab="methylation", main="Median Methylation at NME6 by cancer 
status")
points(rep(start(ranges(NME6_rel))*10^-6), median_NME6_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(NME6_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(NME6_rel))[1]*10^-6)-0.00001, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
abline(v=48335857*10^-6, col="black", lwd=1)
legend(x=(48335857*10^-6)-0.000009, y=1.16, legend="CpG-SNP: UTR in 
open sea", bty="n", cex=.8)
plot(rep(start(ranges(NME6_rel))*10^-6), median_NME6_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", main="NME6: 
Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(NME6_rel))*10^-6), median_NME6_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(NME6_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(NME6_rel))[1]*10^-6)-0.00001, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
abline(v=48335857*10^-6, col="black", lwd=1)
legend(x=(48335857*10^-6)-0.000009, y=1.16, legend="CpG-SNP: UTR in 
open sea", bty="n", cex=.8)
dev.off()
# MCC
median_MCC_cancer <- rowMedians(methLevel(MCC_rel[, 
which(MCC_raw@colData$Disease=="A")]), na.rm=T)
median_MCC_control <- rowMedians(methLevel(MCC_rel[, 
which(MCC_raw@colData$Disease=="DVA_control")]), na.rm=T)
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type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="MCC: 
Individual Methylation Level", ylim=c(0,1.1), xlim=c(112.4830999, 
112.4837))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(MCC_rel))*10^-6, ncol(control)), 
methLevel(MCC_rel[, which(MCC_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
points(rep(start(ranges(MCC_rel))*10^-6), median_MCC_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Position (Mb)", 
ylab="methylation", main="Median Methylation at MCC by cancer 
status")
points(rep(start(ranges(MCC_rel))*10^-6), median_MCC_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=112483149*10^-6, col="black", lwd=1)
legend(x=(112483149*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in open sea", bty="n", cex=.8)
legend(x=(start(ranges(MCC_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(MCC_rel))[1]*10^-6)+0.00005, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(MCC_rel))*10^-6), median_MCC_cancer, type="o", 
pch=16, cex=0.5, col="red", xlab="", ylab="", main="MCC: Median 
Methylation by Group", ylim=c(0,1.1), xlim=c(112.4830999, 
112.4837))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(MCC_rel))*10^-6), median_MCC_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=112483149*10^-6, col="black", lwd=1)
legend(x=(112483149*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in open sea", bty="n", cex=.8)
legend(x=(start(ranges(MCC_rel))[1]*10^-6)+0.00013,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(MCC_rel))[1]*10^-6)+0.00005, y=1.17, pch=17, 
col="blue", legend="Control", cex=1, bty="n")
dev.off()
# C10orf46
median_C10orf46_cancer <- rowMedians(methLevel(C10orf46_rel[, 
which(C10orf46_rel@colData$Disease=="A")]), na.rm=T)
median_C10orf46_control <- rowMedians(methLevel(C10orf46_rel[, 
which(C10orf46_rel@colData$Disease=="DVA_control")]), na.rm=T)
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$Disease=="A")]), type="p", pch=16, cex=0.5, col="red", xlab="", 
ylab="", main="C10orf46: Individual Methylation Levels", 
ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(C10orf46_rel))*10^-6, ncol(control)), 
methLevel(C10orf46_rel[, which(C10orf46_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=120516119*10^-6, col="black", lwd=1)
legend(x=(120516119*10^-6)-0.00025, y=1.16, legend="CpG-SNP; 
intronic in CpG shore", bty="n", cex=.8)
points(rep(start(ranges(C10orf46_rel))*10^-6), 
median_C10orf46_cancer, type="o", pch=16, cex=0.5, col="red", 
xlab="Genomic Position (Mb)", ylab="Methylation", main="Median 
Methylation at C10orf46 by cancer status")
points(rep(start(ranges(C10orf46_rel))*10^-6), 
median_C10orf46_control, pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(C10orf46_rel))[1]*10^-6)+0.0001,y=1.17, 
pch=16, col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(C10orf46_rel))[1]*10^-6)-0.00002, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(C10orf46_rel))*10^-6), median_C10orf46_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="C10orf46: Median Methylation per Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(C10orf46_rel))*10^-6), 
median_C10orf46_control, pch=17, col="blue", cex=0.5, type="o")
abline(v=120516119*10^-6, col="black", lwd=1)
legend(x=(120516119*10^-6)-0.00025, y=1.16, legend="CpG-SNP; 
intronic in CpG shore", bty="n", cex=.8)
legend(x=(start(ranges(C10orf46_rel))[1]*10^-6)+0.0001,y=1.17, 
pch=16, col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(C10orf46_rel))[1]*10^-6)-0.00002, y=1.17, 




median_MGMT_cancer <- rowMedians(methLevel(MGMT_rel[, 
which(MGMT_raw@colData$Disease=="A")]), na.rm=T)
median_MGMT_control <- rowMedians(methLevel(MGMT_rel[, 
which(MGMT_raw@colData$Disease=="DVA_control")]), na.rm=T)
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type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", main="MGMT: 
Individual Methylation Level", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(MGMT_rel))*10^-6, ncol(control)), 
methLevel(MGMT_rel[, which(MGMT_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=131529435*10^-6, col="black", lwd=1)
legend(x=(131529435*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in open sea", bty="n", cex=.8)
points(rep(start(ranges(MGMT_rel))*10^-6), median_MGMT_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at MGMT by cancer 
status")
points(rep(start(ranges(MGMT_rel))*10^-6), median_MGMT_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(MGMT_rel))[1]*10^-6)+0.0002,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(MGMT_rel))[1]*10^-6)+0.000115, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(MGMT_rel))*10^-6), median_MGMT_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", main="MGMT: 
Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(MGMT_rel))*10^-6), median_MGMT_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=131529435*10^-6, col="black", lwd=1)
legend(x=(131529435*10^-6)+0.0003, y=1.16, legend="CpG-SNP: intronic 
in open sea", bty="n", cex=.8)
legend(x=(start(ranges(MGMT_rel))[1]*10^-6)+0.0002,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(MGMT_rel))[1]*10^-6)+0.000115, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
# SEPT9
median_SEPT9_cancer <- rowMedians(methLevel(SEPT9_rel[, 
which(SEPT9_raw@colData$Disease=="A")]), na.rm=T)
median_SEPT9_control <- rowMedians(methLevel(SEPT9_rel[, 
which(SEPT9_raw@colData$Disease=="DVA_control")]), na.rm=T)
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type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="SEPT9: Individual Methylation Level", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(SEPT9_rel))*10^-6, ncol(control)), 
methLevel(SEPT9_rel[, which(SEPT9_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=75378036*10^-6, col="black", lwd=1)
legend(x=(75378036*10^-6)-0.000015, y=1.16, legend="CpG-SNP: 
intronic in open sea", bty="n", cex=.8)
points(rep(start(ranges(SEPT9_rel))*10^-6), median_SEPT9_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at SEPT9 by cancer 
status")
points(rep(start(ranges(SEPT9_rel))*10^-6), median_SEPT9_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(SEPT9_rel))[1]*10^-6)+0.00012,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(SEPT9_rel))[1]*10^-6)-0.00002, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(SEPT9_rel))*10^-6), median_SEPT9_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="SEPT9: Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(SEPT9_rel))*10^-6), median_SEPT9_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=75378036*10^-6, col="black", lwd=1)
legend(x=(75378036*10^-6)-0.000015, y=1.16, legend="CpG-SNP: 
intronic in open sea", bty="n", cex=.8)
legend(x=(start(ranges(SEPT9_rel))[1]*10^-6)+0.00012,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(SEPT9_rel))[1]*10^-6)-0.00002, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
# RAB11
median_RAB11_cancer <- rowMedians(methLevel(RAB11_rel[, 
which(RAB11_raw@colData$Disease=="A")]), na.rm=T)
median_RAB11_control <- rowMedians(methLevel(RAB11_rel[, 
which(RAB11_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/





type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="RAB11: Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(RAB11_rel))*10^-6, ncol(control)), 
methLevel(RAB11_rel[, which(RAB11_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=8464538*10^-6, col="black", lwd=1)
legend(x=(8464538*10^-6)-0.00023, y=1.16, legend="CpG-SNP: intronic 
in CpG shore", bty="n", cex=.8)
points(rep(start(ranges(RAB11_rel))*10^-6), median_RAB11_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at RAB11 by cancer 
status")
points(rep(start(ranges(RAB11_rel))*10^-6), median_RAB11_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(RAB11_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(RAB11_rel))[1]*10^-6)-0.00001, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(RAB11_rel))*10^-6), median_RAB11_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="RAB11: Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(RAB11_rel))*10^-6), median_RAB11_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=8464538*10^-6, col="black", lwd=1)
legend(x=(8464538*10^-6)-0.00023, y=1.16, legend="CpG-SNP: intronic 
in CpG shore", bty="n", cex=.8)
legend(x=(start(ranges(RAB11_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(RAB11_rel))[1]*10^-6)-0.00001, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
# ITGB2 
median_ITGB2_cancer <- rowMedians(methLevel(ITGB2_rel[, 
which(ITGB2_raw@colData$Disease=="A")]), na.rm=T)
median_ITGB2_control <- rowMedians(methLevel(ITGB2_rel[, 
which(ITGB2_raw@colData$Disease=="DVA_control")]), na.rm=T)
png(file="/Users/ecazaly/Dropbox/Thesis/Chapter_5/Drafts/





type="p", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="ITGB2: Individual Methylation Levels", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(ITGB2_rel))*10^-6, ncol(control)), 
methLevel(ITGB2_rel[, which(ITGB2_raw@colData
$Disease=="DVA_control")]), pch=17, col="blue", cex=0.5)
abline(v=46349496*10^-6, col="black", lwd=1)
legend(x=(46349496*10^-6)+0.000002, y=1.16, legend="CpG-SNP: UTR in 
CpG shore", bty="n", cex=.8)
points(rep(start(ranges(ITGB2_rel))*10^-6), median_ITGB2_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="Genomic Position (Mb)", 
ylab="Methylation", main="Median Methylation at ITGB2 by cancer 
status")
points(rep(start(ranges(ITGB2_rel))*10^-6), median_ITGB2_control, 
pch=17, col="blue", cex=0.5, type="o")
legend(x=(start(ranges(ITGB2_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(ITGB2_rel))[1]*10^-6)-0.000015, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
plot(rep(start(ranges(ITGB2_rel))*10^-6), median_ITGB2_cancer, 
type="o", pch=16, cex=0.5, col="red", xlab="", ylab="", 
main="ITGB2: Median Methylation by Group", ylim=c(0,1.1))
title(ylab="Methylation Level", line=2.2, cex.lab=1.2)
title(xlab="Position (Mb)", line=2.2, cex.lab=1.2)
points(rep(start(ranges(ITGB2_rel))*10^-6), median_ITGB2_control, 
pch=17, col="blue", cex=0.5, type="o")
abline(v=46349496*10^-6, col="black", lwd=1)
legend(x=(46349496*10^-6)+0.000002, y=1.16, legend="CpG-SNP: UTR in 
CpG shore", bty="n", cex=.8)
legend(x=(start(ranges(ITGB2_rel))[1]*10^-6)+0.00008,y=1.17, pch=16, 
col="red", legend="Cancer", cex=1, bty="n")
legend(x=(start(ranges(ITGB2_rel))[1]*10^-6)-0.000015, y=1.17, 
pch=17, col="blue", legend="Control", cex=1, bty="n")
dev.off()
